var title_f30_63_31728="Evaluate and treat pheo";
var content_f30_63_31728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Evaluation and treatment of catecholamine-producing tumors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 614px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     See text for details.",
"     <br>",
"      VMA: vanillylmandelic acid; CT: computed tomography; MRI: magnetic resonance imaging; 123I-MIBG: 123I-meta-iodobenzylguanidine.",
"      <br>",
"       * Clinical suspicion is triggered by paroxysmal symptoms (especially hypertension); hypertension that is intermittent, unusually labile, or resistant to treatment; family history of pheochromocytoma or associated conditions; or an incidentally discovered adrenal mass.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified and reprinted with permission from Young, WF Jr. Pheochromocytoma: 1926-1993. In: Trends in Endocrinology and Metabolism, vol 4, Elsevier Science, Inc 1993. p 122.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_63_31728=[""].join("\n");
var outline_f30_63_31728=null;
var title_f30_63_31729="Severe influenza pneumonia CT";
var content_f30_63_31729=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Influenza pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High-resolution computed tomography (CT) (1-mm collimation) scan at the level of the aortic arch demonstrates extensive bilateral ground-glass opacities, patchy areas of consolidation, and several centrilobular nodules (arrows). The patient was a 61-year-old woman with influenza pneumonia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Muller NL, Franquet T, Lee KS, Silva CIS. Viruses, Mycoplasma, and Chlamydia. In: Imaging of Pulmonary Infections, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_63_31729=[""].join("\n");
var outline_f30_63_31729=null;
var title_f30_63_31730="Patient information: E. coli (The Basics)";
var content_f30_63_31730=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86006\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27072\">",
"          Anatomy of the urinary tract",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/34/557\">",
"           Tips for safe food handling",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/62/32738\">",
"         Patient information: Dehydration (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/5/9299\">",
"         Patient information: Diarrhea in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/34/34338\">",
"         Patient information: Diarrhea in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/3/20530\">",
"         Patient information: Travelers&rsquo; diarrhea (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/29/36308\">",
"         Patient information: Acute diarrhea in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/1/27\">",
"         Patient information: Acute diarrhea in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/2/16421\">",
"         Patient information: General travel advice (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: E. coli (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1821985176\">",
"      <span class=\"h1\">",
"       What is E. coli?",
"      </span>",
"      &nbsp;&mdash;&nbsp;E. coli are bacteria that live in the digestive systems of animals and people (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"mobipreview.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). Everyone has them, and they do not usually cause problems. But there are different types of E. coli. Some types cause disease. Eating or drinking something with 1 of these types in it can cause diarrhea and other symptoms.",
"     </p>",
"     <p>",
"      When E. coli causes disease, it usually happens in the digestive system. But E. coli can sometimes cause illness if it gets into areas of the body where it does not normally live. For example, E. coli can cause a urinary tract infection if it gets into the urinary tract (",
"      <a class=\"graphic graphic_figure graphicRef79864 \" href=\"mobipreview.htm?26/28/27072\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1821985225\">",
"      <span class=\"h1\">",
"       What are the symptoms of E. coli?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Diarrhea &ndash; This can be watery or bloody and mild or severe.",
"       </li>",
"       <li>",
"        Belly pain",
"       </li>",
"       <li>",
"        Vomiting &ndash; This is more common in babies infected with 1 specific type of E. coli.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1821985240\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have more than 6 runny bowel movements in 24 hours.",
"       </li>",
"       <li>",
"        You have diarrhea for longer than 48 hours.",
"       </li>",
"       <li>",
"        You have bloody diarrhea.",
"       </li>",
"       <li>",
"        You have a fever higher than 101.3&ordm;F (38.5&ordm;C).",
"       </li>",
"       <li>",
"        You have severe belly pain.",
"       </li>",
"       <li>",
"        You have diarrhea or fever and are age 70 or older.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should also see a doctor or nurse if your body has lost too much water from diarrhea. This is called &ldquo;dehydration.&rdquo; Signs of dehydration include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Having lots of diarrhea that is very watery",
"       </li>",
"       <li>",
"        Feeling very tired",
"       </li>",
"       <li>",
"        Thirst",
"       </li>",
"       <li>",
"        Dry mouth or tongue",
"       </li>",
"       <li>",
"        Muscle cramps",
"       </li>",
"       <li>",
"        Dizziness, especially when you stand up",
"       </li>",
"       <li>",
"        Confusion",
"       </li>",
"       <li>",
"        Urine that is very yellow, or not needing to urinate for more than 5 hours",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1821985255\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people do not need tests for E. coli. But the doctor or nurse might want to do:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Tests on a sample of your bowel movements",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        Blood tests",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      E. coli that cause diarrhea can sometimes also cause problems with the kidneys or blood. These problems can be serious. If you get sick with E. coli, doctors might do tests to check for these problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1821985270\">",
"      <span class=\"h1\">",
"       How is E. coli treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people do not need any specific treatment. Diarrhea from E. coli is not usually treated with antibiotic medicines. With some E. coli that cause diarrhea, antibiotics can actually make the illness worse. But if E. coli causes symptoms in other parts of the body, you might need antibiotics.",
"     </p>",
"     <p>",
"      People who get dehydrated might need fluids through a thin tube called an &ldquo;IV.&rdquo; The tube goes into a vein. This treatment is usually given in the hospital.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1821985285\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have diarrhea, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Drink a lot of liquids that have water, salt, and sugar. Good choices are soup broth and water mixed with juice. If you are drinking enough fluids, your urine will be light yellow or almost clear.",
"       </li>",
"       <li>",
"        Eat a little food if you feel hungry. Good choices are potatoes, noodles, rice, oatmeal, crackers, bananas, soup, and boiled vegetables. Salty foods help the most.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Ask your doctor or nurse before you take any over-the-counter medicines for diarrhea. If you have E. coli, some of these medicines can be harmful.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1821985300\">",
"      <span class=\"h1\">",
"       Can E. coli be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To reduce your chances of getting and spreading E. coli, be sure to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wash your hands after changing diapers, cooking, eating, going to the bathroom, taking out the trash, or touching animals",
"       </li>",
"       <li>",
"        Stay home from work or school until you feel better, if you get diarrhea",
"       </li>",
"       <li>",
"        Pay attention to food safety. Here are some tips:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Do not drink unpasteurized milk or foods made with it.",
"       </li>",
"       <li>",
"        Wash fruits and vegetables well before eating them.",
"       </li>",
"       <li>",
"        Keep the refrigerator colder than 40&ordm;F and the freezer below 0&ordm;F.",
"       </li>",
"       <li>",
"        Cook meat and seafood until well done.",
"       </li>",
"       <li>",
"        Cook eggs until the yolk is firm.",
"       </li>",
"       <li>",
"        Wash hands, knives, and cutting boards after they touch raw food.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For more tips on food safety, see the table (",
"      <a class=\"graphic graphic_table graphicRef60529 \" href=\"mobipreview.htm?0/34/557\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1821985374\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/5/9299?source=see_link\">",
"       Patient information: Diarrhea in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/34/34338?source=see_link\">",
"       Patient information: Diarrhea in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/62/32738?source=see_link\">",
"       Patient information: Dehydration (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/3/20530?source=see_link\">",
"       Patient information: Travelers&rsquo; diarrhea (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/29/36308?source=see_link\">",
"       Patient information: Acute diarrhea in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/1/27?source=see_link\">",
"       Patient information: Acute diarrhea in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/2/16421?source=see_link\">",
"       Patient information: General travel advice (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/63/31730?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86006 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-211.167.112.14-E9FFDB1ABC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_63_31730=[""].join("\n");
var outline_f30_63_31730=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1821985176\">",
"      What is E. coli?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1821985225\">",
"      What are the symptoms of E. coli?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1821985240\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1821985255\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1821985270\">",
"      How is E. coli treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1821985285\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1821985300\">",
"      Can E. coli be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1821985374\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86006\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27072\">",
"       Anatomy of the urinary tract",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/34/557\">",
"        Tips for safe food handling",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/29/36308?source=related_link\">",
"      Patient information: Acute diarrhea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/1/27?source=related_link\">",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/62/32738?source=related_link\">",
"      Patient information: Dehydration (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/5/9299?source=related_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/34/34338?source=related_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/3/20530?source=related_link\">",
"      Patient information: Travelers&rsquo; diarrhea (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_63_31731="Contents: Primary care cardiology";
var content_f30_63_31731=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care cardiology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care cardiology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Advanced cardiovascular life support",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/33/13850\">",
"           Advanced cardiac life support (ACLS) in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiac arrhythmias",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/32/36361\">",
"           Ambulatory monitoring in the assessment of cardiac arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/28/20938\">",
"           Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/27/35257\">",
"           Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/32/42506\">",
"           Antithrombotic therapy to prevent embolization in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/19/31034\">",
"           Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/41/23192\">",
"           Arrhythmia in athletes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/28/33223\">",
"           Arrhythmia management for the primary care clinician",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/24/36228\">",
"           Atrial flutter: Epidemiology, classification, and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/35/39481\">",
"           Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/36/36424\">",
"           Clinical significance and treatment of ventricular premature beats",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/50/12074\">",
"           Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/57/18328\">",
"           Control of ventricular rate in atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/5/4184\">",
"           Electrocardiographic abnormalities and conduction disturbances in athletes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/40/37511\">",
"           Embolic risk and the role of anticoagulation in atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/54/28522\">",
"           Epidemiology of and risk factors for atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/16/32007\">",
"           Etiology of atrioventricular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/24/4490\">",
"           Evaluation of the survivor of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/38/41574\">",
"           First degree atrioventricular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/24/20874\">",
"           Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/52/27463\">",
"           Indications for permanent cardiac pacing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/19/24888\">",
"           Maintenance of sinus rhythm after cardioversion in atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/6/39016\">",
"           Management of new onset atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/26/22952\">",
"           Management of nonsustained ventricular tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/31/22008\">",
"           Manifestations and causes of the sick sinus syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/14/26858\">",
"           Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/41/13974\">",
"           Nonsustained VT in the absence of apparent structural heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/2/2086\">",
"           Normal sinus rhythm and sinus arrhythmia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/22/361\">",
"           Overview of atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/11/20665\">",
"           Overview of palpitations in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/55/890\">",
"           Overview of sudden cardiac arrest and sudden cardiac death",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/60/13256\">",
"           Overview of the evaluation and management of atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/41/31384\">",
"           Paroxysmal atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/6/9320\">",
"           Prevalence and evaluation of ventricular premature beats",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/57/22426\">",
"           Restoration of sinus rhythm in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/43/5817\">",
"           Rhythm control versus rate control in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/36/13898\">",
"           Risk of sudden cardiac death in athletes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/62/15338\">",
"           Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/42/18087\">",
"           Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/62/998\">",
"           Second degree atrioventricular block: Mobitz type II",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/50/3878\">",
"           Sinus bradycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/25/14742\">",
"           Sinus tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/27/441\">",
"           Supraventricular premature beats",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/59/15285\">",
"           Third degree (complete) atrioventricular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/44/37576\">",
"           Treatment of the sick sinus syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Coronary heart disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/30/26088\">",
"           Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/55/13175\">",
"           Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/12/37066\">",
"           Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/28/28101\">",
"           Biomarkers of cardiac injury other than troponins and creatine kinase",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/53/31576\">",
"           Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/38/27240\">",
"           Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/0/27658\">",
"           C-reactive protein in cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/33/31258\">",
"           Cardiovascular benefits and risks of moderate alcohol consumption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/28/1482\">",
"           Cardiovascular risk of smoking and benefits of smoking cessation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/51/37685\">",
"           Cardiovascular risks of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/56/15240\">",
"           Chest pain of esophageal origin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/53/28505\">",
"           Classification of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/9/41113\">",
"           Clinical features and diagnosis of coronary heart disease in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/35/28217\">",
"           Coronary heart disease and myocardial infarction in young men and women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/59/16314\">",
"           Coronary reperfusion for acute myocardial infarction in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/39/25209\">",
"           Criteria for the diagnosis of acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/57/28570\">",
"           Determinants and management of cardiovascular risk in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/15/34042\">",
"           Diagnostic approach to chest pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/0/26634\">",
"           Differential diagnosis of chest pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/12/6344\">",
"           Elective noncardiac surgery after percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/20/44361\">",
"           Epidemiology of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/60/36810\">",
"           Estimation of cardiac risk prior to noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/8/39048\">",
"           Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/28/14793\">",
"           Exercise and fitness in the prevention of cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/43/1721\">",
"           Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/24/20874\">",
"           Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/43/15034\">",
"           Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/9/2201\">",
"           Major causes of musculoskeletal chest pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/45/29402\">",
"           Management of cardiac risk for noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/63/11258\">",
"           Management of coronary heart disease in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/51/9018\">",
"           Medical therapy versus revascularization in the management of stable angina pectoris",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/35/3641\">",
"           Obesity, weight reduction, and cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/41/44697\">",
"           Overview of the acute management of ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/20/37193\">",
"           Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/28/3529\">",
"           Overview of the care of patients with stable ischemic heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/59/7098\">",
"           Overview of the non-acute management of ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/33/44569\">",
"           Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/37/34394\">",
"           Overview of the possible risk factors for cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/59/39866\">",
"           Overview of the risk equivalents and established risk factors for cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/6/35945\">",
"           Performance of exercise ECG testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/36/29258\">",
"           Postmenopausal hormone therapy and cardiovascular risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/43/2746\">",
"           Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/52/35658\">",
"           Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/62/15338\">",
"           Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/54/34665\">",
"           Screening for cardiovascular risk with C-reactive protein",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/50/26409\">",
"           Screening for coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/31/37369\">",
"           Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/30/44520\">",
"           Selecting the optimal cardiac stress test",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/33/28180\">",
"           Silent myocardial ischemia: Diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/35/4665\">",
"           Silent myocardial ischemia: Prognosis and therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/57/26521\">",
"           Stress testing for the diagnosis of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/58/2986\">",
"           Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/20/41289\">",
"           Treatment of acute myocardial infarction in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/38/39530\">",
"           Troponins and creatine kinase as biomarkers of cardiac injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/39/3706\">",
"           Variant angina",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Electrocardiography",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/40/5763\">",
"           Advanced ECG test",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/44/9923\">",
"           Basic ECG test",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/16/262\">",
"           Basic principles of electrocardiographic interpretation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/10/22689\">",
"           Differential diagnosis of basic electrocardiographic abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/40/34438\">",
"           ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/21/17749\">",
"           ECG tutorial: Atrioventricular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/51/37687\">",
"           ECG tutorial: Basic principles of ECG analysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/36/27204\">",
"           ECG tutorial: Chamber enlargement and hypertrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/22/37220\">",
"           ECG tutorial: Electrical components of the ECG",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/33/22038\">",
"           ECG tutorial: Intraventricular block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/46/35558\">",
"           ECG tutorial: Miscellaneous diagnoses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/6/9317\">",
"           ECG tutorial: Myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/62/996\">",
"           ECG tutorial: Pacemakers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/4/9283\">",
"           ECG tutorial: Physiology of the conduction system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/43/21171\">",
"           ECG tutorial: Preexcitation syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/25/29077\">",
"           ECG tutorial: Rhythms and arrhythmias of the sinus node",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/52/16198\">",
"           ECG tutorial: ST and T wave changes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/57/1942\">",
"           ECG tutorial: Ventricular arrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/24/11658\">",
"           Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/26/4521\">",
"           Electrocardiogram in the prognosis of myocardial infarction or unstable angina",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/48/6916\">",
"           Intermediate ECG test",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/54/39784\">",
"           Left bundle branch block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/6/10344\">",
"           Right bundle branch block",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Heart failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/45/16090\">",
"           ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/53/35672\">",
"           Alcoholic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/39/2680\">",
"           Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/0/19465\">",
"           Causes of dilated cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/22/43368\">",
"           Clinical manifestations and diagnosis of diastolic heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/8/15497\">",
"           Epidemiology and causes of heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/59/28601\">",
"           Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/28/39369\">",
"           Evaluation of the patient with heart failure or cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/30/19945\">",
"           Evaluation of the patient with suspected heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/56/7048\">",
"           Indications for antithrombotic therapy in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/37/7769\">",
"           Inotropic agents in heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/63/38906\">",
"           Overview of the therapy of heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/61/4058\">",
"           Prognosis of heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/54/7018\">",
"           Treatment and prognosis of diastolic heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/56/34698\">",
"           Treatment of acute decompensated heart failure: Components of therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/7/41079\">",
"           Treatment of acute decompensated heart failure: General considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/22/29031\">",
"           Treatment of hypertension in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/54/28521\">",
"           Use of aldosterone antagonists in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/38/12905\">",
"           Use of beta blockers in heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/4/18504\">",
"           Use of digoxin in heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/55/3962\">",
"           Use of diuretics in patients with heart failure",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infective endocarditis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/36/585\">",
"           Antimicrobial prophylaxis for bacterial endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/37/20058\">",
"           Antimicrobial therapy of native valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/57/34712\">",
"           Antimicrobial therapy of prosthetic valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/52/18249\">",
"           Complications and outcome of infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/24/41352\">",
"           Diagnostic approach to infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/40/2697\">",
"           Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/31/14840\">",
"           Epidemiology, risk factors and microbiology of infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/17/40215\">",
"           Infective endocarditis in injection drug users",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/23/31094\">",
"           Infective endocarditis: Historical and Duke criteria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/49/22297\">",
"           Surgery for native valve endocarditis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lipid disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/47/35578\">",
"           Approach to the patient with hypertriglyceridemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/50/19240\">",
"           Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/38/43626\">",
"           Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/42/19111\">",
"           Compliance with lipid altering medications and recommended lifestyle changes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/2/39978\">",
"           HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/25/37274\">",
"           Inherited disorders of LDL-cholesterol metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/56/28550\">",
"           Lipid abnormalities in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/51/28474\">",
"           Lipid lowering with diet or dietary supplements",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/14/42217\">",
"           Lipid lowering with drugs other than statins and fibrates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/39/7800\">",
"           Lipid lowering with fibric acid derivatives",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/45/18138\">",
"           Lipoprotein classification; metabolism; and role in atherosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/19/40248\">",
"           Lipoprotein(a) and cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/2/32\">",
"           Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/36/29258\">",
"           Postmenopausal hormone therapy and cardiovascular risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/29/33241\">",
"           Screening guidelines for dyslipidemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/38/43621\">",
"           Secondary causes of dyslipidemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/0/33802\">",
"           Statin myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/35/32314\">",
"           Statins: Actions, side effects, and administration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/5/10329\">",
"           Treatment of drug-resistant hypercholesterolemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/32/10760\">",
"           Treatment of dyslipidemia in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/32/14856\">",
"           Treatment of lipids (including hypercholesterolemia) in primary prevention",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/30/38375\">",
"           Cardiovascular effects of caffeine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/59/4025\">",
"           Diagnosis and treatment of pericardial effusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/12/32966\">",
"           Major side effects and safety of calcium channel blockers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/50/35626\">",
"           Management of anticoagulation before and after elective surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/15/8442\">",
"           Sexual activity in patients with heart disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Myocarditis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/12/37066\">",
"           Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/16/26889\">",
"           Clinical manifestations and diagnosis of myocarditis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/28/22986\">",
"           Etiology and pathogenesis of myocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/39/10874\">",
"           Natural history and therapy of myocarditis in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/12/37066\">",
"           Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/33/31258\">",
"           Cardiovascular benefits and risks of moderate alcohol consumption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/53/26456\">",
"           Nutritional antioxidants in coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/37/19034\">",
"           Overview of homocysteine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/28/5576\">",
"           Overview of primary prevention of coronary heart disease and stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/60/40906\">",
"           Secondary prevention of cardiovascular disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Syncope",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/22/10598\">",
"           Carotid sinus hypersensitivity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/15/18682\">",
"           Evaluation of syncope in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/11/28855\">",
"           Management of the patient with syncope",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/9/5272\">",
"           Pathogenesis and etiology of syncope",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/0/18442\">",
"           Reflex syncope",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Valvular and aortic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/11/18618\">",
"           Antithrombotic therapy in patients with prosthetic heart valves",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/12/21706\">",
"           Clinical features and evaluation of aortic stenosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/20/23879\">",
"           Clinical manifestations and diagnosis of acute rheumatic fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/19/25914\">",
"           Clinical manifestations and diagnosis of aortic dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/62/39910\">",
"           Clinical manifestations and diagnosis of pulmonic stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/57/25497\">",
"           Complications of prosthetic heart valves",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/29/25050\">",
"           Course and management of chronic aortic regurgitation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/24/13705\">",
"           Definition and diagnosis of mitral valve prolapse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/8/8327\">",
"           Epidemiology and pathogenesis of acute rheumatic fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/30/9705\">",
"           Etiology, clinical features, and evaluation of chronic mitral regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/9/149\">",
"           Etiology, clinical features, and evaluation of tricuspid regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/8/31881\">",
"           Indications for valve replacement in aortic stenosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/48/30471\">",
"           Management and prognosis of tricuspid regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/37/4697\">",
"           Medical management and indications for intervention in mitral stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/43/41654\">",
"           Medical management of symptomatic aortic stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/25/3476\">",
"           Mitral valve prolapse syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/53/30551\">",
"           Natural history of aortic stenosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/31/6649\">",
"           Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/29/18901\">",
"           Natural history of mitral stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/51/33593\">",
"           Overview of the management of chronic mitral regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/2/36901\">",
"           Pathophysiology and stages of chronic mitral regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/9/38039\">",
"           Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/18/13610\">",
"           Pathophysiology, clinical features, and evaluation of mitral stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/4/17480\">",
"           Surgical management of mitral stenosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vascular medicine",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/43/33462\">",
"           Diagnostic evaluation of chronic venous insufficiency",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-F9E1799FE7-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f30_63_31731=[""].join("\n");
var outline_f30_63_31731=null;
var title_f30_63_31732="What's new in pulmonary, critical care, and sleep medicine";
var content_f30_63_31732=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   What's new in pulmonary, critical care, and sleep medicine",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/63/31732/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31732/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31732/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31732/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/63/31732/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     ASTHMA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Anti-IgE therapy for nasal polyposis",
"    </span>",
"   </p>",
"   <p>",
"    Nasal polyposis is currently managed with intranasal and systemic glucocorticoids, although many patients require repeated sinonasal surgeries to debulk polyp tissue despite these therapies. The anti-IgE drug, omalizumab, is approved only for the treatment of moderate to severe allergic asthma by most regulatory agencies, but has been studied in the treatment of other related diseases. In a randomized trial, 24 patients with both nasal polyposis and asthma (with and without sensitization to environmental allergens, including eight patients with aspirin exacerbated respiratory disease [AERD]), were treated with omalizumab or placebo for 16 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/1\">",
"     1",
"    </a>",
"    ].&nbsp;Omalizumab resulted in significant reduction in polyp size and improvement in symptom scores, compared&nbsp;with placebo. Similar responses were seen in patients with and without allergy and in those with AERD. Thus, omalizumab&nbsp;is a potential&nbsp;therapy for patients with both nasal polyposis and moderate to severe asthma, although practical issues, such as cost&nbsp;effectiveness and duration of treatment require further study. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=see_link&amp;anchor=H983890166#H983890166\">",
"     \"Management of chronic rhinosinusitis\", section on 'Omalizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mepolizumab in eosinophilic asthma",
"    </span>",
"   </p>",
"   <p>",
"    It is hypothesized that anti-eosinophil therapy with the anti-IL-5 monoclonal antibody, mepolizumab, may be beneficial in patients with the combination of uncontrolled asthma and persistent airways eosinophilia despite glucocorticoid therapy. In the multicenter Dose Ranging Efficacy And safety with Mepolizumab in severe asthma (DREAM) trial, over 600 patients with severe recurrent asthma exacerbations and evidence of eosinophilic inflammation (eg, sputum eosinophils, peripheral blood eosinophilia, elevated exhaled nitric oxide) were randomly assigned to one of three doses of mepolizumab, given as 13 monthly infusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/2\">",
"     2",
"    </a>",
"    ]. The rate of clinically significant exacerbations was decreased in all mepolizumab groups compared with placebo with the greatest reduction in the highest dose group. However, symptoms and pulmonary function were not consistently improved. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33354?source=see_link&amp;anchor=H20#H20\">",
"     \"Alternative and experimental agents for the treatment of asthma\", section on 'Anti-IL-5 antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tiotropium in severe asthma",
"    </span>",
"   </p>",
"   <p>",
"    Tiotropium, a once daily inhaled anticholinergic bronchodilator widely used in COPD, may be of benefit for patients with severe asthma. In two separate randomized trials with a combined total of over 900 patients, the addition of tiotropium was compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/3\">",
"     3",
"    </a>",
"    ]. At study entry, participants&rsquo; asthma was poorly controlled despite an inhaled glucocorticoid and a long-acting beta agonist (LABA) and their baseline forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) after bronchodilator was &le;80 percent of the predicted value. At 24 weeks, the two tiotropium groups had a significant improvement over placebo in the adjusted peak FEV",
"    <sub>",
"     1",
"    </sub>",
"    . The addition of tiotropium also increased the time to the first severe exacerbation by 56 days more than placebo. We reserve tiotropium for patients who have ongoing asthma symptoms and airflow limitation despite combination therapy with inhaled",
"    <span class=\"nowrap\">",
"     glucocorticoid/LABA.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3354?source=see_link&amp;anchor=H16608339#H16608339\">",
"     \"Treatment of severe asthma in adolescents and adults\", section on 'Tiotropium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COPD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Long-term azithromycin for bronchiectasis",
"    </span>",
"   </p>",
"   <p>",
"    The role of long-term azithromycin in preventing exacerbations of bronchiectasis has been examined in patients with non-cystic fibrosis bronchiectasis. In the Effectiveness of Macrolides in patients with Bronchiectasis using Azithromycin to Control Exacerbations (EMBRACE) trial, 141 patients with at least one exacerbation of bronchiectasis in the prior year were randomly assigned to take azithromycin 500 mg or placebo, three times a week for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/4\">",
"     4",
"    </a>",
"    ]. Azithromycin was associated with a significant decrease in exacerbations compared with placebo. Although no significant difference was noted in lung function or quality of life, long-term azithromycin may be useful in some patients with bronchiectasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38073?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of bronchiectasis in adults\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CRITICAL CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Surviving Sepsis Campaign releases new guidelines",
"    </span>",
"   </p>",
"   <p>",
"    The Surviving Sepsis Campaign has&nbsp;published&nbsp;updated guidelines for the management of patients with sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/5\">",
"     5",
"    </a>",
"    ].&nbsp;A notable revision from&nbsp;2008&nbsp;is that the recommended&nbsp;goals for fluid resuscitation in the first six hours are specified:&nbsp;central venous pressure 8 to 12 mmHg, central venous (superior vena cava) or mixed venous oxygen saturation&nbsp;&ge;70 or 65 percent, respectively, mean arterial pressure &ge;65 mmHg, and urine output &ge;0.5",
"    <span class=\"nowrap\">",
"     mL/kg/hour.",
"    </span>",
"    Additional recommendations are to administer an initial fluid challenge in patients with suspected hypovolemia&nbsp;with a&nbsp;minimum of 30",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of crystalloids and to initiate broad-spectrum antimicrobial therapy within&nbsp;one hour&nbsp;of recognition of septic shock. Further, norepinephrine is preferred as the initial vasopressor&nbsp;agent for septic shock.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=see_link&amp;anchor=H3877337#H3877337\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Goals of initial resuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     High-frequency oscillatory ventilation in adults with ARDS",
"    </span>",
"   </p>",
"   <p>",
"    High-frequency oscillatory ventilation (HFOV),&nbsp;with respiratory rates up to 900 breaths per minute,&nbsp;improves oxygenation in patients with severe hypoxemia due to&nbsp;adult respiratory distress syndrome (ARDS), although two new studies have&nbsp;shown it does not improve survival for most patients.&nbsp;In&nbsp;one large&nbsp;multicenter trial (OSCILLATE), adult patients with new-onset, moderate-to-severe ARDS were randomly assigned to HFOV or to an ARDSNet&nbsp;(low tidal volume) ventilation strategy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/6\">",
"     6",
"    </a>",
"    ]. The study was terminated for harm&nbsp;after enrollment of 548 of a planned 1200 patients, due to&nbsp;an in-hospital mortality of 47 percent in the HFOV arm compared with&nbsp;35 percent in the ARDSNet arm. The OSCAR trial, which enrolled nearly 800 patients in the United Kingdom, also failed to demonstrate a mortality benefit with HFOV at 30 days, although the detrimental effect of HFOV on mortality observed in the OSCILLATE trial was not seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/7\">",
"     7",
"    </a>",
"    ].&nbsp;Thus, HFOV&nbsp;is&nbsp;not recommended as&nbsp;an initial treatment strategy for adult patients with ARDS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/29/5591?source=see_link&amp;anchor=H10#H10\">",
"     \"High-frequency ventilation in adults\", section on 'HF oscillatory ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Guidelines for managing pain, agitation, and delirium in critically-ill adults",
"    </span>",
"   </p>",
"   <p>",
"    The Society of Critical Care Medicine has published updated guidelines for managing pain, agitation, and delirium in&nbsp;adults in the ICU&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/8\">",
"     8",
"    </a>",
"    ]. To reduce the incidence and duration of delirium, the new guidelines recommend mobilization as early as is feasible. Compared to&nbsp;the 2002&nbsp;guidelines, the use of haloperidol and atypical antipsychotics (eg, quetiapine) to reduce the duration of delirium is de-emphasized, based upon&nbsp;absent or weak proof of efficacy. For pharmacologic sedation in intubated patients, analgesia-first sedation is now preferred&nbsp;over sedative hypnotic medication, and nonbenzodiazepine agents (eg, propofol or dexmedetomidine) are preferred over benzodiazepines.&nbsp;Adherence to the 2013 guidelines should not usurp physician&nbsp;judgement regarding the management of delirium and agitation in the ICU setting.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15833?source=see_link&amp;anchor=H6#H6\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\", section on 'Initiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chlorhexidine bathing for intensive care and hematopoietic cell transplant patients",
"    </span>",
"   </p>",
"   <p>",
"    Use of antiseptic agents for patient bathing has been demonstrated to reduce the rate of hospital-acquired bloodstream infections and the risk of colonization with drug-resistant organisms. The greatest efficacy has been demonstrated with chlorhexidine gluconate, an antiseptic agent with broad-spectrum activity. Among more than 7000 patients in intensive care and&nbsp;hematopoietic cell&nbsp;transplant units randomly assigned&nbsp;to bathing with either 2 percent chlorhexidine-impregnated washcloths or nonantimicrobial washcloths for a six-month period (followed by crossover for the alternate product for the subsequent six months), chlorhexidine bathing was associated with reduction in the rate of hospital-acquired bloodstream infections by 28 percent and reduction in the rate of colonization with drug-resistant organisms by 23 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link&amp;anchor=H3992580#H3992580\">",
"     \"General principles of infection control\", section on 'Patient bathing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Blood transfusion thresholds for acute upper GI bleeding",
"    </span>",
"   </p>",
"   <p>",
"    The decision to initiate blood transfusions in patients with acute upper gastrointestinal bleeding is based on the rapidity of bleeding and the patients' comorbid conditions. A randomized trial of patients with and without cardiovascular disease suggests that in patients who are not at increased risk for complications from anemia, outcomes are improved if a lower hemoglobin threshold (&lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    rather than &lt;9",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    is used for initiating blood transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients transfused when the hemoglobin was &lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    had lower mortality rates, were less likely to have further bleeding, and were less likely to suffer complications.",
"    <br/>",
"    <br/>",
"    We recommend giving blood transfusions to maintain the hemoglobin at &ge;7",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    rather than &ge;9",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    for the majority of patients with acute upper gastrointestinal bleeding who do not have significant comorbid illnesses. However, patients with active bleeding and hypovolemia may require blood transfusion despite an apparently normal hemoglobin. Additionally, we suggest transfusing to maintain the hemoglobin at &ge;9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for patients at increased risk of adverse events in the setting of significant anemia, such as those with unstable coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=see_link&amp;anchor=H5079586#H5079586\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Blood transfusions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44569?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Blood transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hydroxyethyl starch solutions in severe sepsis and septic shock",
"    </span>",
"   </p>",
"   <p>",
"    Randomized trials have demonstrated potential harm from using certain colloid solutions rather than a crystalloid solution in the management of severe sepsis and septic shock. In the Scandinavian Starch for Severe Sepsis and Septic Shock trial, 804 patients with severe sepsis were randomly assigned to receive either 6 percent hydroxyethyl starch (a colloid solution) or Ringer&rsquo;s acetate (a crystalloid solution) at a volume of up to 33",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of ideal body weight per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/11\">",
"     11",
"    </a>",
"    ]. When assessed 90 days after randomization, mortality was increased in the hydroxyethyl starch group and more patients in the hydroxyethyl starch group had required renal replacement therapy at some time during their illness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Intravenous fluids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hydroxyethyl starch solutions in hypovolemia",
"    </span>",
"   </p>",
"   <p>",
"    Concern has been raised about the potential risks of using hydroxyethyl starch solutions for fluid resuscitation. The validity of this concern was demonstrated in a randomized trial, in which 7000 critically-ill patients were randomly assigned to receive 6% hydroxyethyl starch or isotonic saline for all fluid resuscitation until discharge from the intensive care unit, death, or 90 days&nbsp;post randomization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/12\">",
"     12",
"    </a>",
"    ]. More patients in the hydroxyethyl starch group required renal replacement therapy, although no difference was found in the risk of death at 90 days in the two groups. Thus, saline solutions are preferred over hydroxyethyl starch solutions for most critically-ill patients with hypovolemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Colloid versus crystalloid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INTERSTITIAL LUNG DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chapel Hill Consensus Conference on nomenclature of vasculitides",
"    </span>",
"   </p>",
"   <p>",
"    Revisions in the commonly used terms for the various vasculitides have been proposed by the 2012 International Chapel Hill Consensus Conference (CHCC) on nomenclature of vasculitides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/13\">",
"     13",
"    </a>",
"    ]. The&nbsp;2012 CHCC suggests&nbsp;\"eosinophilic granulomatosis with polyangiitis (Churg-Strauss),\" abbreviated EGPA, in place of Churg-Strauss syndrome, and formal adoption of \"antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)\" for the group&nbsp;of disorders&nbsp;that includes&nbsp;microscopic polyangiitis, granulomatosis with polyangiitis (Wegener&rsquo;s), and EGPA. Some of the other changes suggested by the 2012 CHCC included \"immunoglobulin A (IgA) vasculitis (Henoch-Sch&ouml;nlein)\" in lieu of Henoch-Sch&ouml;nlein purpura, further definition of hypocomplementemic urticarial vasculitis (HUV) as \"HUV (anti-C1q vasculitis),\" and \"cryoglobulinemic vasculitis\" in place of essential cryoglobulinemic vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37241?source=see_link&amp;anchor=H2#H2\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Adalimumab for cutaneous sarcoidosis",
"    </span>",
"   </p>",
"   <p>",
"    Case reports and case series have documented benefit of adalimumab for cutaneous sarcoidosis.&nbsp;A new randomized trial compared adalimumab with placebo in 15 patients with cutaneous sarcoidosis&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/14\">",
"     14",
"    </a>",
"    ]. The trial found a statistically-nonsignificant difference in&nbsp;the physician global assessment score (5 of 10 patients in the adalimumab group versus 1 of 5 patients in the placebo group achieved at least a two grade improvement). However, the area of target lesions in the adalimumab group decreased by an average of 32 percent compared to an average 54 percent increase in the area of target lesions in the placebo group; this difference was statistically significant.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/8/16522?source=see_link&amp;anchor=H7842116#H7842116\">",
"     \"Management of cutaneous sarcoidosis\", section on 'Adalimumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     LUNG CANCER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Guidelines for subsolid pulmonary nodules",
"    </span>",
"   </p>",
"   <p>",
"    The Fleischner Society has proposed new guidelines for the management of subsolid (ground glass or mixed ground glass and solid) solitary pulmonary nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/15\">",
"     15",
"    </a>",
"    ]. An important recommendation is that subsolid solitary nodules &gt;5 mm be monitored by serial thin-slice computed tomography for at least three years due to the risk of adenocarcinoma in situ or minimally invasive adenocarcinoma (formerly called bronchioloalveolar carcinoma or BAC), which tend to be slow-growing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44537?source=see_link&amp;anchor=H1770441#H1770441\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\", section on 'Guidelines for ground-glass and part-solid nodules'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PULMONARY VASCULAR DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bosentan in portopulmonary hypertension",
"    </span>",
"   </p>",
"   <p>",
"    Bosentan is an endothelin receptor antagonist that is beneficial in the treatment of idiopathic pulmonary arterial hypertension. The effect of first-line treatment with bosentan for portopulmonary hypertension was examined in a case series of&nbsp;34&nbsp;consecutive patients&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/16\">",
"     16",
"    </a>",
"    ].&nbsp;Over a mean treatment duration of 43 months, significant improvements were noted in the New York Heart Association (NYHA) functional class, six-minute walk distance, and hemodynamics. Four patients died during follow-up, and seven had significant elevations in liver enzymes. Further studies are needed to fully clarify the&nbsp;role of bosentan in the&nbsp;treatment of portopulmonary hypertension.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35064?source=see_link&amp;anchor=H15#H15\">",
"     \"Portopulmonary hypertension\", section on 'Bosentan and ambrisentan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Apixaban for secondary prevention of venous thromboembolism",
"    </span>",
"   </p>",
"   <p>",
"    The randomized, double-blind AMPLIFY-EXT study compared the efficacy and safety of apixaban with placebo in over 2000 subjects with venous thromboembolism (VTE) who had completed 6 to 12 months of anticoagulation and for whom there was uncertainty regarding the further continuation of anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/17\">",
"     17",
"    </a>",
"    ]. Symptomatic recurrent VTE or death from VTE occurred in 8.8 and 1.7 percent of those receiving placebo or apixaban, respectively, for an overall 80 percent reduction in the risk of VTE recurrence with apixaban. Major bleeding was not increased in the group receiving apixaban. A randomized trial comparing this agent with standard-dose warfarin will help to determine the future role of apixaban for the continued treatment of VTE. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H7480111#H7480111\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Apixaban'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Issues to consider'",
"    </a>",
"    .)&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Aspirin for secondary prevention of venous thromboembolism",
"    </span>",
"   </p>",
"   <p>",
"    Two randomized trials, WARFASA and ASPIRE, examined the use of low-dose aspirin (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for the prevention of recurrent venous thromboembolism (VTE)&nbsp;following&nbsp;6 to 18 months of anticoagulation for a&nbsp;first unprovoked episode of VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. WARFASA showed a significant reduction in the rate of VTE recurrence, in contrast to&nbsp;ASPIRE, which failed&nbsp;to meet&nbsp;its primary end point of significant&nbsp;risk reduction of recurrent&nbsp;VTE.&nbsp;A prospectively planned combined analysis of both trials indicated that aspirin, compared with placebo, significantly reduced both the rate of VTE recurrence and major vascular events (a composite&nbsp;secondary endpoint of&nbsp;recurrent VTE, myocardial infarction, stroke, and cardiovascular death) by 32 and 34 percent, respectively, with no excess bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/19\">",
"     19",
"    </a>",
"    ]. After completing anticoagulant therapy following a first-time unprovoked VTE, switching to low-dose aspirin,&nbsp;is an option that may reduce the risk&nbsp; of VTE recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/20\">",
"     20",
"    </a>",
"    ].&nbsp;Direct comparison of aspirin and warafarin for the prevention of VTE was not performed&nbsp;in either&nbsp;trial and warrants further study. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H11015892#H11015892\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Use of aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SLEEP MEDICINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Zolpidem dosing for insomnia in women",
"    </span>",
"   </p>",
"   <p>",
"    Zolpidem is a nonbenzodiazepine sedative that is widely used for treatment of insomnia and is known to cause residual daytime sedation, drowsiness, cognitive impairment, and motor incoordination in some individuals. Recent studies reviewed by the US Food and Drug Administration (FDA) suggest that 15 percent of women and 3 percent of men have next-morning zolpidem blood levels capable of impairing driving after a 10 mg dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31732/abstract/21\">",
"     21",
"    </a>",
"    ]. Based on these findings, the FDA has recommended lowering the usual dose of zolpidem in women to 5 mg. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13290?source=see_link&amp;anchor=H947212#H947212\">",
"     \"Treatment of insomnia\", section on 'Nonbenzodiazepines'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/1\">",
"      Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013; 131:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/2\">",
"      Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/3\">",
"      Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/4\">",
"      Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/5\">",
"      Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/6\">",
"      Ferguson ND, Cook DJ, Guyatt GH, et al. High-frequency oscillation in early acute respiratory distress syndrome. N Engl J Med 2013; 368:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/7\">",
"      Young D, Lamb SE, Shah S, et al. High-frequency oscillation for acute respiratory distress syndrome. N Engl J Med 2013; 368:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/8\">",
"      Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013; 41:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/9\">",
"      Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013; 368:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/10\">",
"      Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/11\">",
"      Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; 367:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/12\">",
"      Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/13\">",
"      Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/14\">",
"      Pariser RJ, Paul J, Hirano S, et al. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/15\">",
"      Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology 2013; 266:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/16\">",
"      Savale L, Magnier R, Le Pavec J, et al. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J 2013; 41:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/17\">",
"      Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/18\">",
"      Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/19\">",
"      Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31732/abstract/20\">",
"      Warkentin TE. Aspirin for dual prevention of venous and arterial thrombosis. N Engl J Med 2012; 367:2039.",
"     </a>",
"    </li>",
"    <li>",
"     Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses Including Ambien, Ambien CR, Edluar, and Zolpimist file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm334738.htm (Accessed on January 20, 2013).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8355 Version 2375.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-178.219.2.221-E05E7BC581-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_63_31732=[""].join("\n");
var outline_f30_63_31732=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Anti-IgE therapy for nasal polyposis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mepolizumab in eosinophilic asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tiotropium in severe asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Long-term azithromycin for bronchiectasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CRITICAL CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Surviving Sepsis Campaign releases new guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      High-frequency oscillatory ventilation in adults with ARDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Guidelines for managing pain, agitation, and delirium in critically-ill adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chlorhexidine bathing for intensive care and hematopoietic cell transplant patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Blood transfusion thresholds for acute upper GI bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hydroxyethyl starch solutions in severe sepsis and septic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hydroxyethyl starch solutions in hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INTERSTITIAL LUNG DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chapel Hill Consensus Conference on nomenclature of vasculitides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Adalimumab for cutaneous sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      LUNG CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Guidelines for subsolid pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PULMONARY VASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bosentan in portopulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Apixaban for secondary prevention of venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Aspirin for secondary prevention of venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SLEEP MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Zolpidem dosing for insomnia in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33354?source=related_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44537?source=related_link\">",
"      Diagnostic evaluation and management of the solitary pulmonary nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/29/5591?source=related_link\">",
"      High-frequency ventilation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/8/16522?source=related_link\">",
"      Management of cutaneous sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35064?source=related_link\">",
"      Portopulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15833?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38073?source=related_link\">",
"      Treatment of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3354?source=related_link\">",
"      Treatment of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_63_31733="Bismuth subsalicylate, metronidazole, and tetracycline: Drug information";
var content_f30_63_31733=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bismuth subsalicylate, metronidazole, and tetracycline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/28/16837?source=see_link\">",
"    see \"Bismuth subsalicylate, metronidazole, and tetracycline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Helidac&reg;;",
"     </li>",
"     <li>",
"      Pylera&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F141588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous;",
"     </li>",
"     <li>",
"      Antibiotic, Tetracycline Derivative;",
"     </li>",
"     <li>",
"      Antidiarrheal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F141576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duodenal ulcer associated with",
"     <i>",
"      H. pylori",
"     </i>",
"     infection: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Helidac&reg;: Two bismuth subsalicylate 262.4 mg tablets, 1 metronidazole 250 mg tablet, and 1 tetracycline 500 mg capsule 4 times/day at meals and bedtime, plus an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist (at the appropriate dose) for 14 days; follow with 8 oz of water; the H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist should be continued for a total of 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pylera&trade;: Three capsules 4 times/day after meals and at bedtime, plus omeprazole 20 mg twice daily for 10 days; follow each dose with 8 oz of water (each capsule contains bismuth subcitrate potassium 140 mg, metronidazole 125 mg, and tetracycline 125 mg)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F141577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F141565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pylera&trade;: Bismuth subcitrate potassium 140 mg, metronidazole 125 mg, and tetracycline hydrochloride 125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Combination package:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Helidac&reg; [each package contains 14 blister cards (2-week supply); each card contains the following]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet, chewable: Bismuth subsalicylate: 262.4 mg (8s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet: Metronidazole: 250 mg (4s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Capsule: Tetracycline hydrochloride: 500 mg (4s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F141551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4928305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Helidac&reg;: Chew bismuth tablets; swallow",
"     <b>",
"      (do not chew)",
"     </b>",
"     metronidazole and tetracycline. Take with a full glass (8 oz) of water. Administer an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist at appropriate dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pylera&trade;: Swallow capsules whole with full glass of water. Administer omeprazole after morning meal and evening meal.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F141567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As part of a multidrug regimen for",
"     <i>",
"      H. pylori",
"     </i>",
"     eradication to reduce the risk of duodenal ulcer recurrence in combination with an H",
"     <sub>",
"      2",
"     </sub>",
"     agonist (Helidac&reg;) or omeprazole (Pylera&trade;)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F141586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Helidac&reg; (includes studies with/without concomitant acid-suppression therapy):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Nausea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (2%), headache (2%), insomnia (1%), pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (7%), diarrhea (7%), melena (3%), anorexia (2%), constipation (2%), dyspepsia (2%), tongue discoloration (2%), vomiting (2%), abnormal stools (1%), anal discomfort (1%), duodenal ulcer (1%), flatulence (1%), GI hemorrhage (1%), taste perversion (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (2%), paresthesia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (2%), sinusitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acne, ALT increased, AST increased, arthritis, bruising, cerebral ischemia, chest pain, conjunctivitis, dysphagia, eructation, flu-like syndrome, gastrointestinal moniliasis, glossitis, hypertension, infection, intestinal obstruction, malaise, MI, neoplasm, nervousness, photosensitivity reaction, pruritus, rash, rectal hemorrhage, rheumatoid arthritis, rhinitis, somnolence, stomatitis, syncope, tendonitis, tooth discoloration and enamel hypoplasia, urinary tract infection, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Pylera&trade; (with concomitant omeprazole):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Abnormal stools (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Chest pain (1%), palpitation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Headache (8%), dizziness (3%), pain (2%), anxiety (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Maculopapular rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (9%), diarrhea (9%), dyspepsia (9%), nausea (8%), taste perversion (5%), gastritis (1%), gastroenteritis (1%), vomiting (1%), xerostomia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Vaginitis (4%), urine abnormality (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hepatic: ALT increased (2%), AST increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (4%), back pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Pharyngitis (2%), rhinitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (5%), infection (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Cough, flatulence, rash, sinusitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F141570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bismuth, metronidazole, tetracycline, or any component of the formulation; children; significant renal/hepatic impairment; pregnancy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Helidac&reg; is also contraindicated in patients with hypersensitivity to salicylates",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F141555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F141582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F141560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: MetroNIDAZOLE (Systemic) may increase the serum concentration of Busulfan.  Management: The toxic effects of busulfan may be greatly increased with concomitant use of metronidazole. This combination should probably be avoided when possible.  If these agents must be used together, increased monitoring for busulfan toxicity is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcineurin Inhibitors: MetroNIDAZOLE (Systemic) may decrease the metabolism of Calcineurin Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Systemic): MetroNIDAZOLE (Systemic) may increase the serum concentration of Fluorouracil (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of MetroNIDAZOLE (Systemic). MetroNIDAZOLE (Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mebendazole: May enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic). Particularly the risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: MetroNIDAZOLE (Systemic) may decrease the serum concentration of Mycophenolate. Specifically, metronidazole may decrease concentrations of the active metabolite of mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of MetroNIDAZOLE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: MetroNIDAZOLE (Systemic) may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of MetroNIDAZOLE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Tipranavir. A disulfiram-like reaction may occur due to the alcohol contained in tipranavir capsules.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): MetroNIDAZOLE (Systemic) may increase the serum concentration of Vitamin K Antagonists.  Management: Consider alternatives to concomitant therapy with these agents.  Monitor for increased INR/bleeding risk if metronidazole is initiated/dose increased, or decreased effects if metronidazole is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F141561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4928298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F141579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4370469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Pylera Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     140-125-125 mg (120): $638.23",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F141563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F141554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bismuth, metronidazole, and tetracycline individually have demonstrated",
"     <i>",
"      in vitro",
"     </i>",
"     activity against most susceptible strains of",
"     <i>",
"      H. pylori",
"     </i>",
"     isolated from patients with duodenal ulcers. Resistance to metronidazole is increasing in the U.S.; an alternative regimen, not containing metronidazole, if",
"     <i>",
"      H. pylori",
"     </i>",
"     is not eradicated follow therapy.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F141569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Laine L, Hunt R, El-Zimaity H, et al, &ldquo;Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracyline Given with Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial,&rdquo;",
"      <i>",
"       Am J Gastroent",
"      </i>",
"      , 2003, 98(3):562-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/63/31733/abstract-text/12650788/pubmed\" id=\"12650788\" target=\"_blank\">",
"        12650788",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9157 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4AAF914B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_63_31733=[""].join("\n");
var outline_f30_63_31733=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141573\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141588\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141576\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141577\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141565\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141551\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4928305\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141567\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141586\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141570\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141555\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141582\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141560\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141561\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4928298\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141579\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4370469\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141563\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141554\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141569\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9157\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9157|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/28/16837?source=related_link\">",
"      Bismuth subsalicylate, metronidazole, and tetracycline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_63_31734="Abacavir: Drug information";
var content_f30_63_31734=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Abacavir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/53/18261?source=see_link\">",
"    see \"Abacavir: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/18/19751?source=see_link\">",
"    see \"Abacavir: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5696175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F128749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ziagen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F128750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ziagen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F128776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleoside)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F128752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV treatment:",
"     </b>",
"     Oral: 300 mg twice daily or 600 mg once daily in combination with other antiretroviral agents",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F128767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/18/19751?source=see_link\">",
"      see \"Abacavir: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV treatment:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants and Children &ge;3 months to &lt;16 years: 8 mg/kg body weight twice daily (maximum: 300 mg twice daily) in combination with other antiretroviral agents.",
"     <b>",
"      Note:",
"     </b>",
"     May consider 16-20 mg/kg  once daily dosing (maximum: 600 mg/day) in stable patients with undetectable viral load and stable CD4 count (DHHS [pediatric], 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     U.S. manufacturer labeling: Alternative dosing to be considered for pediatric patients &ge;14 kg who are able to swallow tablets:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     14-21 kg: 150 mg (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;21 kg to &lt;30 kg: 150 mg (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet) in the morning and 300 mg (1 tablet) in the evening",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;30 kg: 300 mg (1 tablet) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;16 years: 300 mg twice daily or 600 mg once daily in combination with other antiretroviral agents (DHHS, 2013; DHHS [pediatric], 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children &ge;3 months to 12 years: 8 mg/kg body weight twice daily (maximum: 300 mg twice daily) in combination with other antiretroviral agents",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents &gt;12 years: 300 mg twice daily in combination with other antiretroviral agents",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F128753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13334512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Canadian labeling (not in U.S. labeling): Use in ESRD or use of 600 mg once daily dosing is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F128754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild impairment (Child-Pugh score 5-6): 200 mg twice daily (oral solution is recommended)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate-to-severe impairment (Child-Pugh score &gt;6): Use is contraindicated by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F128722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ziagen&reg;: 20 mg/mL (240 mL) [contains propylene glycol; strawberry-banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ziagen&reg;: 300 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F128708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM224556.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM224556.pdf",
"     </a>",
"     , must be dispensed with this medication. A Warning Card (summarizing symptoms of hypersensitivity), which is available with the product information, must also be dispensed with this medication for each new outpatient prescription and refill.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F128725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F128723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infections in combination with other antiretroviral agents",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F128774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity reactions (which may be fatal) occur in ~5% of patients. Symptoms may include anaphylaxis, fever, rash (including erythema multiforme), fatigue, diarrhea, abdominal pain; respiratory symptoms (eg, pharyngitis, dyspnea, cough, adult respiratory distress syndrome, or respiratory failure); headache, malaise, lethargy, myalgia, myolysis, arthralgia, edema, paresthesia, nausea and vomiting, mouth ulcerations, conjunctivitis, lymphadenopathy, hepatic failure, and renal failure.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Rates of adverse reactions were defined during combination therapy with other antiretrovirals (lamivudine and efavirenz",
"     <b>",
"      or",
"     </b>",
"     lamivudine and zidovudine). Only reactions which occurred at a higher frequency in adults (except where noted) than in the comparator group are noted. Adverse reaction rates attributable to abacavir alone are not available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (7% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (7% to 19%, children 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression (6%), fever/chills (6%, children 9%), anxiety (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (5% to 6%, children 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Triglycerides increased (2% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (7%), vomiting (children 9%), amylase increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain (5% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions (2% to 9%; may include reactions to other components of antiretroviral regimen), infection (ENT 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Erythema multiforme, fat redistribution, GGT increased, hepatic steatosis, hepatomegaly, hepatotoxicity, immune reconstitution syndrome, lactic acidosis, MI, pancreatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F128728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to abacavir or any component of the formulation (do not rechallenge patients who have experienced hypersensitivity to abacavir regardless of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status); moderate-to-severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F128712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Serious and sometimes fatal hypersensitivity reactions have occurred.",
"     </b>",
"     Patients testing positive for the presence of the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele are at an increased risk for hypersensitivity reactions. Screening for",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele status is recommended prior to initiating therapy or reinitiating therapy in patients of unknown status, including patients who previously tolerated therapy. Therapy is",
"     <b>",
"      not",
"     </b>",
"     recommended in patients testing positive for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele.  An allergy to abacavir should be reported in the patient&rsquo;s medical record (DHHS, 2013). Reactions usually occur within 9 days of starting abacavir; ~90% occur within 6 weeks. Patients exhibiting symptoms from two or more of the following: Fever, skin rash, constitutional symptoms (malaise, fatigue, aches), respiratory symptoms (eg, pharyngitis, dyspnea, cough), and GI symptoms (eg, abdominal pain, diarrhea, nausea, vomiting) should discontinue therapy immediately and call for medical attention. Abacavir should be permanently discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible and regardless of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status. Abacavir SHOULD NOT be restarted because more severe symptoms may occur within hours, including LIFE-THREATENING HYPOTENSION AND DEATH. Fatal hypersensitivity reactions have occurred following the reintroduction of abacavir in patients whose therapy was interrupted (ie, interruption in drug supply, temporary discontinuation while treating other conditions). In some cases, signs of hypersensitivity may have been previously present, but attributed to other medical conditions (eg, acute onset respiratory diseases, gastroenteritis, reactions to other medications). If abacavir is restarted following an interruption in therapy, evaluate the patient for previously unsuspected symptoms of hypersensitivity. A higher incidence of severe hypersensitivity reactions may be associated with a 600 mg once daily dosing regimen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis/hepatomegaly:",
"     <b>",
"      [U.S Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogues, including fatal cases;",
"     </b>",
"     use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy or prolonged exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary heart disease: Use has been associated with an increased risk of myocardial infarction (MI) in observational studies; however, based on a meta-analysis of 26 randomized trials, the FDA has concluded there is not an increased risk. Consider using with caution in patients with risks for coronary heart disease and minimizing modifiable risk factors (eg, hypertension, hyperlipidemia, diabetes mellitus, and smoking) prior to use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild hepatic dysfunction (contraindicated in moderate-to-severe dysfunction).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV: Appropriate use: Abacavir should always be used as a component of a multidrug regimen. Use with caution in patients with plasma HIV RNA levels &ge;100,000 copies/mL as earlier virologic failure has been observed in one study (DHHS, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;3 months of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Propylene glycol: Products may contain propylene glycol.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F128716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F128745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Ethanol may increase the risk of toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F128718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F128732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. Abacavir crosses the human placenta. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Cases of lactic acidosis/hepatic steatosis syndrome related to mitochondrial toxicity have been reported in pregnant women with prolonged use of nucleoside analogues. It is not known if pregnancy itself potentiates this known side effect; however, women may be at increased risk of lactic acidosis and liver damage. In addition, these adverse events are similar to other rare but life-threatening syndromes which occur during pregnancy (eg, HELLP syndrome). Hepatic enzymes and electrolytes should be monitored in women receiving nucleoside analogues and clinicians should watch for early signs of the syndrome. In addition, mitochondrial dysfunction may develop in infants following",
"     <i>",
"      in utero",
"     </i>",
"     exposure. The pharmacokinetics of abacavir are not significantly changed by pregnancy and dose adjustment is not needed for pregnant women. The DHHS Perinatal HIV Guidelines consider abacavir to be an alternative NRTI in dual nucleoside combination regimens.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F128757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F128733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F128734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F128731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ziagen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (240 mL): $176.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Abacavir Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (60): $602.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ziagen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (60): $670.37",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5564468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, serum creatine kinase, CD4 count, HIV RNA plasma levels, serum transaminases, triglycerides, serum amylase;",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     genotype status prior to initiation of therapy and prior to reinitiation of therapy in patients of unknown",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status; signs and symptoms of hypersensitivity, particularly in patients untested for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F128735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abamune (IN, UY);",
"     </li>",
"     <li>",
"      Abavan (CO, PE);",
"     </li>",
"     <li>",
"      Abec (IN);",
"     </li>",
"     <li>",
"      Ampi-quim (MX);",
"     </li>",
"     <li>",
"      Filabac (AR);",
"     </li>",
"     <li>",
"      Virol (IN);",
"     </li>",
"     <li>",
"      Zepril (AR);",
"     </li>",
"     <li>",
"      Ziagen (AT, AU, BB, BE, BG, BM, BS, BZ, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, GY, HK, HN, IE, IL, IT, JM, KP, MT, NI, NL, NO, NZ, PA, PE, PL, PT, RU, SE, SG, SK, SR, SV, TR, TT, TW, VE);",
"     </li>",
"     <li>",
"      Ziagenavir (AR, BR, MX, TH, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F128711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nucleoside reverse transcriptase inhibitor. Abacavir is a guanosine analogue which is phosphorylated to carbovir triphosphate which interferes with HIV viral RNA-dependent DNA polymerase resulting in inhibition of viral replication.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F128727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and extensive absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.86 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via alcohol dehydrogenase and glucuronyl transferase to inactive carboxylate and glucuronide metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 83%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 0.7-1.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as metabolites, 1.2% as unchanged drug); feces (16% total dose)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, Department of Health and Human Services,&rdquo; August 11, 2011;1-268. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foster RH and Faulds D, &ldquo;Abacavir,&rdquo;",
"      <i>",
"       Drugs,",
"      </i>",
"      1998, 55(5):729-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/63/31734/abstract-text/9585869/pubmed\" id=\"9585869\" target=\"_blank\">",
"        9585869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Havlir DV and Lange JM, &ldquo;New Antiretrovirals and New Combinations,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 1998, 12(Suppl A):165-74.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kline MW, Blanchard S, Fletcher CV, et al, &ldquo;A Phase I Study of Abacavir (1592U89) Alone and in Combination With Other Antiretroviral Agents in Infants and Children With Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1999, 103(4):e47. Available at  file://www.pediatrics.org/cgi/content/full/103/4/e47",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/63/31734/abstract-text/10103339/pubmed\" id=\"10103339\" target=\"_blank\">",
"        10103339",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lucas A, Nolan D, and Mallal S, &ldquo;HLA-B*5701 Screening for Susceptibility to Abacavir Hypersensitivity,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2007, 59(4):591-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/63/31734/abstract-text/17317695/pubmed\" id=\"17317695\" target=\"_blank\">",
"        17317695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mallal S, Nolan D, Witt C, et al, &ldquo;Association Between Presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and Hypersensitivity to HIV-1 Reverse-Transcriptase Inhibitor Abacavir,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359:727-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/63/31734/abstract-text/11888582/pubmed\" id=\"11888582\" target=\"_blank\">",
"        11888582",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmit JC and Weber B, &ldquo;Recent Advances in Antiretroviral Therapy and HIV Infection Monitoring,&rdquo;",
"      <i>",
"       Intervirology",
"      </i>",
"      , 1997, 40(5-6):304-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/63/31734/abstract-text/9675636/pubmed\" id=\"9675636\" target=\"_blank\">",
"        9675636",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Three New Drugs for HIV Infection,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1998, 40(1041):114-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/63/31734/abstract-text/9854567/pubmed\" id=\"9854567\" target=\"_blank\">",
"        9854567",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weverling GJ, Lange JM, Jurriaans S, et al, &ldquo;Alternative Multidrug Regimen Provides Improved Suppression of HIV-1 Replication Over Triple Therapy,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 1998, 12(11):F117-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/63/31734/abstract-text/9708401/pubmed\" id=\"9708401\" target=\"_blank\">",
"        9708401",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8993 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-C38B34FA94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_63_31734=[""].join("\n");
var outline_f30_63_31734=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5696175\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128749\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128750\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128776\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128752\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128767\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128753\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13334512\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128754\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128722\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128708\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874271\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128725\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128723\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128774\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128728\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128712\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298624\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128716\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128745\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128718\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128732\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128757\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128733\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128734\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128731\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5564468\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128735\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128711\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128727\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8993\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8993|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/53/18261?source=related_link\">",
"      Abacavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/18/19751?source=related_link\">",
"      Abacavir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_63_31735="Liver flukes: Fascioliasis";
var content_f30_63_31735=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Liver flukes: Fascioliasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/63/31735/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31735/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31735/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/63/31735/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31735/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/63/31735/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31735/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/63/31735/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fascioliasis is a trematode flatworm infection caused by Fasciola hepatica or Fasciola gigantica [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/1\">",
"     1",
"    </a>",
"    ]. F. hepatica has a worldwide distribution; F. gigantica occurs predominantly in the tropics. Both parasites are hermaphroditic, have similar life cycles, and cause similar clinical manifestations in humans. The organism causes &lsquo;liver rot&rsquo; among sheep and cattle which are the definitive hosts; humans are incidental hosts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FASCIOLA HEPATICA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;F. hepatica occurs mainly in sheep-rearing areas of temperate climates, particularly in parts of Central and South America, Europe, China, Africa, and the Middle East [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/2\">",
"     2",
"    </a>",
"    ]. Sporadic cases have also been reported in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/1\">",
"     1",
"    </a>",
"    ]. An estimated 2.4 to 17 million people are infected in more than 51 countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/3\">",
"     3",
"    </a>",
"    ]; 91 million are at risk worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sheep and cattle are the most important definitive hosts of F. hepatica; goats, buffalo, horses, camels, hogs, deer, and rabbits can also be infected. Snails are intermediate hosts. Humans are incidental hosts and most often acquire infection by eating watercress grown in sheep-raising areas. Infection may be transmitted by other freshwater plants, including water lettuce, mint, alfalfa, and parsley. Humans can also acquire infection by drinking contaminated water containing viable metacercariae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/5\">",
"     5",
"    </a>",
"    ]; outbreaks have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/6\">",
"     6",
"    </a>",
"    ]. The incidence of animal and human infection rises during wet years because of an increased number of snails and longer survival of encysted cercariae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some areas, endemicity is almost 100 percent. In endemic regions very young children and women are most likely to be infected. There is a high incidence of co-infection with other parasites, especially echinococcosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Life cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The life cycle of fascioliasis begins with release of unembryonated eggs into the biliary ducts which are then passed in the stool of herbivores (definitive hosts) or humans (incidental hosts) (",
"    <a class=\"graphic graphic_figure graphicRef50779 \" href=\"mobipreview.htm?14/39/14968\">",
"     figure 1",
"    </a>",
"    ). Eggs become embryonated in water and release miracidia which invade a snail (intermediate host), where the parasites undergo several developmental stages (sporocysts, rediae, and cercariae). The cercariae are released and encyst as metacercariae on aquatic vegetation.&nbsp;",
"   </p>",
"   <p>",
"    Sheep, cattle, or humans acquire infection by eating vegetation containing metacercariae. After ingestion the metacercariae excyst in the duodenum and migrate through the intestinal wall, peritoneal cavity, and liver parenchyma into the biliary ducts, where they develop into adults; in humans this takes three to four months.&nbsp;The adult flukes reside in the large biliary ducts of the mammalian host.",
"   </p>",
"   <p>",
"    Migrating metacercariae cause liver parenchymal destruction, since tracks undergo necrosis and fibrosis. In addition, adult flukes can partially obstruct the bile ducts, causing thickening, dilatation, and fibrosis of the proximal biliary tree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/8\">",
"     8",
"    </a>",
"    ]. The amount of liver damage is correlated with the parasite load; the number of adult flukes that reach the biliary tree and develop to sexual maturity is usually small. The life span of adult F. hepatica flukes within humans is estimated to be 9 to 13 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many infections are mild; morbidity increases with fluke burden [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/9\">",
"     9",
"    </a>",
"    ]. Forms of infection include the acute (liver) phase, chronic (biliary) phase, ectopic fascioliasis, and pharyngeal fascioliasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Acute (liver) phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute symptoms usually begin within 6 to 12 weeks of metacercariae ingestion. The early phase of migration through the liver is often associated with fever, right upper quadrant pain, and hepatomegaly. Jaundice is occasionally observed. Other symptoms include anorexia, nausea, vomiting, myalgia, cough, and urticaria. Marked peripheral eosinophilia is almost always present. The acute phase can be complicated by hemobilia or subcapsular hematomas of the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/5\">",
"     5",
"    </a>",
"    ]. In most cases, acute symptoms generally resolve after about six weeks, although in very heavy infections extensive liver parenchymal necrosis can result.",
"   </p>",
"   <p>",
"    Extrahepatic symptoms may also occur during the acute phase, likely related to an immunologic or allergic mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/7\">",
"     7",
"    </a>",
"    ]. A Loeffler's&ndash;like syndrome or right-sided pleural effusion containing many eosinophils may be observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/2\">",
"     2",
"    </a>",
"    ]. Pericarditis, cardiac conduction abnormalities, meningeal symptoms, focal neurologic changes, or seizures have also been described, but are uncommon.",
"   </p>",
"   <p>",
"    In one review of patients with fascioliasis in developed countries (where fascioliasis is relatively uncommon), symptoms related to acute infection preceded the diagnosis for &ge;1 month in 73 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Chronic (biliary) phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic phase usually begins about six months after infection and may last ten years or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/10\">",
"     10",
"    </a>",
"    ]. This phase is usually asymptomatic, although epigastric and right upper quadrant pain, diarrhea, nausea, vomiting, wasting, hepatomegaly, and jaundice can occur. Common bile duct obstruction can develop, and chronic infection can lead to biliary colic, cholangitis, cholelithiasis, and obstructive jaundice. Secondary pancreatitis has been reported in up to 30 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Prolonged",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    heavy infection can also result in sclerosing cholangitis and biliary cirrhosis. Peripheral eosinophilia may or may not be present in the biliary phase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Ectopic fascioliasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrahepatic involvement may occur; it is unknown whether the parasites migrate to ectopic sites hematogenously or through soft tissues. Ectopic fascioliasis results in eosinophilic and mononuclear infiltration with secondary tissue damage. The most common ectopic site is the subcutaneous tissue of the abdominal wall. The lungs, heart, brain, muscle, genitourinary tract, skin, and the eye may also be affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Tender, migrating, erythematous, itchy nodules (1 to 6 cm in diameter) can develop; in some cases, these may result in localized abscesses. Generalized lymphadenopathy may also develop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pharyngeal fascioliasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharyngeal fascioliasis (&lsquo;halzoun&rsquo;) is a form of fascioliasis that occurs in the Middle East; it is acquired by consumption of raw liver of an infected animal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/15\">",
"     15",
"    </a>",
"    ]. The living fluke can attach to the upper respiratory or digestive tract, causing pharyngitis with edema and congestion; suffocation may result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of fascioliasis should be considered in patients with abdominal pain and hepatomegaly accompanied by peripheral eosinophilia. A careful dietary history should be obtained, including a history of watercress ingestion or consumption of raw vegetables washed in potentially contaminated water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is often a delay in diagnosis of fascioliasis. In one review, patients with hepatic phase fascioliasis had symptoms for 3 to 144 weeks before the diagnosis was made (mean 25 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/12\">",
"     12",
"    </a>",
"    ]. In patients with biliary phase fascioliasis, the delay was even longer (symptoms for 1 to 208 weeks; mean 64 weeks).",
"   </p>",
"   <p>",
"    The diagnosis can be established by identifying eggs in stool, duodenal aspirates, or bile specimens. Alternative approaches to diagnosis include identification of adult worms in endoscopic or surgical specimens, or serology. Imaging can be an adjunctive diagnostic tool. Additional diagnostic clues include anemia, abnormal liver function tests, elevated erythrocyte sedimentation rate (ESR), and hypergammaglobulinemia.",
"   </p>",
"   <p>",
"    Diagnosis of fascioliasis should prompt evaluation of family members. (See",
"    <a class=\"local\" href=\"#H3132174\">",
"     'Follow up'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis can be established by identifying eggs in stool, duodenal aspirates, or bile specimens. Eggs are not detectable in stool during the acute phase of infection or in the setting of ectopic fascioliasis. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Acute (liver) phase'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Ectopic fascioliasis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Eggs of Fasciola hepatica are oval, yellow-brown, and measure 130 to 150 micrometers long by 60 to 90 micrometers wide (",
"    <a class=\"graphic graphic_picture graphicRef70390 \" href=\"mobipreview.htm?41/63/42997\">",
"     picture 1",
"    </a>",
"    ).&nbsp;It can be difficult to distinguish between the eggs of F. hepatica, F. gigantica, and the intestinal fluke, Fasciolopsis buski. Specimen concentration facilitates egg identification. Examination of multiple specimens may be needed because egg excretion may be intermittent; negative stool examinations do not exclude the diagnosis.",
"   </p>",
"   <p>",
"    Stool examination may be negative during the acute phase or in the setting of ectopic fascioliasis. In such cases, the diagnosis may require serology or examination of surgical specimens following removal of the parasite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liver biopsy rarely demonstrates eggs or adult flukes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/18\">",
"     18",
"    </a>",
"    ]. Histopathologic changes that may suggest fascioliasis include Charcot-Leyden crystals, eosinophils, and multiple calcific foci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4733004\">",
"    <span class=\"h3\">",
"     Endoscopy or surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis may be made during surgery or endoscopy for biliary obstruction when adult flukes are found in the biliary tree. Laparoscopy may also demonstrate nodules in the liver capsule. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/6/42087?source=see_link\">",
"     \"Endoscopic diagnosis and management of biliary parasitosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The adult F. hepatica flukes are large, flat, brown, and leaf shaped, measuring approximately 30 mm by 15 mm; adult F. hepatica flukes measure up to 75 mm (",
"    <a class=\"graphic graphic_picture graphicRef65725 \" href=\"mobipreview.htm?6/62/7138\">",
"     picture 2",
"    </a>",
"    ). The broad, anterior portion is covered with scale-like spines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests using indirect hemagglutination, complement fixation, counterimmunoelectrophoresis, immunofluorescence assays, indirect hemagglutination, and enzyme-linked immunosorbent assay (ELISA). In general, these tests have good sensitivity, but many have suboptimal specificity and cross-react with other parasitic infections.",
"   </p>",
"   <p>",
"    ELISA-based assays, especially ones that use genus-specific antigens, have largely replaced other techniques because they are sensitive, rapid, and quantitative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. In a study among 634 Peruvian children with fascioliasis, the Fas2-ELISA (cathepsin L1-based antibody) had high sensitivity and specificity (92 and 84 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/24\">",
"     24",
"    </a>",
"    ]. The CDC recommends enzyme immunoassays (EIA) with excretory-secretory (ES) antigens combined with confirmation of positive results by immunoblot [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/25\">",
"     25",
"    </a>",
"    ]. Specific antibodies to Fasciola may be detectable two to four weeks following infection (which is five to seven weeks before eggs appear in stool). Successful treatment often correlates with a decline in ELISA titers, although antibodies may be detectable for years after infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An ELISA antigen capture technique that detects circulating antigens is available and has a reported sensitivity and specificity of 100 and 98 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/27\">",
"     27",
"    </a>",
"    ]. Antigen levels correlate with burden of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, the assay is diagnostic prior to the appearance of eggs in the stool, so is particularly useful for diagnosis during acute infection. The assay becomes negative in approximately 65 percent of patients one month after successful therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serology usually becomes positive during the early phase of migration through the liver; therefore, it is useful for diagnosing early symptoms prior to the appearance of eggs in the stool. It is also useful in ectopic disease, when eggs are not detectable in the stool. &nbsp;",
"   </p>",
"   <p>",
"    Serum or stool antigen tests may be able to detect the parasite a few weeks before ova appear in the specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Useful radiographic tools for fascioliasis include computed tomography (CT), ultrasonography, cholangiography, and endoscopic retrograde cholangiopancreatography (ERCP) and magnetic resonance imaging (MRI) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86430 \" href=\"mobipreview.htm?13/58/14249\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/33\">",
"     33",
"    </a>",
"    ]. A review of radiographic findings in fascioliasis noted that multiple small nodular and branching lesions were the most common findings; these frequently occur in the subcapsular area of the liver parenchyma. They appear hypoechoic on US, hypodense on CT, and T2 hyper- and T1 hypointense on MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT scanning of the liver may demonstrate characteristic hypodense nodules or tortuous tracks due to migration of the parasite through the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/2\">",
"     2",
"    </a>",
"    ]. Thickening of the liver capsule, subcapsular hematoma, or parenchymal calcifications may also be detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasonography, cholangiography, and ERCP are useful in the biliary stage of infection. These techniques may demonstrate mobile flukes in the bile ducts and gallbladder, often associated with stones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/36\">",
"     36",
"    </a>",
"    ]. Irregular thickening of the common bile duct wall may be observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of choice is triclabendazole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]; bithionol and nitazoxanide are alternative choices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/39\">",
"     39",
"    </a>",
"    ]. Triclabendazole is not yet widely available; in the United States it can be obtained through CDC, under an investigational protocol. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Triclabendazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triclabendazole is an imidazole derivative. It is effective against all stages of fascioliasis with a cure rate of &gt;90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/10,40\">",
"     10,40",
"    </a>",
"    ]; evidence is based on observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/23,41-46\">",
"     23,41-46",
"    </a>",
"    ]. Dosing consists of 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally for one or two days. The drug is relatively well tolerated; absorption is improved by postprandial administration.",
"   </p>",
"   <p>",
"    In one study of 40 Egyptian children with fascioliasis, triclabendazole (single dose) was curative in 78 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/41\">",
"     41",
"    </a>",
"    ]. The remaining children achieved cure after administration of a second dose. No side effects were observed.",
"   </p>",
"   <p>",
"    Cases of triclabendazole resistance in livestock have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Triclabendazole is not routinely available in the United States but is available through the CDC under an investigational protocol (telephone 1-404-718-4745 or email",
"    <a class=\"external\" href=\"file://parasites@cdc.gov/\">",
"     parasites@cdc.gov",
"    </a>",
"    ). It may also be obtained from Victoria Pharmacy in Zurich, Switzerland (www.pharmaworld.com) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Alternative agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative agents to triclabendazole for treatment of fascioliasis include bithionol and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence for bithionol is based on observational data. Reported cure rates vary from 50 to 90 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/7,49,50\">",
"       7,49,50",
"      </a>",
"      ]. Dosing consists of 30 to 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in three divided doses on alternate days for 10 to 15 doses. Side effects are common and include anorexia, nausea, abdominal pain, and pruritus. Bithionol is not routinely available in the United States, but may be obtained via the CDC or the Victoria Pharmacy (contact details above).",
"     </li>",
"     <li>",
"      Evidence for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5508?source=see_link\">",
"       nitazoxanide",
"      </a>",
"      is based on observational data and one trial of 65 Peruvian patients with fascioliasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. Nitazoxanide was well-tolerated and cure was achieved in 40 percent of children and 60 percent of adults who received nitazoxanide, compared with 6 percent in the placebo group (p&lt;0.05). Dosing consists of 500 mg twice daily for seven days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, F. hepatica responds poorly to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/42/12965?source=see_link\">",
"     Mebendazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    are not effective.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/54/4965?source=see_link\">",
"     Artesunate",
"    </a>",
"    is also not effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of ascending cholangitis requires antibiotics and surgery. Biliary obstruction may require ERCP and direct removal of the parasites if possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/36,37,54\">",
"     36,37,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/6/42087?source=see_link\">",
"     \"Endoscopic diagnosis and management of biliary parasitosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3132174\">",
"    <span class=\"h3\">",
"     Follow up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up after therapy should include monitoring for resolution of eosinophilia, clearance of eggs in stool, and a decrease in serology titers. It is reasonable to repeat all tests that were initially positive at three months. Resolution of biliary tract findings on ultrasound after therapy may also be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis of fascioliasis should prompt screening of family members with serology (stool microscopy is not generally helpful since eggs are often absent early in infection). Asymptomatic patients should be treated to avoid the risk of future complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection can be prevented by avoiding ingestion of raw freshwater plants in endemic areas. Elimination of the snail intermediate hosts has also been attempted by molluscicide application and pasture drainage, but, in general, is not practical.",
"   </p>",
"   <p>",
"    Vaccine studies in animal models have shown reduction in worm burdens and egg production of approximately 70 percent; no vaccines are available for human use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     FASCIOLA GIGANTICA",
"    </span>",
"    &nbsp;&mdash;&nbsp;F. gigantica is closely related to F. hepatica. It infects domestic livestock in tropical and subtropical areas, particularly in Africa, the Western Pacific, Hawaii, and Southeast Asia. Herbivorous mammals are the definitive hosts and snails (genus Lymnaea) are the intermediate hosts; humans are incidental hosts.",
"   </p>",
"   <p>",
"    F. gigantica has a similar life cycle and pathology to F. hepatica and also causes similar clinical manifestations in the acute (liver) phase, in the chronic (biliary) phase, and in ectopic sites. The eggs (190 by 90 microns) and the adult worms (up to 7.5 cm) are larger than F. hepatica.",
"   </p>",
"   <p>",
"    Diagnosis of F. gigantica can be challenging. Eggs are often not detected in the stool and serodiagnosis is often inconclusive. Two reports have suggested that specific antigens of F. gigantica can be detected by indirect ELISA or immunoblot with good sensitivity and specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. A PCR-restriction fragment length polymorphism (RFLP) assay has been used to distinguish between Fasciola hepatica and Fasciola gigantica, but is not widely available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31735/abstract/59\">",
"     59",
"    </a>",
"    ]. Until diagnostic techniques improve, recovery of adult flukes in the appropriate epidemiologic setting can be used to exclude or confirm the diagnosis.",
"   </p>",
"   <p>",
"    Treatment and preventive measures are the same as for F. hepatica.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3132407\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fascioliasis is a trematode flatworm infection caused by F. hepatica or F. gigantica. F. hepatica has a worldwide distribution; F. gigantica occurs predominantly in the tropics. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Herbivorous mammals are the definitive hosts, snails are intermediate hosts, and humans are incidental hosts (",
"      <a class=\"graphic graphic_figure graphicRef50779 \" href=\"mobipreview.htm?14/39/14968\">",
"       figure 1",
"      </a>",
"      ). Sheep, cattle, or humans acquire infection by eating aquatic vegetation containing metacercariae, which excyst in the duodenum and migrate through the intestinal wall, peritoneal cavity and liver parenchyma into the biliary ducts, where they develop into adults. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Life cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many infections are mild; morbidity increases with fluke burden. The acute (liver) phase of migration is often associated with fever, right upper quadrant pain, and hepatomegaly. Jaundice is occasionally observed. Other symptoms include anorexia, nausea, vomiting, myalgia, cough, and urticaria. Marked peripheral eosinophilia is frequently present. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Acute (liver) phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The chronic (biliary) phase usually begins about six months after infection and may last ten years or more. This phase is usually asymptomatic, although epigastric and right upper quadrant pain, diarrhea, nausea, vomiting, wasting, hepatomegaly, and jaundice can occur. Common bile duct obstruction can develop, and chronic infection can lead to biliary colic, cholangitis, cholelithiasis, pancreatitis, and obstructive jaundice. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Chronic (biliary) phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis can be established by identifying eggs in stool, duodenal aspirates, or bile specimens (",
"      <a class=\"graphic graphic_picture graphicRef70390 \" href=\"mobipreview.htm?41/63/42997\">",
"       picture 1",
"      </a>",
"      ). Alternative approaches to diagnosis include identification of adult worms in endoscopic or surgical specimens, or serology. Imaging can be a helpful adjunctive diagnostic tool. Additional diagnostic clues include eosinophilia, abnormal liver function tests, and anemia (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest triclabendazole for treatment of fascioliasis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); bithionol and nitazoxanide are alternative choices. Dosing is outlined above. Management of ascending cholangitis requires antibiotics and surgery. Biliary obstruction may require endoscopic retrograde cholangiopancreatography, and direct removal of the parasites if possible. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/1\">",
"      Mas-Coma S. Epidemiology of fascioliasis in human endemic areas. J Helminthol 2005; 79:207.",
"     </a>",
"    </li>",
"    <li>",
"     Maclean JD, Cross J, Mahanty S. Liver, lung, and intestinal fluke infections. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd ed, Guerrant RL, Walker DH, Weller PF (Eds), Churchill Livingstone, Philadelphia 2006. p.854.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/3\">",
"      Mas-Coma S, Valero MA, Bargues MD. Chapter 2. Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control. Adv Parasitol 2009; 69:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/4\">",
"      Keiser J, Utzinger J. Food-borne trematodiases. Clin Microbiol Rev 2009; 22:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/5\">",
"      Chan CW, Lam SK. Diseases caused by liver flukes and cholangiocarcinoma. Baillieres Clin Gastroenterol 1987; 1:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/6\">",
"      Bjorland J, Bryan RT, Strauss W, et al. An outbreak of acute fascioliasis among Aymara Indians in the Bolivian Altiplano. Clin Infect Dis 1995; 21:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/7\">",
"      Arjona R, Riancho JA, Aguado JM, et al. Fascioliasis in developed countries: a review of classic and aberrant forms of the disease. Medicine (Baltimore) 1995; 74:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/8\">",
"      Harinasuta T, Pungpak S, Keystone JS. Trematode infections. Opisthorchiasis, clonorchiasis, fascioliasis, and paragonimiasis. Infect Dis Clin North Am 1993; 7:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/9\">",
"      Adachi S, Kotani K, Shimizu T, et al. Asymptomatic fascioliasis. Intern Med 2005; 44:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/10\">",
"      Marcos LA, Terashima A, Gotuzzo E. Update on hepatobiliary flukes: fascioliasis, opisthorchiasis and clonorchiasis. Curr Opin Infect Dis 2008; 21:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/11\">",
"      Sezgn O, Altinta E, Tombak A, U&ccedil;blek E. Fasciola hepatica-induced acute pancreatitis: report of two cases and review of the literature. Turk J Gastroenterol 2010; 21:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/12\">",
"      Kaya M, Beta R, Cetin S. Clinical presentation and management of Fasciola hepatica infection: single-center experience. World J Gastroenterol 2011; 17:4899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/13\">",
"      Xuan le T, Hung NT, Waikagul J. Cutaneous fascioliasis: a case report in Vietnam. Am J Trop Med Hyg 2005; 72:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/14\">",
"      Dalimi A, Jabarvand M. Fasciola hepatica in the human eye. Trans R Soc Trop Med Hyg 2005; 99:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/15\">",
"      Saleha AA. Liver fluke disease (fascioliasis): epidemiology, economic impact and public health significance. Southeast Asian J Trop Med Public Health 1991; 22 Suppl:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/16\">",
"      el-Shabrawi M, el-Karaksy H, Okasha S, el-Hennawy A. Human fascioliasis: clinical features and diagnostic difficulties in Egyptian children. J Trop Pediatr 1997; 43:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/17\">",
"      Prociv P, Walker JC, Whitby M. Human ectopic fascioliasis in Australia: first case reports. Med J Aust 1992; 156:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/18\">",
"      Price TA, Tuazon CU, Simon GL. Fascioliasis: case reports and review. Clin Infect Dis 1993; 17:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/19\">",
"      Acosta-Ferreira W, Vercelli-Retta J, Falconi LM. Fasciola hepatica human infection. Histopathological study of sixteen cases. Virchows Arch A Pathol Anat Histol 1979; 383:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/20\">",
"      Hillyer GV, Soler de Galanes M, Rodriguez-Perez J, et al. Use of the Falcon assay screening test--enzyme-linked immunosorbent assay (FAST-ELISA) and the enzyme-linked immunoelectrotransfer blot (EITB) to determine the prevalence of human fascioliasis in the Bolivian Altiplano. Am J Trop Med Hyg 1992; 46:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/21\">",
"      Espino AM, Finlay CM. Sandwich enzyme-linked immunosorbent assay for detection of excretory secretory antigens in humans with fascioliasis. J Clin Microbiol 1994; 32:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/22\">",
"      Mansour WA, Kaddah MA, Shaker ZA, et al. A monoclonal antibody diagnoses active Fasciola infection in humans. J Egypt Soc Parasitol 1998; 28:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/23\">",
"      Apt W, Aguilera X, Vega F, et al. Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. Am J Trop Med Hyg 1995; 52:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/24\">",
"      Espinoza JR, Maco V, Marcos L, et al. Evaluation of Fas2-ELISA for the serological detection of Fasciola hepatica infection in humans. Am J Trop Med Hyg 2007; 76:977.",
"     </a>",
"    </li>",
"    <li>",
"     CDC - Fascioliasis file://dpd.cdc.gov/dpdx/HTML/Fascioliasis.htm (Accessed on January 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/26\">",
"      Santiago N, Hillyer GV. Antibody profiles by EITB and ELISA of cattle and sheep infected with Fasciola hepatica. J Parasitol 1988; 74:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/27\">",
"      Shaheen HI, Kamal KA, Farid Z, et al. Dot-enzyme-linked immunosorbent assay (dot-ELISA) for the rapid diagnosis of human fascioliasis. J Parasitol 1989; 75:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/28\">",
"      Hassan MM, Saad M, Hegab MH, Metwally S. Evaluation of circulating Fasciola antigens in specific diagnosis of fascioliasis. J Egypt Soc Parasitol 2001; 31:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/29\">",
"      Shehab AY, Hassan EM, Basha LM, et al. Detection of circulating E/S antigens in the sera of patients with fascioliasis by IELISA: a tool of serodiagnosis and assessment of cure. Trop Med Int Health 1999; 4:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/30\">",
"      Hammouda NA, el Mansoury ST, el Azzouni MZ, Hussein ED. Detection of circulating antigens in blood to evaluate treatment of fascioliasis. J Egypt Soc Parasitol 1997; 27:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/31\">",
"      Jones EA, Kay JM, Milligan HP, Owens D. Massive infection with Fasciola hepatica in man. Am J Med 1977; 63:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/32\">",
"      Espino AM, D&iacute;az A, P&eacute;rez A, Finlay CM. Dynamics of antigenemia and coproantigens during a human Fasciola hepatica outbreak. J Clin Microbiol 1998; 36:2723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/33\">",
"      Cevikol C, Karaali K, Senol U, et al. Human fascioliasis: MR imaging findings of hepatic lesions. Eur Radiol 2003; 13:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/34\">",
"      Ko&ccedil; Z, Ulusan S, Tokmak N. Hepatobiliary fascioliasis: imaging characteristics with a new finding. Diagn Interv Radiol 2009; 15:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/35\">",
"      Van Beers B, Pringot J, Geubel A, et al. Hepatobiliary fascioliasis: noninvasive imaging findings. Radiology 1990; 174:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/36\">",
"      Sezgin O, Altinta E, Diibeyaz S, et al. Hepatobiliary fascioliasis: clinical and radiologic features and endoscopic management. J Clin Gastroenterol 2004; 38:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/37\">",
"      Dias LM, Silva R, Viana HL, et al. Biliary fascioliasis: diagnosis, treatment and follow-up by ERCP. Gastrointest Endosc 1996; 43:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/38\">",
"      Keiser J, Utzinger J. Chemotherapy for major food-borne trematodes: a review. Expert Opin Pharmacother 2004; 5:1711.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for Parasitic Infections, Medical Letter, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/40\">",
"      Marcos LA, Tagle M, Terashima A, et al. Natural history, clinicoradiologic correlates, and response to triclabendazole in acute massive fascioliasis. Am J Trop Med Hyg 2008; 78:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/41\">",
"      el-Karaksy H, Hassanein B, Okasha S, et al. Human fascioliasis in Egyptian children: successful treatment with triclabendazole. J Trop Pediatr 1999; 45:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/42\">",
"      Hammouda NA, el-Mansoury ST, el-Azzouni MZ, el-Gohari Y. Therapeutic effect of triclabendazole in patients with fascioliasis in Egypt. A preliminary study. J Egypt Soc Parasitol 1995; 25:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/43\">",
"      Laird PP, Boray JC. Human fascioliasis successfully treated with triclabendazole. Aust N Z J Med 1992; 22:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/44\">",
"      Graham CS, Brodie SB, Weller PF. Imported Fasciola hepatica infection in the United States and treatment with triclabendazole. Clin Infect Dis 2001; 33:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/45\">",
"      Picot S, Querrec M, Ghez JL, et al. A new report of triclabendazole efficacy during invading phase fasciolasis. Eur J Clin Microbiol Infect Dis 1992; 11:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/46\">",
"      Calvopi&ntilde;a M, Guderian RH, Paredes W, et al. Treatment of human pulmonary paragonimiasis with triclabendazole: clinical tolerance and drug efficacy. Trans R Soc Trop Med Hyg 1998; 92:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/47\">",
"      Fairweather I. Triclabendazole progress report, 2005-2009: an advancement of learning? J Helminthol 2009; 83:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/48\">",
"      Garcia HH, Moro PL, Schantz PM. Zoonotic helminth infections of humans: echinococcosis, cysticercosis and fascioliasis. Curr Opin Infect Dis 2007; 20:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/49\">",
"      Bacq Y, Besnier JM, Duong TH, et al. Successful treatment of acute fascioliasis with bithionol. Hepatology 1991; 14:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/50\">",
"      Farag HF, Salem A, el-Hifni SA, Kandil M. Bithionol (Bitin) treatment in established fascioliasis in Egyptians. J Trop Med Hyg 1988; 91:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/51\">",
"      Rossignol JF, Abaza H, Friedman H. Successful treatment of human fascioliasis with nitazoxanide. Trans R Soc Trop Med Hyg 1998; 92:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/52\">",
"      Favennec L, Jave Ortiz J, Gargala G, et al. Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment Pharmacol Ther 2003; 17:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/53\">",
"      Hien TT, Truong NT, Minh NH, et al. A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam. Am J Trop Med Hyg 2008; 78:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/54\">",
"      Danilewitz M, Kotfila R, Jensen P. Endoscopic diagnosis and management of Fasciola hepatica causing biliary obstruction. Am J Gastroenterol 1996; 91:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/55\">",
"      Richter J, Freise S, Mull R, Mill&aacute;n JC. Fascioliasis: sonographic abnormalities of the biliary tract and evolution after treatment with triclabendazole. Trop Med Int Health 1999; 4:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/56\">",
"      Spithill TW, Piedrafita D, Smooker PM. Immunological approaches for the control of fasciolosis. Int J Parasitol 1997; 27:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/57\">",
"      Maleewong W, Wongkham C, Intapan PM, Pipitgool V. Fasciola gigantica-specific antigens: purification by a continuous-elution method and its evaluation for the diagnosis of human fascioliasis. Am J Trop Med Hyg 1999; 61:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/58\">",
"      Intapan PM, Maleewong W, Wongkham C, et al. Excretory-secretory antigenic components of adult Fasciola gigantica recognized by infected human sera. Southeast Asian J Trop Med Public Health 1998; 29:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31735/abstract/59\">",
"      Marcilla A, Bargues MD, Mas-Coma S. A PCR-RFLP assay for the distinction between Fasciola hepatica and Fasciola gigantica. Mol Cell Probes 2002; 16:327.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5676 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_63_31735=[""].join("\n");
var outline_f30_63_31735=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3132407\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FASCIOLA HEPATICA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Acute (liver) phase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Chronic (biliary) phase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Ectopic fascioliasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pharyngeal fascioliasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Microscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4733004\">",
"      - Endoscopy or surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Triclabendazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Alternative agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3132174\">",
"      - Follow up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      FASCIOLA GIGANTICA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3132407\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5676\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5676|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?13/58/14249\" title=\"diagnostic image 1\">",
"      CT scan fasciola hepatica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5676|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/39/14968\" title=\"figure 1\">",
"      Fascioliasis life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5676|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/63/42997\" title=\"picture 1\">",
"      Fasciolopsiasis egg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/62/7138\" title=\"picture 2\">",
"      Fasciola hepatica adult",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24790?source=related_link\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/6/42087?source=related_link\">",
"      Endoscopic diagnosis and management of biliary parasitosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_63_31736="Calcium channel blocker poisoning";
var content_f30_63_31736=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Calcium channel blocker poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/63/31736/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31736/contributors\">",
"     Fermin Barrueto, Jr, MD, FACEP, FAAEM, FACMT",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/63/31736/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31736/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/63/31736/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31736/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/63/31736/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers (CCBs) are used in the treatment of hypertension, angina pectoris, cardiac arrhythmias, and other disorders. These medications are available in both immediate-release and extended-release preparations; the latter are in wide clinical use (",
"    <a class=\"graphic graphic_figure graphicRef51498 \" href=\"mobipreview.htm?12/47/13054\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential toxicity of these agents is substantial, and is often under appreciated by the public. As an example, over 9500 cases of CCB intoxication, caused by intentional or unintentional overdosage, were reported to poison centers in the United States during 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/2\">",
"     2",
"    </a>",
"    ]. Although only 16 percent of all cardiovascular drug exposures were due to CCBs, this class accounted for 38 percent of deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of CCB intoxication will be reviewed here. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef63193 \" href=\"mobipreview.htm?32/31/33277\">",
"     table 1",
"    </a>",
"    ). An overview of the major side effects of CCBs is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32966?source=see_link\">",
"     \"Major side effects and safety of calcium channel blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcium channel blockers (CCBs) can be divided into two major categories based upon their predominant physiologic effects: the dihydropyridines, which preferentially block the L-type calcium channels in the vasculature; and the nondihydropyridines, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , which selectively block L-type calcium channels in the myocardium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The L-type calcium channels are responsible for myocardial contractility and vascular smooth muscle contractility; they also affect conducting and pacemaker cells. The dihydropyridines (including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22295?source=see_link\">",
"     nisoldipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/56/903?source=see_link\">",
"     isradipine",
"    </a>",
"    , and lacidipine) are potent vasodilators that have little negative effect upon cardiac contractility or conduction at standard doses. In contrast,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and, to a lesser extent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    are weak vasodilators, but have a depressive effect on cardiac conduction and contractility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dihydropyridine intoxication generally results in arterial vasodilation and reflex tachycardia, whereas",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    toxicity cause peripheral vasodilation, decreased cardiac inotropy, and bradycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/4\">",
"     4",
"    </a>",
"    ]. However, as the dose is increased, this selectivity can be lost, and dihydropyridine CCBs (including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ) may affect the myocardium and conducting system like verapamil and diltiazem (ie, decreased inotropy and bradycardia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most CCBs are highly protein bound, have a large volume of distribution, and are metabolized in the liver. As the dose is increased, the rate of CCB clearance decreases, prolonging the half-life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/5\">",
"     5",
"    </a>",
"    ]. Extended-release preparations slowly release the drug from a matrix to facilitate once-daily dosing. In overdose, this property makes absorption unpredictable, and prolongs the duration of toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever possible, determine the time of ingestion, as well as the type, amount, and preparation (immediate or sustained release) of drug ingested. The identity of the drug ingested will help predict toxicity, and the type of preparation will help determine the appropriate approach to gastrointestinal decontamination. Patients ingesting more than 5 to 10 times the usual dose can develop signs of severe intoxication.",
"   </p>",
"   <p>",
"    It is important to clarify whether the ingestion was accidental or intentional, and to assess the patient for suicidality; however, this determination is often made after resolution of the acute episode. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=see_link\">",
"     \"Suicidal ideation and behavior in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vital sign abnormalities include hypotension, which may be seen in any calcium channel blocker (CCB) overdose, and bradycardia, which usually is seen only in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    overdose. However, bradycardia may also be seen with severe dihydropyridine (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ) poisoning. Jugular venous distension, pulmonary crackles, and other signs of heart failure may be noted in some cases. Despite hypotension, CCB-poisoned patients may maintain a surprisingly clear mental status, possibly due to the neuroprotective effects of CCBs. However, neurologic status may deteriorate precipitously once cerebral perfusion becomes critically limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An electrocardiogram (ECG) should be obtained in patients with known or suspected calcium channel blocker (CCB) intoxication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/6\">",
"     6",
"    </a>",
"    ]. ECG changes associated with CCB intoxication include PR interval prolongation and any bradydysrhythmia. A finger stick blood glucose measurement may reveal hyperglycemia, which is caused by inhibition of calcium-mediated insulin release; however, this elevation is rarely clinically significant, except for diagnostic purposes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The presence of hyperglycemia in a non-diabetic patient may help to distinguish CCB from beta blocker poisoning. Serum toxicology can confirm coingestion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or salicylates, which should be excluded in suicidal patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum electrolytes, blood urea nitrogen (BUN), creatinine, calcium, and glucose concentrations should be assessed. A chest radiograph should be obtained if there are any signs of pulmonary edema, hypoxia, or respiratory distress. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11744693\">",
"    <span class=\"h2\">",
"     Initial resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulation is the main focus of the treatment of calcium channel blockers (CCB) exposures. Hypotension and bradycardia can be profound and refractory even to maximal treatment. Intravenous fluids are the initial therapy for hypotension, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    the initial treatment for bradycardia, but both may be insufficient.",
"   </p>",
"   <p>",
"    CCB-poisoned patients may maintain a clear mental status despite hypotension and bradycardia. However, clinicians need to reassess these patients",
"    <strong>",
"     frequently",
"    </strong>",
"    , as precipitous deterioration is common, and many will eventually require intubation and mechanical ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11744580\">",
"    <span class=\"h2\">",
"     Approach to the selection of specific therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is ideal to institute treatments individually to assess their success or failure, this is often not possible in patients who are severely poisoned with calcium channel blockers (CCBs), especially",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    . These patients are frequently moribund on presentation, but even when initially well-appearing may deteriorate rapidly and disastrously. Our suggested approaches to therapy, based upon the severity of clinical signs, are described below; a summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef63193 \" href=\"mobipreview.htm?32/31/33277\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11744587\">",
"    <span class=\"h3\">",
"     Severely symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our suggested approach to patients manifesting signs of severe CCB poisoning (profound hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bradycardia) consists of multiple",
"    <strong>",
"     simultaneous",
"    </strong>",
"    interventions, including",
"    <strong>",
"     all",
"    </strong>",
"    of the following treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stabilization of the airway as necessary (avoid induction agents that exacerbate hypotension)",
"     </li>",
"     <li>",
"      Additional IV boluses of isotonic crystalloid",
"     </li>",
"     <li>",
"      IV calcium salts",
"     </li>",
"     <li>",
"      IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"     </li>",
"     <li>",
"      IV high-dose insulin and glucose",
"     </li>",
"     <li>",
"      IV vasopressor (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/28/16838?source=see_link\">",
"       norepinephrine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      IV lipid emulsion therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dosing for each of these therapies is provided below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Specific therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11744630\">",
"    <span class=\"h3\">",
"     Mildly symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our suggested approach to patients with mild hypotension or bradycardia begins with IV boluses of isotonic crystalloid and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    respectively. However, these therapies often do not reverse the cardiotoxic effects of CCB poisoning. In such cases, we add the following treatments in succession based upon patient response. As an example, we begin treatment with a calcium salt if IV crystalloid is ineffective, but if hypotension resolves following treatment with a calcium salt, we do",
"    <strong>",
"     not",
"    </strong>",
"    proceed to IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    or any other treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IV boluses of isotonic crystalloid",
"     </li>",
"     <li>",
"      IV calcium salts",
"     </li>",
"     <li>",
"      IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"     </li>",
"     <li>",
"      IV high-dose insulin and glucose",
"     </li>",
"     <li>",
"      IV vasopressor (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/28/16838?source=see_link\">",
"       norepinephrine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      IV lipid emulsion therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A period of 15 minutes is reasonable to determine the effectiveness of a specific therapy before proceeding to the next treatment. Dosing for each of these therapies is provided below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Specific therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11744713\">",
"    <span class=\"h3\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with an isolated CCB overdose remain asymptomatic (primarily those with dihydropyridine (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ) poisoning) and may be discharged after a period of observation, unless the overdose was intentional. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Disposition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gastrointestinal decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orogastric lavage may be necessary in patients who present within one to two hours of a potentially dangerous ingestion. Vagal stimulation from orogastric lavage may exacerbate CCB-induced hypotension and bradycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    (AC) should be administered to patients with CCB overdose, even if they are asymptomatic. AC is maximally effective if administered within one hour of ingestion, but patients with delayed presentation after CCB exposure may still benefit. Charcoal should be withheld in patients with a depressed mental status who may not be able to protect their airway, unless endotracheal intubation is performed first. AC is given as a single dose of 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    for children up to the adult dose of 50 grams. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=see_link\">",
"     \"Enhanced elimination of poisons\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whole bowel irrigation (WBI) may be implemented if a sustained-release or extended-release preparation has been used or is strongly suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/11\">",
"     11",
"    </a>",
"    ]. If the history is in doubt, WBI may be delayed until the patient develops signs or symptoms of toxicity. If the ingestion is certain, particularly if the drug is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , WBI should be started even in the asymptomatic patient. Whole bowel irrigation involves the administration of",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/17/4374?source=see_link\">",
"      polyethylene glycol",
"     </a>",
"     /electrolyte",
"    </span>",
"    lavage solution by mouth at a rate of 2 L per hour for adults (up to 500 mL per hour in children) until the rectal effluent is clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=see_link&amp;anchor=H18993876#H18993876\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Whole bowel irrigation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Specific therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Atropine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    should be administered to any patient with symptomatic bradycardia; however, it is often ineffective after significant CCB exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/14\">",
"     14",
"    </a>",
"    ]. Atropine is administered in a dose of 0.5 to 1.0 mg intravenously every two to three minutes to a maximum of 3 mg. Pediatric dosing is 0.02",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously, with a minimum dose of 0.1 mg to avoid the paradoxical bradycardia that may result from very small doses of this medication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15738?source=see_link&amp;anchor=H14#H14\">",
"     \"Primary drugs in pediatric resuscitation\", section on 'Atropine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Intravenous calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium salts are often used to overcome the cardiovascular effects of CCBs. However, treatment with calcium salts is often ineffective. This is because CCB poisoning interferes with both the serum concentration and the intracellular handling of calcium.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=see_link\">",
"     Calcium gluconate",
"    </a>",
"    may be administered via peripheral or central venous access;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15799?source=see_link\">",
"     calcium chloride",
"    </a>",
"    is more irritating, and should be administered via central venous access, if at all possible. In adults, calcium chloride, 10 to 20 mL of a 10 percent solution, can be administered over 10 minutes; if no effect is noted, the dose can be repeated up to four times approximately every 20 minutes. If calcium gluconate is used, the dose must be adjusted (30 to 60 mL of 10 percent calcium gluconate), as calcium gluconate has only one third the calcium of calcium chloride [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A high-dose continuous infusion of calcium has been used anecdotally with success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]; we believe a reasonable infusion is 0.5 meq of",
"    <span class=\"nowrap\">",
"     calcium/kg",
"    </span>",
"    per hour (or 0.2 to 0.4",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour of 10 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15799?source=see_link\">",
"     calcium chloride",
"    </a>",
"    ; or 0.6 to 1.2",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour of 10 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    ). Close monitoring of the serum or ionized calcium concentration (measurements every two hours) and serial ECGs is necessary to avoid clinically significant hypercalcemia, which is reported with intensive calcium therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Glucagon",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"     Glucagon",
"    </a>",
"    increases intracellular levels of cyclic AMP and, in animal models, has been shown to increase heart rate in calcium channel blocker toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/20\">",
"     20",
"    </a>",
"    ]. However, it has minimal effects on the mean arterial pressure. Glucagon has been effective in treating human cases of CCB toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dosing regimen for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    in the treatment of CCB has not been established in human clinical trials. For the adult patient, an initial 5 mg intravenous bolus is a reasonable start, and may be repeated twice at 10 minute intervals. A glucagon infusion can be started at the total dose at which a response is noted. Nausea and vomiting are common side effects of this medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Vasopressors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal vasopressor in CCB poisoning would be a direct-acting agent with positive inotropy, positive chronotropy, and vasoconstrictive effects.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/28/16838?source=see_link\">",
"     Norepinephrine",
"    </a>",
"    is the initial vasopressor of choice. Invasive hemodynamic monitoring (with a pulmonary artery catheter) or echocardiography may point to a selective failure of inotropy or vascular resistance, thus helping to refine the choice of catecholamine and the titration rate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with profound CCB toxicity may require higher doses of vasopressors than those typically used in the treatment of severe sepsis or other causes of shock. However, the drugs&rsquo; arrhythmogenic effects become more prominent at higher doses and may limit their use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Insulin and glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose insulin therapy has positive inotropic effects in patients with CCB toxicity. Its effectiveness and safety have been noted in animal models and an increasing number of case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/24-27\">",
"     24-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relative hypoglycemia and hypokalemia must be corrected prior to initiating high-dose insulin therapy. For patients with a serum glucose concentration below 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.25",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    we administer 50 mL of 50 percent dextrose (D50W) intravenously (IV). In young children the initial dose of dextrose is 0.25",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    body weight, usually given as 2.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of 10 percent dextrose solution. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8201?source=see_link&amp;anchor=H12#H12\">",
"     \"Approach to hypoglycemia in infants and children\", section on 'Clinical management'",
"    </a>",
"    .) For patients with a serum potassium concentration below 3",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (3",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    we administer 20 mEq of potassium IV.",
"   </p>",
"   <p>",
"    We initiate high-dose insulin therapy with a bolus of 1",
"    <span class=\"nowrap\">",
"     Unit/kg",
"    </span>",
"    of regular, short-acting insulin given IV. Following this bolus, we begin a continuous infusion at 0.5",
"    <span class=\"nowrap\">",
"     Units/kg",
"    </span>",
"    per hour IV and titrate upwards until hypotension is corrected or a maximum dose of 2",
"    <span class=\"nowrap\">",
"     Units/kg",
"    </span>",
"    is reached. One approach is to increase the infusion rate by 50 percent every 20 minutes until either target is met.",
"   </p>",
"   <p>",
"    CCB overdose often causes hyperglycemia that is refractory to high dose insulin. Therefore, not all patients require supplemental dextrose. Nevertheless, if necessary, euglycemia can be maintained by means of a continuous IV infusion of 5 to 10 percent dextrose. A reasonable initial rate for such an infusion is 0.5 to 1 g of",
"    <span class=\"nowrap\">",
"     dextrose/kg",
"    </span>",
"    per hour. Titration of the dextrose infusion and additional boluses of 50 percent dextrose are provided based upon serum glucose measurements (finger stick glucose), which are obtained every 15 to 30 minutes until the concentration is stable, and every hour thereafter until several hours after therapy is complete.",
"   </p>",
"   <p>",
"    The serum potassium concentration is measured every 30 minutes until it is stable, and every one to two hours thereafter. Supplementation is given as necessary to maintain a potassium concentration in the low normal range. Magnesium replacement is often needed in hypokalemic patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=see_link\">",
"     \"Clinical manifestations and treatment of hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A hemodynamic response to high-dose insulin therapy is delayed for 30 to 60 minutes, therefore simultaneous implementation of other therapies to support the patient's pulse and blood pressure are generally required.",
"   </p>",
"   <p>",
"    Animal studies of CCB toxicity have shown improved survival associated with",
"    <span class=\"nowrap\">",
"     hyperinsulinemia/euglycemia",
"    </span>",
"    therapy compared with calcium, epinephrine, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/24,28\">",
"     24,28",
"    </a>",
"    ]. Clinical experience with this approach is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]; in one case series of four",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    -poisoned patients,",
"    <span class=\"nowrap\">",
"     hyperinsulinemia/euglycemia",
"    </span>",
"    therapy improved blood pressure and ejection fraction without changing heart rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/26\">",
"     26",
"    </a>",
"    ]. High-dose insulin therapy is also used in beta blocker poisoning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/19/33081?source=see_link\">",
"     \"Beta blocker poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism by which hyperinsulinemia-euglycemia therapy works remains unclear, though there are several theories. Though the mechanism is not completely understood, CCBs appear to disrupt fatty acid metabolism and create relative insulin resistance within the myocardium. This state of carbohydrate dependence and insulin resistance can theoretically be overcome with high-dose insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In addition, calcium is needed to facilitate exocytosis of insulin from the &szlig;-islet cells of the pancreas. CCBs block the influx of calcium and prevent insulin release from the &szlig;-islet cells. High-dose insulin therapy is thought to compensate for this impaired secretion of&nbsp;insulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6162826\">",
"    <span class=\"h3\">",
"     Lipid emulsion therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid emulsions are the fats used in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN). Initially used to treat overdoses of local anesthetics, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    , intravenous lipid emulsion (ILE) is being studied as a therapy for poisonings involving a number of lipophilic medications. Studies of ILE therapy are preliminary. A systematic review of lipid emulsion therapy for acute poisoning found the overall quality of studies supporting this treatment to be weak but found evidence of benefit in patients with toxicity from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , beta blockers, some tricyclic antidepressants, bupivacaine, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/31\">",
"     31",
"    </a>",
"    ]. ILE may have a useful role in the treatment of patients who are hemodynamically unstable from such poisonings.",
"   </p>",
"   <p>",
"    We suggest consultation with a medical toxicologist or poison control center to determine whether ILE therapy is appropriate. The dosing protocol most widely reported consists of an intravenous bolus of 1 to 1.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    given over one minute of a 20 percent lipid emulsion solution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. If there is no response, the same dose may be repeated in cases of cardiac arrest every three to five minutes, for a total of three bolus doses. Following the initial bolus, an infusion is started at a rate of 0.25 to 0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per minute until hemodynamic recovery occurs. The infusion is generally maintained for 30 to 60 minutes. The infusion rate may be increased if the patient&rsquo;s blood pressure drops. Potential adverse effects from ILE include hypertriglyceridemia, fat embolism, infection, and hypersensitivity reactions.",
"   </p>",
"   <p>",
"    ILE therapy interferes with some laboratory measurements and therapeutic drug monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/35\">",
"     35",
"    </a>",
"    ]. As examples, serum glucose concentrations when determined by colorimetric testing and serum magnesium concentrations become inaccurate following the administration of ILE, while creatinine and lipase become unmeasurable. Potassium and troponin-I are not affected. Centrifugation of blood samples substantially reduces any interference.",
"   </p>",
"   <p>",
"    Two mechanisms are believed to account for the effectiveness of ILE. The first is that the emulsion acts as a &ldquo;lipid sink,&rdquo; surrounding a lipophilic drug molecule and rendering it ineffective. The second is that the fatty acids from the ILE provide the myocardium with a ready energy source, thereby improving cardiac function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Phosphodiesterase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphodiesterases inhibitors, such as inamrinone (formerly known as amrinone) increase cyclic AMP levels by preventing intracellular degradation of cyclic AMP. Although there are reports of successful treatment with inamrinone in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    poisoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/36\">",
"     36",
"    </a>",
"    ], phosphodiesterases inhibitors may exacerbate hypotension and should NOT be used routinely. We recommend that inamrinone not be considered unless therapy with a readily titratable vasopressor has been instituted, and a pulmonary artery catheter is in place to help guide management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7156442\">",
"    <span class=\"h3\">",
"     Other proposed treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some have proposed levosimendan as a treatment for CCB poisoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/37\">",
"     37",
"    </a>",
"    ]. However, studies of levosimendan are limited and we do",
"    <strong>",
"     not",
"    </strong>",
"    recommend its use for this purpose. Levosimendan sensitizes the calcium channels and promotes the influx of calcium into the cell. Theoretically this would appear beneficial in a calcium channel blocker overdose, but results from animal models are conflicting and the drug has some phosphodiesterase activity which may exacerbate hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Invasive treatment measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transvenous pacemaker can be inserted to assist with electrical conduction. However, pacing does not counteract the negative inotropic effects of these drugs, and successful capture may not correct the patient's hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/42\">",
"     42",
"    </a>",
"    ]. Intraaortic balloon insertion can be considered in the absence of contraindications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=see_link\">",
"     \"Temporary cardiac pacing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=see_link\">",
"     \"Intraaortic balloon pump counterpulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are anecdotal reports of complete recovery in severely poisoned pediatric and adult patients placed on prolonged cardiopulmonary bypass or extracorporeal membrane oxygenation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31736/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37863?source=see_link\">",
"     \"Extracorporeal membrane oxygenation (ECMO) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Extracorporeal removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;CCBs are highly protein bound, therefore extracorporeal removal by hemodialysis is not effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient who ingests or claims to have ingested an immediate-release CCB but remains asymptomatic after six to eight hours may be considered medically cleared. If the CCB preparation was a sustained or extended-release preparation, admission and cardiac monitoring for 24 hours is warranted. In the symptomatic patient, continuous hemodynamic monitoring is required until the patient does not require any pharmacologic assistance to maintain blood pressure. If multiple agents are being utilized, invasive monitoring with a pulmonary artery catheter should be strongly considered to help guide therapy. If an intentional overdose is known or suspected, psychiatric evaluation is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe calcium channel blocker (CCB) poisoning is life threatening and management is often challenging. Patients may be moribund at presentation and those who are not may deteriorate precipitously. A summary table to facilitate emergent management is provided (",
"      <a class=\"graphic graphic_table graphicRef63193 \" href=\"mobipreview.htm?32/31/33277\">",
"       table 1",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       Diltiazem",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      are the most cardiotoxic of the CCBs, although any of these agents can be dangerous when large doses are ingested.",
"     </li>",
"     <li>",
"      Patients ingesting more than 5 to 10 times the usual dose can develop signs of severe intoxication, including drowsiness and confusion. Vital sign abnormalities can include hypotension and bradycardia. Jugular venous distension, pulmonary crackles, and other signs of heart failure may be noted. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ECG changes associated with CCB intoxication include PR interval prolongation and any bradydysrhythmia. A finger stick blood glucose measurement may reveal hyperglycemia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment varies according to the severity of symptoms and may include gastrointestinal decontamination, possibly including gastric lavage, and the administration of intravenous calcium,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      , catecholamines, and high-dose insulin therapy may be necessary. Intralipid therapy may be of benefit in critically ill, hemodynamically unstable patients resistant to standard medical therapies. A transvenous pacemaker, intraaortic balloon pump, and extracorporeal membrane oxygenation are treatment options for the severely poisoned. (See",
"      <a class=\"local\" href=\"#H11744693\">",
"       'Initial resuscitation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11744580\">",
"       'Approach to the selection of specific therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severely symptomatic CCB poisoning, we suggest simultaneous treatment with all of the following therapies (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Dosing is provided in the text and the rapid overview table (",
"      <a class=\"graphic graphic_table graphicRef63193 \" href=\"mobipreview.htm?32/31/33277\">",
"       table 1",
"      </a>",
"      ). Severe beta blocker poisoning can be difficult to manage and consultation with a medical toxicologist or regional poison control center is prudent. (see",
"      <a class=\"local\" href=\"#H11744587\">",
"       'Severely symptomatic patients'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Specific therapies'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stabilization of the airway as necessary (avoid induction agents that exacerbate hypotension)",
"     </li>",
"     <li>",
"      IV boluses of isotonic crystalloid",
"     </li>",
"     <li>",
"      IV calcium salts (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Intravenous calcium'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Glucagon'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      IV high-dose insulin and glucose (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Insulin and glucose'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      IV vasopressor (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/28/16838?source=see_link\">",
"       norepinephrine",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Vasopressors'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      IV lipid emulsion therapy (see",
"      <a class=\"local\" href=\"#H6162826\">",
"       'Lipid emulsion therapy'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A suggested treatment approach for patients with mild hypotension or bradycardia caused by CCB toxicity is provided in the text. (See",
"      <a class=\"local\" href=\"#H11744630\">",
"       'Mildly symptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/1\">",
"      Eisenberg MJ, Brox A, Bestawros AN. Calcium channel blockers: an update. Am J Med 2004; 116:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/2\">",
"      Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003; 21:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/3\">",
"      Katz AM. Cardiac ion channels. N Engl J Med 1993; 328:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/4\">",
"      Hofer CA, Smith JK, Tenholder MF. Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options. Am J Med 1993; 95:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/5\">",
"      McAllister RG Jr, Hamann SR, Blouin RA. Pharmacokinetics of calcium-entry blockers. Am J Cardiol 1985; 55:30B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/6\">",
"      Sporer KA, Khayam-Bashi H. Acetaminophen and salicylate serum levels in patients with suicidal ingestion or altered mental status. Am J Emerg Med 1996; 14:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/7\">",
"      Spurlock BW, Virani NA, Henry CA. Verapamil overdose. West J Med 1991; 154:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/8\">",
"      Levine M, Boyer EW, Pozner CN, et al. Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. Crit Care Med 2007; 35:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/9\">",
"      Ashraf M, Chaudhary K, Nelson J, Thompson W. Massive overdose of sustained-release verapamil: a case report and review of literature. Am J Med Sci 1995; 310:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/10\">",
"      Thompson AM, Robins JB, Prescott LF. Changes in cardiorespiratory function during gastric lavage for drug overdose. Hum Toxicol 1987; 6:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/11\">",
"      Position paper: whole bowel irrigation. J Toxicol Clin Toxicol 2004; 42:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/12\">",
"      Tenenbein M. Position statement: whole bowel irrigation. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1997; 35:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/13\">",
"      Tenenbein M, Cohen S, Sitar DS. Whole bowel irrigation as a decontamination procedure after acute drug overdose. Arch Intern Med 1987; 147:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/14\">",
"      Proano L, Chiang WK, Wang RY. Calcium channel blocker overdose. Am J Emerg Med 1995; 13:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/15\">",
"      Kerns W 2nd, Kline J, Ford MD. Beta-blocker and calcium channel blocker toxicity. Emerg Med Clin North Am 1994; 12:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/16\">",
"      Isbister GK. Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium. Emerg Med J 2002; 19:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/17\">",
"      Lam YM, Tse HF, Lau CP. Continuous calcium chloride infusion for massive nifedipine overdose. Chest 2001; 119:1280.",
"     </a>",
"    </li>",
"    <li>",
"     DeRoos F. Calcium channel blockers. In: Goldfrank's Toxicologic Emergencies, 8th, McGraw-Hill, New York 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/19\">",
"      Sim MT, Stevenson FT. A fatal case of iatrogenic hypercalcemia after calcium channel blocker overdose. J Med Toxicol 2008; 4:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/20\">",
"      Bailey B. Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review. J Toxicol Clin Toxicol 2003; 41:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/21\">",
"      Mahr NC, Valdes A, Lamas G. Use of glucagon for acute intravenous diltiazem toxicity. Am J Cardiol 1997; 79:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/22\">",
"      Walter FG, Frye G, Mullen JT, et al. Amelioration of nifedipine poisoning associated with glucagon therapy. Ann Emerg Med 1993; 22:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/23\">",
"      Doyon S, Roberts JR. The use of glucagon in a case of calcium channel blocker overdose. Ann Emerg Med 1993; 22:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/24\">",
"      Kline JA, Tomaszewski CA, Schroeder JD, Raymond RM. Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharmacol Exp Ther 1993; 267:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/25\">",
"      Boyer EW, Shannon M. Treatment of calcium-channel-blocker intoxication with insulin infusion. N Engl J Med 2001; 344:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/26\">",
"      Greene SL, Gawarammana I, Wood DM, et al. Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: a prospective observational study. Intensive Care Med 2007; 33:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/27\">",
"      Patel NP, Pugh ME, Goldberg S, Eiger G. Hyperinsulinemic euglycemia therapy for verapamil poisoning: a review. Am J Crit Care 2007; 16:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/28\">",
"      Kline JA, Leonova E, Raymond RM. Beneficial myocardial metabolic effects of insulin during verapamil toxicity in the anesthetized canine. Crit Care Med 1995; 23:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/29\">",
"      Kline JA, Raymond RM, Schroeder JD, Watts JA. The diabetogenic effects of acute verapamil poisoning. Toxicol Appl Pharmacol 1997; 145:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/30\">",
"      Bechtel LK, Haverstick DM, Holstege CP. Verapamil toxicity dysregulates the phosphatidylinositol 3-kinase pathway. Acad Emerg Med 2008; 15:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/31\">",
"      Jamaty C, Bailey B, Larocque A, et al. Lipid emulsions in the treatment of acute poisoning: a systematic review of human and animal studies. Clin Toxicol (Phila) 2010; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/32\">",
"      Young AC, Velez LI, Kleinschmidt KC. Intravenous fat emulsion therapy for intentional sustained-release verapamil overdose. Resuscitation 2009; 80:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/33\">",
"      Sirianni AJ, Osterhoudt KC, Calello DP, et al. Use of lipid emulsion in the resuscitation of a patient with prolonged cardiovascular collapse after overdose of bupropion and lamotrigine. Ann Emerg Med 2008; 51:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/34\">",
"      Gueret G, Pennec JP, Arvieux CC. Hemodynamic effects of intralipid after verapamil intoxication may be due to a direct effect of fatty acids on myocardial calcium channels. Acad Emerg Med 2007; 14:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/35\">",
"      Grunbaum AM, Gilfix BM, Gosselin S, Blank DW. Analytical interferences resulting from intravenous lipid emulsion. Clin Toxicol (Phila) 2012; 50:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/36\">",
"      Wolf LR, Spadafora MP, Otten EJ. Use of amrinone and glucagon in a case of calcium channel blocker overdose. Ann Emerg Med 1993; 22:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/37\">",
"      Varpula T, Rapola J, Sallisalmi M, Kurola J. Treatment of serious calcium channel blocker overdose with levosimendan, a calcium sensitizer. Anesth Analg 2009; 108:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/38\">",
"      Kurola J, Leppikangas H, Magga J, et al. Effect of levosimendan in experimental verapamil-induced myocardial depression. Scand J Trauma Resusc Emerg Med 2010; 18:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/39\">",
"      Abraham MK, Scott SB, Meltzer A, Barrueto F Jr. Levosimendan does not improve survival time in a rat model of verapamil toxicity. J Med Toxicol 2009; 5:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/40\">",
"      Osthoff M, Bernsmeier C, Marsch SC, Hunziker PR. Levosimendan as treatment option in severe verapamil intoxication: a case report and review of the literature. Case Rep Med 2010; 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/41\">",
"      Graudins A, Wong KK. Comparative hemodynamic effects of levosimendan alone and in conjunction with 4-aminopyridine or calcium chloride in a rodent model of severe verapamil poisoning. J Med Toxicol 2010; 6:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/42\">",
"      Salhanick SD, Shannon MW. Management of calcium channel antagonist overdose. Drug Saf 2003; 26:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/43\">",
"      Frierson J, Bailly D, Shultz T, et al. Refractory cardiogenic shock and complete heart block after unsuspected verapamil-SR and atenolol overdose. Clin Cardiol 1991; 14:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/44\">",
"      Holzer M, Sterz F, Schoerkhuber W, et al. Successful resuscitation of a verapamil-intoxicated patient with percutaneous cardiopulmonary bypass. Crit Care Med 1999; 27:2818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/45\">",
"      Durward A, Guerguerian AM, Lefebvre M, Shemie SD. Massive diltiazem overdose treated with extracorporeal membrane oxygenation. Pediatr Crit Care Med 2003; 4:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/46\">",
"      Babatasi G, Massetti M, Verrier V, et al. [Severe intoxication with cardiotoxic drugs: value of emergency percutaneous cardiocirculatory assistance]. Arch Mal Coeur Vaiss 2001; 94:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31736/abstract/47\">",
"      Hendren WG, Schieber RS, Garrettson LK. Extracorporeal bypass for the treatment of verapamil poisoning. Ann Emerg Med 1989; 18:984.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 331 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.96.59.103-C3E2CEE167-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_63_31736=[""].join("\n");
var outline_f30_63_31736=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11744693\">",
"      Initial resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11744580\">",
"      Approach to the selection of specific therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11744587\">",
"      - Severely symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11744630\">",
"      - Mildly symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11744713\">",
"      - Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gastrointestinal decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Specific therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Atropine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Intravenous calcium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Glucagon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Vasopressors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Insulin and glucose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6162826\">",
"      - Lipid emulsion therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Phosphodiesterase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7156442\">",
"      - Other proposed treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Invasive treatment measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Extracorporeal removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/331\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/331|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/47/13054\" title=\"figure 1\">",
"      Use of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/331|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/31/33277\" title=\"table 1\">",
"      Calcium channel blocker poisoning - Rapid overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/19/33081?source=related_link\">",
"      Beta blocker poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=related_link\">",
"      Enhanced elimination of poisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37863?source=related_link\">",
"      Extracorporeal membrane oxygenation (ECMO) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13896?source=related_link\">",
"      Intraaortic balloon pump counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15738?source=related_link\">",
"      Primary drugs in pediatric resuscitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=related_link\">",
"      Temporary cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_63_31737="Mechanisms of bone metastases";
var content_f30_63_31737=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mechanisms of bone metastases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/63/31737/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31737/contributors\">",
"     G David Roodman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/63/31737/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31737/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/63/31737/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31737/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/63/31737/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone metastases are a frequent complication in patients with advanced cancer. Skeletal involvement is most common in patients with metastatic breast or prostate cancer, but bone is a frequent site of metastases in most advanced malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the overall incidence of bone metastasis is not known, over one-half of people who die of cancer in the United States each year are thought to have bone involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone metastases can cause a wide range of symptoms that can impair the quality of life or shorten survival. Direct complications of bone involvement include severe pain, pathologic fractures, and epidural spinal cord compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition to these local effects, osteolytic metastases can result in life-threatening hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=see_link\">",
"     \"Overview of cancer pain syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=see_link\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms by which bone metastases develop and affect normal bone will be reviewed here. The control of normal bone remodeling is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OSTEOLYTIC VERSUS OSTEOBLASTIC BONE METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone metastases are generally classified as either osteolytic, characterized by destruction of normal bone, or osteoblastic, with the deposition of new bone based upon the predominant radiologic appearance. This distinction is not absolute; many patients with bone metastases have both osteolytic and osteoblastic lesions, and individual metastatic lesions can contain both osteolytic and osteoblastic components (",
"    <a class=\"graphic graphic_table graphicRef54124 \" href=\"mobipreview.htm?21/17/21787\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In both types of lesions there is a dysregulation of the normal bone remodeling process. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=see_link&amp;anchor=H1207796#H1207796\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\", section on 'Bone modeling and remodeling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The spectrum of osteolytic and osteoblastic bone involvement is illustrated by three tumors that are frequently associated with skeletal metastases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple myeloma &mdash; The classical bone lesions in multiple myeloma are purely osteolytic (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78569 \" href=\"mobipreview.htm?3/0/3076\">",
"       image 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/4\">",
"       4",
"      </a>",
"      ]. These lesions are often not detectable by bone scans, which rely upon technetium uptake to identify areas of new bone formation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=see_link\">",
"       \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H8\">",
"       'Multiple myeloma'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Prostate cancer - The predominant lesion in men with bone metastases from prostate cancer is osteoblastic with increased numbers of irregular bone trabeculae (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83139 \" href=\"mobipreview.htm?15/18/15655\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/5\">",
"       5",
"      </a>",
"      ]. Although these metastases are osteoblastic, there is increased bone resorption as well [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/6\">",
"       6",
"      </a>",
"      ]. Thus, agents that block bone resorption are used to decrease bone pain and the risk of pathologic fractures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/36999?source=see_link&amp;anchor=H19250956#H19250956\">",
"       \"Management of bone metastases in advanced prostate cancer\", section on 'Osteoclast inhibition'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Breast cancer - Although bone metastases due to breast cancer are predominantly osteolytic lesions, osteoblastic areas are also usually present and at least 15 to 20 percent of cases have predominantly osteoblastic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/7\">",
"       7",
"      </a>",
"      ]. In addition, destruction of bone in osteolytic lesions induces secondary new bone formation. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Breast cancer'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Research is beginning to elucidate the multiple mechanisms that cause these different patterns of metastases, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BONE AS A PREFERENTIAL SITE FOR METASTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferential localization and growth of tumor cells in bone is caused both by properties of the tumor cells and by factors in the bone microenvironment. This involvement of both the tumor and the bone microenvironment has been referred to as the \"seed and soil\" hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumor cells may produce or express various adhesive molecules, which bind to the corresponding receptors on the stromal cells of the marrow and bone matrix. Examples of such factors include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor cells express the chemokine receptor CXCR4 that mediates their attachment to the stromal-cell derived factor 1 (SDF-1, also known as CXCL12) in bone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/9\">",
"       9",
"      </a>",
"      ]. Increased expression of CXCR4 in primary neuroblastoma tumors has been associated with a higher frequency of bone and bone marrow metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Expression of RANKL (receptor activator of nuclear factor kappa B ligand) in bone may also contribute to the development of bone metastases by binding to its receptor (receptor activator of nuclear factor kappa B, RANK) on the surface of tumor cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/11\">",
"       11",
"      </a>",
"      ]. Further, RANKL may also mediate progestin-induced epithelial proliferation and carcinogenesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/12\">",
"       12",
"      </a>",
"      ], and high",
"      <span class=\"nowrap\">",
"       RANKL/RANK",
"      </span>",
"      expression in breast adenocarcinoma is associated with a poor prognosis and metastasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Expression of bone sialoprotein by non-small cell lung cancer may facilitate binding to collagen type I and other components of the extracellular matrix in bone. Expression of bone sialoprotein in the primary tumor has been correlated with the subsequent development of bone metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Annexin II and its receptor may be involved in prostate cancer cells homing to bone. Prostate cancer cells and myeloma cells bind to annexin II and the annexin II receptor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/15,16\">",
"       15,16",
"      </a>",
"      ] on osteoblasts, analogous to hematopoietic stem cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These adhesive interactions between tumor cell receptors and the bone microenvironment can increase production of angiogenic factors and bone resorbing factors by the tumor cells. This in turn can further enhance tumor growth in bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, bone contains various growth factors that are released and activated during the process of bone resorption, further stimulating tumor growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/18\">",
"     18",
"    </a>",
"    ]. These include transforming growth factor-beta, insulin-like growth factors one and two, fibroblast growth factors, platelet-derived growth factors, bone morphogenetic proteins, and calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, more recent data suggest an alternative molecular basis for the preferential metastases of prostate cancer cells to the bone. Using a prostate cancer xenograft model, investigators were able to show that prostate cancer cells compete for and co-opt the endosteal niche occupied by hematopoietic stem cells via overexpression of CXCR4, the receptor for CXCL12 (stromal-derived factor-1), which, through its interactions with CXCR4, regulates hematopoietic stem cell quiescence and homing to the bone marrow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NORMAL BONE REMODELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal bone constantly undergoes a remodeling process that includes the resorption of bone by osteoclasts and the deposition of new bone by osteoblasts. This process is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Osteoclasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoclasts are derived from precursor cells of monocyte macrophage origin, which differentiate into inactive osteoclasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/21\">",
"     21",
"    </a>",
"    ]. These osteoclasts are then activated, resorb bone, and eventually undergo apoptosis.",
"   </p>",
"   <p>",
"    The formation and activation of osteoclasts is regulated by both locally-produced cytokines and systemic hormones. The macrophage colony stimulating factor (M-CSF, CSF1) and RANKL are produced by stromal cells or osteoblasts within bone and play a critical role in the formation of osteoclasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Systemic factors that induce osteoclast formation, such as parathyroid hormone (PTH), 1,25-dihydroxy vitamin D3, and prostaglandins, act indirectly by increasing the expression of RANKL on marrow stromal cells and osteoblasts&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef66130 \" href=\"mobipreview.htm?33/12/33985\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. RANKL then binds the RANK receptor on precursor cells, inducing the formation of osteoclasts.",
"   </p>",
"   <p>",
"    The importance of RANKL in osteoclast formation is supported by evidence from animal models and translational clinical trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Knockout mice in which either the RANKL or RANK gene has been deleted lack osteoclasts. The resulting unopposed activity of osteoblasts results in the development of severe osteopetrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/23,26\">",
"       23,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Osteoprotegerin (OPG), which is normally present in the bone marrow, competitively binds RANKL, thereby inhibiting osteoclast differentiation and resorption in vitro and in vivo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/27\">",
"       27",
"      </a>",
"      ]. Evidence supporting an important role for OPG is derived from mouse models that either overexpress [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/28\">",
"       28",
"      </a>",
"      ] or lack [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/29\">",
"       29",
"      </a>",
"      ] OPG.",
"     </li>",
"     <li>",
"      A human monoclonal antibody directed against RANKL (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      ) was evaluated in a double-blind trial of 54 patients with metastatic breast cancer or multiple myeloma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/30\">",
"       30",
"      </a>",
"      ]. Blocking RANKL activity resulted in a prolonged antiresorptive effect, as assessed by decreases in markers of bone turnover.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Results of phase III trials have shown that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      is as effective and possibly more effective than IV bisphosphonates at reducing the risk of skeletal-related events in patients with bone metastases from a variety of malignancies including breast and prostate cancer and myeloma. Denosumab also has biological activity in patients with skeletal metastases and persistently elevated markers of bone turnover despite ongoing treatment with intravenous bisphosphonates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=see_link\">",
"       \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/36999?source=see_link&amp;anchor=H19250956#H19250956\">",
"       \"Management of bone metastases in advanced prostate cancer\", section on 'Osteoclast inhibition'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8042?source=see_link&amp;anchor=H608404691#H608404691\">",
"       \"Osteoclast inhibition in the management of bone metastases from breast cancer\", section on 'Denosumab'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/13/23769?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of the complications of multiple myeloma\", section on 'Prevention of skeletal events'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Osteoclasts also are major contributors to cancer-induced bone pain, one of the most common complications of skeletal metastasis. Studies in animal models of cancer-induced bone pain have shown that inhibition of osteoclastic bone resorption reduced bone pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/33\">",
"     33",
"    </a>",
"    ] and that protons released from bone-resorbing osteoclasts cause bone pain by activating acid sensing-receptors TRPV1 expressed on the sensory neurons innervating bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/34\">",
"     34",
"    </a>",
"    ]. Clinical studies have shown that osteoclast inhibitors, including bisphosphonates and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    , effectively reduce bone pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link&amp;anchor=H30#H30\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Adjuvant drugs used for bone pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Osteoblasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoblasts are bone-forming cells that arise from mesenchymal stem cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/35\">",
"     35",
"    </a>",
"    ]. The factors controlling osteoblast differentiation are less well understood than for osteoclasts.",
"   </p>",
"   <p>",
"    The one transcription factor that has been clearly linked to osteoblast differentiation is core binding factor alpha 1 (Cbfa1), also known as Runx-2. Cbfa1 is responsible for the expression of most genes associated with osteoblast differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/36\">",
"     36",
"    </a>",
"    ]. In mice lacking the Cbfa1 gene, bone does not develop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Many extracellular factors can enhance the growth and differentiation of osteoblasts, including platelet derived growth factor (PDGF), fibroblast growth factor, and transforming growth factor beta (",
"    <a class=\"graphic graphic_figure graphicRef79869 \" href=\"mobipreview.htm?32/25/33170\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OSTEOLYTIC METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone destruction observed in osteolytic metastases is primarily mediated by osteoclasts and is not a direct effect of tumor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Alterations in the normal balance between bone resorption and formation can result in the bone destruction observed in osteolytic metastases. The mechanisms underlying the osteolytic process are best understood in multiple myeloma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Multiple myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Key factors that may have an important role in the development of lytic bone disease in patients with myeloma include interleukin-6 (IL-6), RANKL, macrophage inflammatory protein 1a (MIP1), interleukin-3 (IL-3) and osteoblast dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Interleukin-6",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several lines of evidence implicate interleukin-6 (IL-6) as one of the factors contributing to bone disease in patients with myeloma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The adherence of myeloma cells to stromal cells in the marrow results in an increased production of IL-6 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/42\">",
"       42",
"      </a>",
"      ], and IL-6 in turn can increase the numbers of myeloma cells present, either by stimulating their proliferation or blocking apoptosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IL-6 is present in marrow plasma samples from patients with myeloma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/44\">",
"       44",
"      </a>",
"      ], although levels of IL-6 do not correlate with the presence of bone lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IL-6 may have a direct stimulatory effect on osteoclasts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although IL-6 may enhance the growth or prolong the survival of myeloma cells, IL-6 may not be directly involved in the osteolytic process itself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     RANKL and OPG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myeloma cells produce RANKL, a key factor in the pathway for osteoclast formation and activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In addition, production of OPG is decreased in bone in myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/50\">",
"     50",
"    </a>",
"    ]. In an animal model of myeloma, bone destruction was inhibited by an increase in OPG or the use of a soluble RANK receptor, both of which blocked the interaction of RANKL with its target receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Osteoclasts'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In phase III trials conducted in patients with myeloma as well as bone metastases from breast and advanced prostate cancer, and a variety of other malignancies,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    significantly prolonged the time to a first skeletal-related event (SRE) compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    . However, in myeloma, concerns as to a survival detriment have limited the use of denosumab. These data are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/13/23769?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of the complications of multiple myeloma\", section on 'Prevention of skeletal events'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8042?source=see_link&amp;anchor=H608404691#H608404691\">",
"     \"Osteoclast inhibition in the management of bone metastases from breast cancer\", section on 'Denosumab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/36999?source=see_link&amp;anchor=H19251250#H19251250\">",
"     \"Management of bone metastases in advanced prostate cancer\", section on 'Denosumab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=see_link&amp;anchor=H18#H18\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\", section on 'Denosumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Macrophage inflammatory protein 1a",
"    </span>",
"    &nbsp;&mdash;&nbsp;MIP1 appears to be a key regulator of the osteolytic process in myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. MIP1 is a potent in vitro inducer of osteoclast formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/55\">",
"     55",
"    </a>",
"    ]. Although MIP1 can induce osteoclasts independent of the effects of RANKL, it also may enhance the effects of both IL-6 and RANKL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27977?source=see_link&amp;anchor=H23#H23\">",
"     \"Pathobiology of multiple myeloma\", section on 'Osteolytic bone lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In mouse models of myeloma, blocking expression of the MIP1 gene or the activity of MIP1 protein decreases both bone destruction and the myeloma tumor burden [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Similarly, blocking chemokine receptor 1 (CCR1), a MIP 1 receptor, with a small molecule antagonist that can be given orally also blocked tumor growth and bone destruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/58\">",
"     58",
"    </a>",
"    ]. MIP1 also enhances adhesive interactions between myeloma cells and stromal cells by upregulating expression of b1 integrins on myeloma cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/56\">",
"     56",
"    </a>",
"    ]. Adhesive interactions between marrow stromal cells and myeloma cells increase production of interleukin-6, RANKL, and MIP1, further increasing bone destruction.",
"   </p>",
"   <p>",
"    Myeloma cells produce MIP1 in approximately 70 percent of patients, and the levels of this protein correlate strongly with the presence of osteolytic lesions. Moreover, DNA microanalysis of myeloma cells has shown that expression of the MIP1 gene is markedly increased and correlates with bone disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/59\">",
"     59",
"    </a>",
"    ] and possibly survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MIP1 also is elevated in patients with Waldenstrom's macroglobulinemia, and this is associated with increased bone resorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/61\">",
"     61",
"    </a>",
"    ]. However, there is increased production of OPG and new bone formation, and osteolytic lesions generally are not present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Interleukin-3",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL-3 may contribute to the bone disease in patients with myeloma both by stimulating osteoclasts and inhibiting osteoblast formation through a factor produced by macrophages in the marrow microenvironment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/62\">",
"     62",
"    </a>",
"    ]. In one study IL-3 levels were increased in peripheral blood of 40 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/63\">",
"     63",
"    </a>",
"    ]. In another study, both messenger RNA expression and IL-3 protein levels were significantly increased in samples from patients with myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Osteoblast dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In about one-half of patients with myeloma, bone scans are normal even in the presence of severe osteolytic bone destruction. This most likely is due to decreased osteoblast activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signaling through the Wnt pathway appears to be important in osteoblast differentiation. One study found that myeloma cells express dickkopf-1 (DKK1), a",
"    <span class=\"nowrap\">",
"     Wnt/b-catenin",
"    </span>",
"    signaling antagonist; the presence of high levels of DKK1 was associated with focal bone lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/66\">",
"     66",
"    </a>",
"    ]. Signaling through the Wnt pathway appears to be important in osteoblast differentiation. One study found that myeloma cells express dickkopf-1 (DKK1), a",
"    <span class=\"nowrap\">",
"     Wnt/b-catenin",
"    </span>",
"    signaling antagonist; the presence of high levels of DKK1 was associated with focal bone lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/66\">",
"     66",
"    </a>",
"    ]. DKK1 inhibition of osteoblast differentiation in myeloma may be responsible for the increased expression of RANKL, which is expressed by immature osteoblasts, and the low levels of OPG, since OPG is normally expressed by mature osteoblasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An antibody to DKK1 has been tested in murine models of myeloma bone disease; treatment led to increased osteoblast numbers and decreased myeloma cell growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27977?source=see_link\">",
"     \"Pathobiology of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin-7, soluble frizzled protein-2, activin A, and sclerostin may also contribute to the development of bone disease in patients with myeloma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IL-7 is produced by myeloma cells and inhibits osteoblast differentiation in human bone marrow cultures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/69\">",
"       69",
"      </a>",
"      ]. IL-7 was present at high levels in the marrow of some patients with myeloma; a neutralizing antibody to IL-7 blocked the inhibition of osteoblast differentiation caused by marrow plasma from myeloma patients.",
"     </li>",
"     <li>",
"      Soluble frizzled protein-2 is produced by myeloma cells and can block osteoblast differentiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/70\">",
"       70",
"      </a>",
"      ]. Soluble frizzled protein-2 is a Wnt signaling inhibitor and uses a similar mechanism of action as DKK1 to block osteoblast differentiation.",
"     </li>",
"     <li>",
"      Activin A is produced by osteoclasts, marrow stromal cells, and CD14+ macrophages in the marrow, and is elevated in the bone marrow of myeloma patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/71\">",
"       71",
"      </a>",
"      ]. Activin A blocks osteoblast differentiation. An activin A receptor antagonist has been developed that can block myeloma cell growth, bone destruction, and induce bone formation in an animal model of myeloma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/72\">",
"       72",
"      </a>",
"      ]. It is in clinical trials for patients with myeloma.",
"     </li>",
"     <li>",
"      Sclerostin is produced by osteocytes and inhibits Wnt signaling to block osteoblast differentiation. Sclerostin levels are elevated in myeloma patients, and this glycoprotein also be produced by myeloma cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/73,74\">",
"       73,74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Proteasomes may also be involved in the development of bone disease. Patients with multiple myeloma who are treated with proteosome inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"     carfilzomib",
"    </a>",
"    ) may have increased new bone formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/75-77\">",
"     75-77",
"    </a>",
"    ], although it is unclear whether these effects are transient or prolonged. The effect is thought to be due to increased osteoblast differentiation, possibly by a direct stimulatory effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a reciprocal interaction between breast cancer cells and the bone microenvironment, which results in a \"vicious cycle\" that increases both bone destruction and tumor burden (",
"    <a class=\"graphic graphic_figure graphicRef79869 \" href=\"mobipreview.htm?32/25/33170\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/39\">",
"     39",
"    </a>",
"    ]. Tumor cells produce factors that directly or indirectly induce osteoclast formation. The resulting bone resorption caused by osteoclasts releases growth factors from the bone matrix that stimulate both tumor growth and further bone destruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Key components of this cycle are thought to include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breast cancer cells induce osteoclasts to secrete parathyroid hormone-related peptide (PTHrP).",
"     </li>",
"     <li>",
"      Binding of PTHrP to the parathyroid hormone related peptide receptor (PTHR1) on marrow stromal cells, resulting in the production of RANKL, which stimulates osteoclast differentiation. Osteoclasts demineralize bone, causing the release of growth factors such as bone morphogenetic proteins, IGF-1 and TGF-beta from the bone matrix, all of which support cancer cell proliferation and induce further release of PTHrP.",
"     </li>",
"     <li>",
"      Activation of nuclear factor kappa B also induces expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), which can contribute to osteoclast stimulation and the development of osteolytic metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Induction of osteoclast formation and bone resorption results in the release of transforming growth factor beta. Transforming growth factor beta in turn causes increased production of PTHrP by breast cancer cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, bone destruction increases local calcium concentrations, which promote tumor growth and production of PTHrP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/82\">",
"     82",
"    </a>",
"    ]. Breast cancer cells also produce or induce the synthesis of IL-6, interleukin-8, prostaglandin E2 (PGE2), M-CSF, IL-1, and tumor necrosis factor alpha [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/83,84\">",
"     83,84",
"    </a>",
"    ], which may also induce osteoclast formation in breast cancer metastasis.",
"   </p>",
"   <p>",
"    The potential importance of bone and bone resorption for breast cancer outcomes, including metastases to other organs, has been recognized. Preclinical and early clinical studies have suggested that bisphosphonates may possess inherent antitumor activity and that bisphosphonate therapy may reduce the likelihood of subsequent bone metastases. Furthermore, epidemiologic data suggests that bisphosphonates used in the management of osteopenia and osteoporosis may decrease the risk of developing breast cancer.",
"   </p>",
"   <p>",
"    Despite these theoretical advantages, the available evidence does not support benefit for bisphosphonates as a component of adjuvant treatment, either in terms of improving breast cancer outcomes or reducing the development of skeletal metastases. Benefit remains uncertain for women who have entered menopause. These data are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/35/33336?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the use of osteoclast inhibitors in early breast cancer\", section on 'Prevention of breast cancer recurrence'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OSTEOBLASTIC METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of osteoblastic metastasis is less well understood than that of osteolytic lesions; the key factors involved and their roles are just being identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Endothelin-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelin-1 has been identified as a possible factor involved in the development of osteoblastic metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/85\">",
"     85",
"    </a>",
"    ]. In vitro studies on samples from patients with breast cancer showed that endothelin-1 can stimulate bone formation and osteoblast proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/86\">",
"     86",
"    </a>",
"    ]. Endothelin-1 may increase osteoblast activity by inhibiting expression of DKK1 by marrow stromal cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/87\">",
"     87",
"    </a>",
"    ]. In addition, serum endothelin-1 levels are increased in patients with osteoblastic metastases from prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of a selective endothelin-1 receptor antagonist decreased both osteoblastic metastases and tumor burden in an animal model, although it had no effect on tumor growth at orthotopic sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/85\">",
"     85",
"    </a>",
"    ]. These observations suggest that blocking osteoblast-inducing activity by tumors may decrease tumor growth and osteoblast activity. Thus, as with osteolytic metastases, a feedback cycle may be present in which tumors induce osteoblast activity, and the osteoblasts release growth factors that increase tumor growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other factors may also contribute to the development of osteoblastic bone metastases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelet-derived growth factor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bone morphogenic proteins (BMPs), including BMP-6 and BMP-2, which appear to act independently of endothelin-1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/90\">",
"       90",
"      </a>",
"      ]. Both of these proteins appear to increase the local invasiveness of prostate cancer cells in the bone microenvironment.",
"     </li>",
"     <li>",
"      The Wnt proteins promote bone growth. Wnt messenger RNA has been shown to be expressed in prostate cancer cell lines and is increased in primary prostate cancer compared to noncancerous prostate tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Overproduction of urokinase-type plasminogen activator (uPA) by prostate cancer cells increases in bone metastasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/92\">",
"       92",
"      </a>",
"      ], and cells transfected with an anti-sense DNA to uPA had a threefold decrease in metastases compared to empty vector transfected cells. Human PC3 prostate cancer cells produce a factor that is homologous to uPA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer cells release prostate specific antigen (PSA), a kallikrein serine protease. PSA can cleave parathyroid hormone-related peptide at the amino terminus, which could block tumor-induced bone resorption. It may also activate osteoblastic growth factors released in the bone microenvironment during the process of forming bone metastases, such as insulin-like growth factors one and two or transforming growth factor-b [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/94\">",
"     94",
"    </a>",
"    ]. These data suggest a feedback cycle may contribute to the development of osteoblastic metastasis in prostate cancer.",
"   </p>",
"   <p>",
"    Bone disease in prostate cancer is not purely osteoblastic. Bisphosphonates and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    block osteoclastic bone resorption; in patients with prostate cancer, use of these agents has been associated with a decreased incidence of skeletal-related events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/36999?source=see_link&amp;anchor=H19250956#H19250956\">",
"     \"Management of bone metastases in advanced prostate cancer\", section on 'Osteoclast inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a mouse model of prostate cancer, blocking osteoclast activity did not prevent the development of osteoblastic metastasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/89\">",
"     89",
"    </a>",
"    ], but did inhibit their progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31737/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Thus, it is unclear if bone destruction precedes the development of osteoblastic metastasis or is a consequence of the increased bone formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone metastases result in some of the most common and debilitating problems for patients with malignancies. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bone metastases are generally classified as either osteolytic, characterized by destruction of normal bone, or osteoblastic, with the deposition of new bone based upon the predominant radiologic appearance. This distinction is not absolute. In both types of lesions there is a dysregulation of the normal bone remodeling process. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Osteolytic versus osteoblastic bone metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferential localization and growth of tumor cells in bone is caused both by properties of the tumor cells and by factors in the bone microenvironment. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Bone as a preferential site for metastasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Normal bone constantly undergoes a remodeling process that includes the resorption of bone by osteoclasts and the deposition of new bone by osteoblasts. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Osteolytic versus osteoblastic bone metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The molecular mechanisms responsible for both osteolytic and osteoblastic metastases are being identified. The use of gene arrays and proteomics and the availability of appropriate animal models of bone metastasis have permitted the identification of factors produced by the tumors cells themselves or by the microenvironment in response to the tumor that mediate the bone destructive process. These types of studies have resulted in the development of novel therapeutic agents to treat and potentially prevent this devastating complication of cancer. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Osteolytic metastases'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Osteoblastic metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several new agents are in clinical trial for treating and possibly preventing bone metastasis. In phase III clinical trials, one of these agents,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      , a human antibody to RANKL (receptor activator of nuclear factor kappa B ligand) is highly effective for preventing bone complications in patients with bone metastasis from prostate cancer, breast cancer and other solid tumors, and it prevents treatment-related bone loss in patients treated with androgen deprivation therapy for prostate cancer and women with breast cancer who are treated with aromatase inhibitors. The available evidence does not support the use of bisphosphonates as a component of adjuvant treatment for breast cancer, either in terms of improving cancer outcomes or reducing the development of skeletal metastases. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Breast cancer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Prostate cancer'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=see_link\">",
"       \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/36999?source=see_link\">",
"       \"Management of bone metastases in advanced prostate cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8042?source=see_link\">",
"       \"Osteoclast inhibition in the management of bone metastases from breast cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link&amp;anchor=H11#H11\">",
"       \"Side effects of androgen deprivation therapy\", section on 'Denosumab'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/42/37545?source=see_link&amp;anchor=H20#H20\">",
"       \"Evaluation and management of aromatase inhibitor-induced bone loss\", section on 'Denosumab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/1\">",
"      Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/2\">",
"      Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/3\">",
"      Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/4\">",
"      Roodman GD. Skeletal imaging and management of bone disease. Hematology Am Soc Hematol Educ Program 2008; :313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/5\">",
"      Roudier MP, Vesselle H, True LD, et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 2003; 20:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/6\">",
"      Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23:4925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/7\">",
"      Coleman RE, Seaman JJ. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. Semin Oncol 2001; 28:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/8\">",
"      Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/9\">",
"      Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res 2005; 15:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/10\">",
"      Russell HV, Hicks J, Okcu MF, Nuchtern JG. CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J Pediatr Surg 2004; 39:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/11\">",
"      Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006; 440:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/12\">",
"      Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010; 468:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/13\">",
"      Palafox M, Ferrer I, Pellegrini P, et al. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res 2012; 72:2879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/14\">",
"      Papotti M, Kalebic T, Volante M, et al. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study. J Clin Oncol 2006; 24:4818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/15\">",
"      Jung Y, Wang J, Song J, et al. Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood 2007; 110:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/16\">",
"      D'Souza S, Kurihara N, Shiozawa Y, et al. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood 2012; 119:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/17\">",
"      van der Pluijm G, Sijmons B, Vloedgraven H, et al. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J Bone Miner Res 2001; 16:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/18\">",
"      Pfeilschifter J, Mundy GR. Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A 1987; 84:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/19\">",
"      Hauschka PV, Mavrakos AE, Iafrati MD, et al. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 1986; 261:12665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/20\">",
"      Shiozawa Y, Pedersen EA, Havens AM, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011; 121:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/21\">",
"      Roodman GD. Cell biology of the osteoclast. Exp Hematol 1999; 27:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/22\">",
"      Kodama H, Nose M, Niida S, Yamasaki A. Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med 1991; 173:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/23\">",
"      Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/24\">",
"      Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95:3597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/25\">",
"      Tsukii K, Shima N, Mochizuki S, et al. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun 1998; 246:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/26\">",
"      Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/27\">",
"      Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/28\">",
"      Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000; 192:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/29\">",
"      Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998; 247:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/30\">",
"      Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/31\">",
"      Body JJ, Lipton A, Gralow J, et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res 2010; 25:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/32\">",
"      Fizazi K, Bosserman L, Gao G, et al. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009; 182:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/33\">",
"      Clohisy DR, Mantyh PW. Bone cancer pain. Cancer 2003; 97:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/34\">",
"      Yoneda T, Hata K, Nakanishi M, et al. Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone 2011; 48:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/35\">",
"      Aubin JE. Bone stem cells. J Cell Biochem Suppl 1998; 30-31:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/36\">",
"      Yang X, Karsenty G. Transcription factors in bone: developmental and pathological aspects. Trends Mol Med 2002; 8:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/37\">",
"      Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997; 89:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/38\">",
"      Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/39\">",
"      Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/40\">",
"      Taube T, Elomaa I, Blomqvist C, et al. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 1994; 15:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/41\">",
"      Boyde A, Maconnachie E, Reid SA, et al. Scanning electron microscopy in bone pathology: review of methods, potential and applications. Scan Electron Microsc 1986; :1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/42\">",
"      Teoh G, Anderson KC. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 1997; 11:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/43\">",
"      Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia 2002; 16:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/44\">",
"      Bataille R, Chappard D, Klein B. Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 1992; 6:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/45\">",
"      Iwasaki T, Hamano T, Ogata A, Kakishita E. Clinical significance of interleukin-6 gene expression in the bone marrow of patients with multiple myeloma. Int J Hematol 1999; 70:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/46\">",
"      Ballester OF, Moscinski LC, Lyman GH, et al. High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. Blood 1994; 83:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/47\">",
"      Kurihara N, Bertolini D, Suda T, et al. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 1990; 144:4226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/48\">",
"      Sezer O, Heider U, Jakob C, et al. Human bone marrow myeloma cells express RANKL. J Clin Oncol 2002; 20:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/49\">",
"      Sezer O, Heider U, Jakob C, et al. Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 2002; 99:4646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/50\">",
"      Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001; 98:11581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/51\">",
"      Oyajobi BO, Mundy GR. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. Cancer 2003; 97:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/52\">",
"      Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001; 98:3534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/53\">",
"      Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000; 96:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/54\">",
"      Uneda S, Hata H, Matsuno F, et al. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 2003; 120:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/55\">",
"      Han JH, Choi SJ, Kurihara N, et al. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001; 97:3349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/56\">",
"      Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001; 108:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/57\">",
"      Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003; 102:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/58\">",
"      Dairaghi DJ, Oyajobi BO, Gupta A, et al. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood 2012; 120:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/59\">",
"      Magrangeas F, Nasser V, Avet-Loiseau H, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 2003; 101:4998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/60\">",
"      Terpos E, Politou M, Szydlo R, et al. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003; 123:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/61\">",
"      Terpos E, Anagnostopoulos A, Kastritis E, et al. Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenstr&ouml;m macroglobulinaemia. Br J Haematol 2006; 133:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/62\">",
"      Ehrlich LA, Chung HY, Ghobrial I, et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 2005; 106:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/63\">",
"      Merico F, Bergui L, Gregoretti MG, et al. Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol 1993; 92:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/64\">",
"      Lee JW, Chung HY, Ehrlich LA, et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004; 103:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/65\">",
"      Leonard RC, Owen JP, Proctor SJ, Hamilton PJ. Multiple myeloma: radiology or bone scanning? Clin Radiol 1981; 32:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/66\">",
"      Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/67\">",
"      Qiang YW, Chen Y, Stephens O, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008; 112:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/68\">",
"      Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009; 114:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/69\">",
"      Giuliani N, Colla S, Morandi F, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005; 106:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/70\">",
"      Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106:3160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/71\">",
"      Vallet S, Mukherjee S, Vaghela N, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A 2010; 107:5124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/72\">",
"      Chantry AD, Heath D, Mulivor AW, et al. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res 2010; 25:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/73\">",
"      Terpos E, Christoulas D, Katodritou E, et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer 2012; 131:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/74\">",
"      Colucci S, Brunetti G, Oranger A, et al. Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J 2011; 1:e27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/75\">",
"      Giuliani N, Morandi F, Tagliaferri S, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007; 110:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/76\">",
"      Mukherjee S, Raje N, Schoonmaker JA, et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008; 118:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/77\">",
"      Hurchla MA, Garcia-Gomez A, Hornick MC, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia 2013; 27:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/78\">",
"      Chiang AC, Massagu&eacute; J. Molecular basis of metastasis. N Engl J Med 2008; 359:2814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/79\">",
"      Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 2000; 10:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/80\">",
"      Park BK, Zhang H, Zeng Q, et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007; 13:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/81\">",
"      Yin JJ, Selander K, Chirgwin JM, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999; 103:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/82\">",
"      Buchs N, Manen D, Bonjour JP, Rizzoli R. Calcium stimulates parathyroid hormone-related protein production in Leydig tumor cells through a putative cation-sensing mechanism. Eur J Endocrinol 2000; 142:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/83\">",
"      Grano M, Mori G, Minielli V, et al. Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts. Biochem Biophys Res Commun 2000; 270:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/84\">",
"      Bendre MS, Margulies AG, Walser B, et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 2005; 65:11001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/85\">",
"      Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003; 97:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/86\">",
"      Kasperk CH, B&ouml;rcs&ouml;k I, Schairer HU, et al. Endothelin-1 is a potent regulator of human bone cell metabolism in vitro. Calcif Tissue Int 1997; 60:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/87\">",
"      Clines GA, Mohammad KS, Bao Y, et al. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 2007; 21:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/88\">",
"      Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/89\">",
"      Yi B, Williams PJ, Niewolna M, et al. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 2002; 62:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/90\">",
"      Dai J, Keller J, Zhang J, et al. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 2005; 65:8274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/91\">",
"      Hall CL, Bafico A, Dai J, et al. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005; 65:7554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/92\">",
"      Achbarou A, Kaiser S, Tremblay G, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994; 54:2372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/93\">",
"      Rabbani SA, Desjardins J, Bell AW, et al. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990; 173:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/94\">",
"      Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 1996; 156:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/95\">",
"      Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/96\">",
"      Lee YP, Schwarz EM, Davies M, et al. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 2002; 62:5564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31737/abstract/97\">",
"      Whang PG, Schwarz EM, Gamradt SC, et al. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res 2005; 23:1475.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2828 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-41.196.66.12-9A2F313DB7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_63_31737=[""].join("\n");
var outline_f30_63_31737=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OSTEOLYTIC VERSUS OSTEOBLASTIC BONE METASTASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BONE AS A PREFERENTIAL SITE FOR METASTASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NORMAL BONE REMODELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Osteoclasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Osteoblasts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OSTEOLYTIC METASTASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Interleukin-6",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - RANKL and OPG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Macrophage inflammatory protein 1a",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Interleukin-3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Osteoblast dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OSTEOBLASTIC METASTASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Endothelin-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2828\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2828|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?3/0/3076\" title=\"diagnostic image 1\">",
"      MM lytic lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/18/15655\" title=\"diagnostic image 2\">",
"      Osteoblastic metastases to the lumbar spine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2828|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/12/33985\" title=\"figure 1\">",
"      RANK ligand and osteo form",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/25/33170\" title=\"figure 2\">",
"      Osteolytic metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2828|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/17/21787\" title=\"table 1\">",
"      Typical radiographic response in bone to select tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/42/37545?source=related_link\">",
"      Evaluation and management of aromatase inhibitor-induced bone loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/36999?source=related_link\">",
"      Management of bone metastases in advanced prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8042?source=related_link\">",
"      Osteoclast inhibition in the management of bone metastases from breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/35/33336?source=related_link\">",
"      Overview of the use of osteoclast inhibitors in early breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27977?source=related_link\">",
"      Pathobiology of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/13/23769?source=related_link\">",
"      Treatment of the complications of multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_63_31738="Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders";
var content_f30_63_31738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/63/31738/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31738/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31738/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/63/31738/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31738/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31738/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/63/31738/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31738/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/63/31738/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/63/31738/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21103650\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-transplant lymphoproliferative disorders (PTLD) are lymphoid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plasmacytic proliferations that occur in the setting of solid organ or allogeneic hematopoietic cell transplantation as a result of immunosuppression. They are among the most serious and potentially fatal complications of transplantation. While the majority appears to be related to the presence of Epstein-Barr virus (EBV), EBV negative disease does occur. Three general types of PTLD have been described in transplant recipients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Early lesions",
"      </strong>",
"      (ie, plasmacytic hyperplasia and infectious mononucleosis-like PTLD) &mdash; This presents as an infectious mononucleosis-type acute illness characterized by polyclonal B cell proliferation with no evidence to suggest malignant transformation.",
"     </li>",
"     <li>",
"      <strong>",
"       Polymorphic PTLD",
"      </strong>",
"      &mdash; Polymorphic PTLD are polyclonal or monoclonal lymphoid infiltrates that demonstrate evidence of malignant transformation but do not meet all of the criteria for one of the B cell or",
"      <span class=\"nowrap\">",
"       T/NK",
"      </span>",
"      cell lymphomas recognized in immunocompetent patients.",
"     </li>",
"     <li>",
"      <strong>",
"       Monomorphic PTLD",
"      </strong>",
"      &mdash; Monomorphic PTLD are monoclonal lymphoid proliferations that meet the criteria for one of the B cell or",
"      <span class=\"nowrap\">",
"       T/NK",
"      </span>",
"      cell lymphomas recognized in immunocompetent patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These conditions lie along a continuum of disease and are categorized by the 2008 WHO classification system as PTLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/1\">",
"     1",
"    </a>",
"    ]. Of importance, small B cell lymphoid neoplasms (eg, follicular lymphomas, small lymphocytic lymphoma) and marginal zone (MALT) lymphomas arising in the post-transplant setting are",
"    <strong>",
"     not",
"    </strong>",
"    considered PTLD.",
"   </p>",
"   <p>",
"    PTLD following solid organ and allogeneic hematopoietic cell transplant will be reviewed here. The treatment and prevention of PTLD and the development of other secondary malignancies following transplant are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28280?source=see_link\">",
"     \"Malignancy after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21103657\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3062230\">",
"    <span class=\"h2\">",
"     EBV positive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of PTLD in most patients appears to be related to B cell proliferation induced by infection with Epstein-Barr virus (EBV) in the setting of chronic immunosuppression and decreased T cell immune surveillance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. EBV is a common pathogen in most parts of the world, as approximately 90 to 95 percent of adults show serologic evidence of infection. Acute EBV infection leads to a polyclonal expansion of B cells harboring the virus. In immunocompetent individuals, viral antigens expressed by these B cells elicit a T cell response that eliminates the vast majority of the infected B cells. However, a small subpopulation of the infected B cells downregulates viral antigen expression and escapes immune surveillance. These latently infected B cells persist throughout life and, if T cell immunity wanes, can give rise to lymphoproliferative disorders such as PTLD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/2/3114?source=see_link\">",
"     \"Virology of Epstein-Barr virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cellular events underlying EBV-induced B cell proliferation have been studied in vitro and in vivo. A number of EBV-encoded proteins drive signaling events that directly contribute to B cell growth and survival. Two membrane proteins, latent membrane protein 1 (LMP-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]) and latent membrane protein 2A (LMP-2A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/10\">",
"     10",
"    </a>",
"    ]), transmit signals that are believed to mimic certain aspects of antigen-mediated B cell activation. Two other nuclear EBV proteins, EBNA-2 and EBNA-LP, form a transcriptional regulatory complex that upregulates pro-growth factors such as c-Myc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/11\">",
"     11",
"    </a>",
"    ]. In concert, these and other EBV-encoded factors can transform B cells into immortal lymphoblastoid B cells. Polymorphisms within cytokine genes may also contribute to the susceptibility of the host to such proliferations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/2/3114?source=see_link\">",
"     \"Virology of Epstein-Barr virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The EBV infected B cells that give rise to PTLD can originate in the host (recipient) or the donor. Following solid organ transplantation, host-derived PTLD is most common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. As an example, in one study utilizing a polymorphism at the D4S174 locus on chromosome 4, 10 of 11 cases originated from host cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/13\">",
"     13",
"    </a>",
"    ]. In solid organ transplant recipients, host-derived PTLD is typically a multisystem disease, while donor-derived PTLD is more commonly limited to the allograft tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In contrast, donor-derived PTLD is much more common than host-derived PTLD following allogeneic hematopoietic cell transplantation (HCT), and involves nodal and extranodal sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/1,17\">",
"     1,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3062244\">",
"    <span class=\"h3\">",
"     Solid organ transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of EBV in the pathogenesis of PTLD among solid organ transplant recipients has been suggested by the identification of EBV in the tumor and by case-control studies. As an example, a study of liver transplant recipients demonstrated EBV mRNA in hepatic tissue in most patients before overt lymphoproliferative disease was documented; this finding was generally absent in controls who did not go on to develop lymphoproliferative disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3062252\">",
"    <span class=\"h3\">",
"     Hematopoietic cell transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike in solid organ transplant recipients, PTLD in HCT recipients is most commonly donor-derived. In this setting, PTLD is thought to be due to the proliferation of EBV-infected B cells in the absence of normal T cell immune surveillance. If a hematopoietic stem cell donor has been infected with EBV, he or she will have a small number of transformed B cells carrying the virus (about one per million B cells). These B cells are \"held in check\" by cytotoxic T cells, resulting in an equilibrium between cell division and death of EBV-infected B cells.",
"   </p>",
"   <p>",
"    Methods of treating bone marrow that remove both mature B and T cells (such as soybean lectin depletion) have a lower rate of EBV lymphoproliferative disease after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. If, however, mature T cells are depleted from a marrow graft (to reduce the risk of GVHD) but B cells are left, then the transformed B cells may \"escape\" from surveillance by these cytotoxic cells and proliferate at a high rate.",
"   </p>",
"   <p>",
"    A retrospective study compared rates of EBV reactivation in 85 EBV seropositive recipients of a T cell depleted allograft (TCD-HCT) with that of 65 EBV seropositive recipients of an unmanipulated allograft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/19\">",
"     19",
"    </a>",
"    ]. Reactivation was observed more frequently in recipients of a TCD-HCT (65 versus 31 percent), and EBV-associated PTLD occurred only in those receiving a TCD-HCT. In addition, plasma EBV DNA levels quantitatively predicted EBV-PTLD.",
"   </p>",
"   <p>",
"    In addition to the risk imposed by the donor, the transplant recipient is also likely to have been infected with EBV. Ablation of the recipient's immune system prior to transplantation may remove enough cytotoxic cells to allow for the preferential proliferation of transformed B cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/21\">",
"     21",
"    </a>",
"    ]. Profound deficiencies of EBV-specific T cell-mediated immunity have been documented in the early post-transplant period, the period of greatest risk for PTLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Presence of the HLA B51 allele in the host or EBV early-antigen antibodies prior to transplantation may be additional risk factors for the development of PTLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. These observations need confirmation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3062237\">",
"    <span class=\"h2\">",
"     EBV negative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBV-negative PTLD has been documented in up to 30 percent of PTLD in some series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/1,26\">",
"     1,26",
"    </a>",
"    ]. The etiology of EBV-negative PTLD has not been fully elucidated, but gene expression profiling studies suggest that they are biologically distinct from EBV positive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/27\">",
"     27",
"    </a>",
"    ]. Some may be related to EBV infections that are no longer detectable. Others may be due to unidentified viruses or other causes of chronic antigenic stimulation. As an example, post-transplantation primary effusion lymphoma is associated with human herpes virus 8 (HHV-8) infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The role of HHV-8 in the pathogenesis of primary effusion lymphoma is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30969?source=see_link&amp;anchor=H3#H3\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16929521\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16929638\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTLD is the most common malignancy complicating solid organ transplantation (excluding nonmelanoma skin cancer and in situ cervical cancer), accounting for approximately 20 percent of all cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In contrast, PTLD accounts for a minority of secondary cancers following allogeneic hematopoietic cell transplantation (HCT).",
"   </p>",
"   <p>",
"    The reported incidence of PTLD varies among transplant centers, likely as a result of different patient populations, allograft types, and immunosuppressive regimens. As will be described in the next section, the risk of PTLD is greatest in patients with marked immunosuppression. This probably explains part of the variability in the incidence of PTLD with different types of transplants. The overall incidence is approximately 1 percent at 10 years, 30 to 50 times higher than in the general population, with a recent trend towards increased frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. The majority (&gt;80 percent) occur in the first year post-transplant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cumulative incidence over five years ranges from 1 to 2 percent in HCT and liver transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/35-37\">",
"     35-37",
"    </a>",
"    ], 1 to 3 percent in renal transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/38-40\">",
"     38-40",
"    </a>",
"    ], 2 to 6 percent in heart transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/36,38,41,42\">",
"     36,38,41,42",
"    </a>",
"    ], 2 to 9 percent in lung transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/36,41,43,44\">",
"     36,41,43,44",
"    </a>",
"    ], and as high as 11 to 33 percent in intestinal or multiorgan transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16930159\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal risk factors underlying the development of PTLD are the degree of T cell immunosuppression and the EBV serostatus of the recipient. Additional risk factors include time post-transplant, recipient age, and ethnicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/34,46\">",
"     34,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16930166\">",
"    <span class=\"h3\">",
"     Degree of immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of immunosuppression has long been considered a major determinant of the development of PTLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/1,31\">",
"     1,31",
"    </a>",
"    ]. In particular, the degree of T cell immunosuppression appears to be more important than the degree of immunosuppression overall, due to the impairment of EBV-specific T cell-mediated immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/22\">",
"     22",
"    </a>",
"    ]. EBV-infected B cells are thought to be normally \"held in check\" by cytotoxic T cells. This defense mechanism is lost when T cell function is impaired, promoting the development of PTLD. (See",
"    <a class=\"local\" href=\"#H3062230\">",
"     'EBV positive disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Initial studies in solid organ transplant demonstrated that the risk of developing PTLD increased with the degree of immunosuppression, particularly among pediatric patients and those exposed to certain types of induction therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/38,39,42,47-51\">",
"     38,39,42,47-51",
"    </a>",
"    ] or those with prolonged exposure to high doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/50,52-54\">",
"     50,52-54",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following observations were noted in a study of over 50,000 kidney and heart transplants from centers in the Europe and North America [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/38\">",
"       38",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The incidence of PTLD was highest in the first year after transplantation, the time of most intense immunosuppression, and fell by approximately 80 percent thereafter (",
"      <a class=\"graphic graphic_figure graphicRef50807 \" href=\"mobipreview.htm?18/28/18893\">",
"       figure 1",
"      </a>",
"      ). Similar observations have been made in other studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/36,43\">",
"       36,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The incidence of PTLD was much greater in heart transplant recipients (",
"      <a class=\"graphic graphic_figure graphicRef50807 \" href=\"mobipreview.htm?18/28/18893\">",
"       figure 1",
"      </a>",
"      ) in whom a greater degree of immunosuppression is required because of the more serious consequences of transplant rejection.",
"     </li>",
"     <li>",
"      Among patients who developed PTLD, renal transplant recipients were much more likely to have renal lymphoma (14.2 versus 0.7 percent in heart transplant recipients), while heart transplant recipients were more likely to develop lymphoma in the heart or especially the lungs (17.9 versus 6.8 percent in renal transplant recipients). In another report of nine lung transplant recipients with PTLD, eight had isolated intrathoracic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/55\">",
"       55",
"      </a>",
"      ]. These findings suggest that the microenvironment of the allograft interferes in some way with T cell surveillance, promoting the outgrowth of B cells transformed by EBV.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of more than 41,000 recipients of a deceased donor first kidney transplant, induction therapy, including polyclonal and monoclonal antibody therapy, was associated with an increased risk of PTLD (RR of 1.78) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/49\">",
"       49",
"      </a>",
"      ]. With respect to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      for maintenance therapy but without induction therapy, the risk of PTLD was significantly higher among those administered tacrolimus (RR of 2.03); if induction therapy was given, there was a nonsignificant trend toward a higher risk with tacrolimus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This hypothesis that heightened overall immunosuppression increases the risk of malignancy was challenged by the results from two clinical trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/41/43669?source=see_link\">",
"     belatacept",
"    </a>",
"    (an anti-CTLA4 antibody) and efalizumab (an anti-lymphocyte functioning antigen-1 antibody) that demonstrated an increase in the likelihood of PTLD despite relatively low efficacy for the prevention of graft rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Additional data have emerged demonstrating that the risk of PTLD varies depending upon the agents used for immunosuppression. In general, agents that suppress T cell activity appear to be associated with an increased risk of PTLD. In one retrospective study of over 100,000 kidney transplant recipients, for example, the incidence ratio of PTLD, compared with the non-transplant population, was 21.5, 4.9, 29.0, 21.6, and 7.8 for those administered induction therapy with OKT3, ATG, ATGAM&reg;, Thymoglobulin&reg;, and interleukin-2 receptor antagonists, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/51\">",
"     51",
"    </a>",
"    ]. ATG has also been associated with an increased risk for PTLD among allogeneic HCT recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/35,59\">",
"     35,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients induced and maintained with OKT3, both the dose and the duration of therapy are important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/47\">",
"     47",
"    </a>",
"    ]. In one series of cardiac transplant recipients, for example, the incidence was 11 percent in those treated with OKT3 for induction and 36 percent (5 of 14) in patients who received more than 75 mg of OKT3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/42\">",
"     42",
"    </a>",
"    ]. For these reasons, OKT3 is not currently used very often for induction therapy.",
"   </p>",
"   <p>",
"    By comparison, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    (an anti-CD52 antibody) may not be associated with an increased risk of PTLD. A case control study using a matched multivariate analysis reported that the risk for PTLD was similar in kidney transplant recipients treated with triple immunosuppressive therapy with or without mycophenolate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/60\">",
"     60",
"    </a>",
"    ]. Similarly, a registry analysis of alemtuzumab showed that it was not associated with as high a rate of PTLD as other lymphocyte depleting agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/61\">",
"     61",
"    </a>",
"    ]. It is not clear whether or not the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (an anti-CD20 antibody) in the peritransplant period significantly reduces the subsequent incidence of PTLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16930173\">",
"    <span class=\"h3\">",
"     EBV serostatus",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased risk of PTLD among EBV-negative recipients of EBV positive donor organs. As an example, risk factors for the development of PTLD were assessed in a series of 381 consecutive adult nonrenal transplant recipients seen at the Mayo Clinic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/63\">",
"     63",
"    </a>",
"    ]. In the absence of the use of OKT3 and CMV seromismatch (ie, a negative recipient and a positive donor), the incidence rate of PTLD for EBV-seronegative recipients was 24 times higher than that for EBV-seropositive recipients. These patients, who had no pre-operative immunity to EBV, usually acquired the infection post-transplant from the donor (approximately 85 percent of whom are EBV-positive). Similar observations have been made in other reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/43,48,64\">",
"     43,48,64",
"    </a>",
"    ]. As an example, upon multivariate analysis in a retrospective study of 276 pediatric kidney transplant recipients, risk factors for PTLD included EBV donor",
"    <span class=\"nowrap\">",
"     positive/recipient",
"    </span>",
"    negative status (hazard ratio [HR] 7.7, 95% CI 1.6-35.9) and age less than five years (HR 3.2, 95% CI 1.1-9.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/48\">",
"     48",
"    </a>",
"    ]. As previously mentioned, PTLD may be more common in children. This is due perhaps to the observation that a higher percentage are EBV-seronegative prior to transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/48,65\">",
"     48,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16930180\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some additional risk factors for PTLD include a history of pretransplant malignancy and fewer HLA matches. In a retrospective analysis of over 25,000 patients, for example, an increased risk was associated with pretransplant malignancy (hazard ratio [HR] 3.54), fewer HLA matches (HR 1.32), younger age (HR 1.91), and treatment with ATG (HR 1.55) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/66\">",
"     66",
"    </a>",
"    ]. However, specific HLA loci mismatches may confer greater risk. In a single center study of 1013 kidney transplant recipients, one mismatch at HLA-B was associated with a hazard ratio of 1.4 and two HLA-B mismatches with a hazard ratio of 5.1 for PTLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/67\">",
"     67",
"    </a>",
"    ]. Mismatches at HLA-A and HLA-DR were not independently associated with an increased hazard ratio.",
"   </p>",
"   <p>",
"    The risk of PTLD also varies with time post-transplant. This was shown in a retrospective analysis of nearly 90,000 patients placed on the renal transplant wait list over a 10-year period, of which 357 cases of lymphoma developed in transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/46\">",
"     46",
"    </a>",
"    ]. The first year post-transplant was associated with the highest lymphoma rate. An increased risk was also noted in those under 25 years of age and Caucasians.",
"   </p>",
"   <p>",
"    A combination of risk factors markedly enhances the overall risk of PTLD. In the Mayo Clinic series, for example, therapy with OKT3 for rejection and CMV seromismatch (ie, a negative recipient and a positive donor) further increased the risk four- to sixfold above that seen in EBV-seronegative recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/63\">",
"     63",
"    </a>",
"    ]. The presence of all three risk factors increased the incidence rate of fatal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    central nervous system PTLD by a factor of 654, compared with patients lacking all three factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16931449\">",
"    <span class=\"h3\">",
"     Risk factors among HCT recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;While many risk factors for PTLD are the same among recipients of solid organ transplant and hematopoietic cell transplantation (HCT), there are a few risk factors, such as the source of stem cells, specific for HCT recipients.",
"   </p>",
"   <p>",
"    The risk of PTLD was assessed in 18,014 bone marrow transplant recipients at 235 centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/35\">",
"     35",
"    </a>",
"    ]. The cumulative incidence was 1 percent at 10 years, with 82 percent occurring in the first year and the risk being highest at one to five months post-transplant followed by a steep decline (120 versus 5 cases per 10,000 patients per year among survivors for more than one year). The major risk factors for early PTLD in this study were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An unrelated or HLA-mismatched related donor (relative risk [RR] 4.1)",
"     </li>",
"     <li>",
"      T cell depletion of donor marrow (RR 12.7), particularly if natural killer cells were also removed",
"     </li>",
"     <li>",
"      Administration of antithymocyte globulin (ATG, RR 6.4) or anti-CD3 antibodies (RR 43) for prophylaxis or treatment of acute graft-versus-host disease",
"     </li>",
"     <li>",
"      Chronic graft-versus-host disease was the major risk factor for late onset PTLD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk imposed by these factors was additive. The rate of PTLD increased from 8 percent in patients with two major risk factors, to 22 percent in patients with three or more risk factors.",
"   </p>",
"   <p>",
"    In a similar study, PTLD occurred in 127 of 26,901 patients (0.47 percent) who underwent allogeneic HCT, with 83 percent of the cases occurring within one year following transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/59\">",
"     59",
"    </a>",
"    ]. Risk factors for development of PTLD included selective T cell depletion, treatment with ATG, unrelated donor or HLA-mismatched donor accompanied by either selective T cell depletion or ATG therapy, and age &ge;50 at the time of HCT. The incidences of PTLD were 0.2, 1.1, 3.6, and 8.1 percent for those with zero, one, two, or &ge;3 risk factors, respectively.",
"   </p>",
"   <p>",
"    The source of stem cells may affect the risk of PTLD development. To date there has been little suggestion that the use of T cell replete bone marrow versus peripheral blood progenitor cells affects the risk of second malignancies following transplantation. In contrast, the risk of PTLD may be increased among recipients of umbilical cord blood transplantations. One report using double umbilical cord blood transplantation found 18 second malignancies in 98 patients (18 percent) at a median of 134 days after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/17\">",
"     17",
"    </a>",
"    ]. Of the patients who developed a second malignancy, 16 had EBV-associated PTLD, of which 14 were donor derived.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21103671\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17288290\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of patients with PTLD is highly variable and depends at least partially upon the type of PTLD and the areas of involvement. Non-specific constitutional symptoms such as fever, weight loss, and fatigue are common. Other symptoms may be related to viral infection, lymphadenopathy, dysfunction of involved organs, or compression of surrounding structures. Viral symptoms can resemble those seen in acute infectious mononucleosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31018?source=see_link&amp;anchor=H5#H5\">",
"     \"Infectious mononucleosis in adults and adolescents\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More than half of PTLD presents with extranodal masses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/68\">",
"     68",
"    </a>",
"    ]. Involved organs include the gastrointestinal tract (stomach, intestine), lungs, skin, liver, central nervous system, and the allograft itself. More specifically, 20 to 25 percent have central nervous system disease (which is rare in the general population), and a similar proportion have infiltrative lesions in the allograft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/69\">",
"     69",
"    </a>",
"    ]. Involvement of the allograft can lead to allograft dysfunction, including renal failure, heart failure, and respiratory dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/55,70-73\">",
"     55,70-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and course of PTLD appear to vary with the origin of the lymphoproliferative cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In one report of 12 renal transplant recipients, lymphoproliferative cells arose from the transplant recipient in eight patients, while lymphoproliferative cells were from the donor in four patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/14\">",
"     14",
"    </a>",
"    ]. Recipient-origin PTLD presented as multisystem disease at a mean of 76 months after transplantation; five of the eight patients with disease from the recipient died. In contrast, donor-origin PTLD was limited to the allograft, developed after a mean of five months after transplantation, and regressed after reduction of immunosuppression.",
"   </p>",
"   <p>",
"    EBV-negative PTLD appears to differ clinically from EBV-related tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/26,74,75\">",
"     26,74,75",
"    </a>",
"    ]. In one study, the clinical presentation and survival of 11 transplant recipients with B cell lymphomas not due to EBV were compared with those of 21 patients with EBV-associated lymphomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/26\">",
"     26",
"    </a>",
"    ]. Tumors not due to EBV presented much later (6.4 versus 1.5 years post-transplantation), suggesting that their incidence may increase with time. In addition, EBV-negative tumors were much more virulent (mean survival of 1 versus 37 months).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17288449\">",
"    <span class=\"h2\">",
"     Measurement of Epstein-Barr viral load",
"    </span>",
"    &nbsp;&mdash;&nbsp;While many healthy transplant recipients will demonstrate a modestly increased EBV viral load post-transplant, the vast majority of patients with EBV-positive PTLD will demonstrate a more marked elevation in the EBV viral load. As an example, in one study, plasma from patients with PTLD had a median EBV viral load of 3225",
"    <span class=\"nowrap\">",
"     copies/100",
"    </span>",
"    microL, while immunosuppressed controls without evidence of PTLD had fewer than 740",
"    <span class=\"nowrap\">",
"     copies/100",
"    </span>",
"    microL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/76\">",
"     76",
"    </a>",
"    ]. This observation has led to the suggestion that PTLD may be detected early by monitoring the EBV viral load by quantitative polymerase chain reaction (PCR) of unfractionated whole blood, plasma, or peripheral blood mononuclear cells of patients at high risk of developing this complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/76-79\">",
"     76-79",
"    </a>",
"    ]. While an increased EBV viral load is suggestive of PTLD, the diagnosis of PTLD is currently made based upon the histologic evaluation of a tissue biopsy. Similarly, while the absence of EBV in the peripheral blood makes PTLD less likely, it does not completely exclude the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27243666\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Many transplant centers have incorporated EBV monitoring into the routine evaluation of patients at high risk for PTLD. Centers differ with regards to their definition of high risk patients and the cutoff used determining EBV positivity. Due to the use of different methods, EBV viral load measurements cannot be compared between institutions. The optimal primer set, the relative importance of intracellular versus free plasma EBV, and the baseline profile in an organ transplant population remain unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the vast majority of EBV-positive PTLD occurs in the first year after transplantation, it is reasonable to monitor high risk patients more frequently during the initial post-transplant period and to increase the time span between samples as the time from transplantation increases. The decision to monitor less frequently must be individualized and take into consideration many factors including the type of graft, the degree of ongoing immunosuppression, and the pattern of EBV viral loads to date. Monitoring for an uncomplicated HCT recipient may begin with screening on the day of transplantation, weekly monitoring for the first three months, followed by monthly monitoring for at least one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/82\">",
"     82",
"    </a>",
"    ]. In contrast, monitoring for an uncomplicated kidney transplant recipient may begin with screening within the first week after transplant followed by monthly monitoring for the next three to six months and then every three months for the rest of the first year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It may be possible to predict the development of PTLD and monitor response to treatment using PCR to detect and quantify serial changes in EBV-DNA levels in plasma or peripheral blood mononuclear cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/19,76,84-90\">",
"     19,76,84-90",
"    </a>",
"    ]. Often, quantitative PCR is more useful in ruling out than in indicating the presence of PTLD. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ability of EBV viral load in peripheral blood monocytes to reflect the development of EBV associated PTLD was prospectively evaluated in 85 allogeneic hematopoietic cell transplantation (HCT) recipients, five of whom developed EBV associated PTLD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/90\">",
"       90",
"      </a>",
"      ]. Using an EBV viral load threshold of &gt;300",
"      <span class=\"nowrap\">",
"       copies/microgram",
"      </span>",
"      DNA, the manifestation of at least one positive EBV viral load demonstrated a sensitivity, specificity, positive, and negative predictive value for the diagnosis of EBV associated PTLD of 100, 81, 25, and 100 percent, respectively. &nbsp;",
"     </li>",
"     <li>",
"      In a study of 13 patients with EBV-lymphoproliferative disease following allogeneic HCT, all of the clinical responders showed decreased levels of EBV-DNA within 72 hours of initiation of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/84\">",
"       84",
"      </a>",
"      ]. In contrast, all of the six non-responders showed an increase in EBV-DNA at 72 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Society guidelines differ in their recommendations regarding EBV surveillance following transplant. Some recommend EBV monitoring for all transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/82,83,91,92\">",
"     82,83,91,92",
"    </a>",
"    ], while others limit its use to children or adults who have received HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/93\">",
"     93",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17288456\">",
"    <span class=\"h2\">",
"     Abnormal laboratory results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to non-transplant patients with lymphoproliferative disorders, the following abnormal laboratory studies may be seen in patients with PTLD:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unexplained anemia, thrombocytopenia, or leukopenia",
"     </li>",
"     <li>",
"      Elevated level of serum lactate dehydrogenase (LDH)",
"     </li>",
"     <li>",
"      Hypercalcemia",
"     </li>",
"     <li>",
"      Hyperuricemia",
"     </li>",
"     <li>",
"      Monoclonal protein in the serum or urine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Abnormal laboratory results'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring for the presence of a persistent monoclonal protein in the serum or urine may serve as a useful, inexpensive, and noninvasive screen for the presence, or future development, of PTLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/94-96\">",
"     94-96",
"    </a>",
"    ]. In one study of 201 patients undergoing liver transplantation, a monoclonal protein was seen in five of the seven patients (71 percent) who developed PTLD and in 52 of the 194 patients (27 percent) who did not have this complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 911 consecutive patients undergoing liver transplantation, a monoclonal protein was present in 18 of the 21 patients who developed PTLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/96\">",
"     96",
"    </a>",
"    ]. Remission, which occurred in 13 patients, was associated with disappearance of gammopathy in 10. For the diagnosis of remission of PTLD, the positive and negative predictive values of disappearance of gammopathy were 91 and 100 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27548826\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PTLD is based upon the evaluation of histologic, immunophenotypic, and genetic studies interpreted in the context of the clinical scenario. The World Health Organization classification of tumors of the hematopoietic and lymphoid tissues uses morphologic, immunophenotypic, genetic, and clinical features to define four main categories of PTLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Plasmacytic hyperplasia and infectious mononucleosis-like PTLD",
"     </li>",
"     <li>",
"      Polymorphic PTLD",
"     </li>",
"     <li>",
"      Monomorphic PTLD",
"     </li>",
"     <li>",
"      Classical Hodgkin lymphoma-like PTLD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathologic features of each of these entities are described in the following sections.",
"   </p>",
"   <p>",
"    Consensus statements and published guidelines have recognized limitations regarding the reliance upon histologic descriptions of PTLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/83,93,97-99\">",
"     83,93,97-99",
"    </a>",
"    ]. The intrinsic weaknesses in relying upon histologic classification alone include the lack of uniformity concerning:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Definitions of a polyclonal or monoclonal process",
"     </li>",
"     <li>",
"      Diagnostic use of nonhistologic features, such as DNA rearrangements, mutations, and clonality",
"     </li>",
"     <li>",
"      Use of EBV positivity within the tumor or the pathologic process",
"     </li>",
"     <li>",
"      Donor or host origin of the tumor",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27548856\">",
"    <span class=\"h2\">",
"     Benign polyclonal lymphoproliferation (early lesions)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early PTLD lesions are comprised of plasmacytic hyperplasia and infectious mononucleosis-like PTLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/1\">",
"     1",
"    </a>",
"    ]. These lesions demonstrate polyclonal lymphoid proliferations, but the normal architecture of involved tissue is preserved. Histology may be consistent with reactive follicular hyperplasia. In such cases, discrete follicles of varying sizes and shapes are separated from one another by interfollicular regions rich in T cells. Tingible body (debris-laden) macrophages may be prominent. The polyclonal B cell proliferation has normal cytogenetics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25322?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\", section on 'Reactive follicular hyperplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27548864\">",
"    <span class=\"h2\">",
"     Polymorphic PTLD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphic PTLD demonstrates effacement of tissue architecture by a pleomorphic lymphoid infiltrate that does not fulfill the criteria for one of the B cell or",
"    <span class=\"nowrap\">",
"     T/NK",
"    </span>",
"    cell lymphomas recognized in immunocompetent patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/1\">",
"     1",
"    </a>",
"    ]. The infiltrate is comprised of polyclonal or monoclonal cells all along the spectrum of B cell maturation and includes immunoblasts, plasma cells, and small and intermediate-sized lymphoid cells. The tumor cells infiltrate and destroy the underlying tissue and may undergo geographic necrosis. Immunophenotypically, the B cells may demonstrate kappa or lambda light chain class restriction, and upon genetic testing, the tumors have clonal immunoglobulin gene rearrangements. In addition, the tumor cells in polymorphic PTLD usually contain EBV, as demonstrated by in situ hybridization for EBV encoded small nuclear RNAs (EBER).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27548872\">",
"    <span class=\"h2\">",
"     Monomorphic PTLD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monomorphic PTLD is a heterogeneous group of tumors comprised of monoclonal malignant cells of B cell or T cell origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/1\">",
"     1",
"    </a>",
"    ]. Histology demonstrates effacement of the normal tissue architecture by a lymphoid infiltrate. These tumors must fulfill the criteria for one of the B cell or",
"    <span class=\"nowrap\">",
"     T/NK",
"    </span>",
"    cell lymphomas recognized in immunocompetent patients. Of importance, small B cell lymphoid neoplasms (eg, follicular lymphomas, small lymphocytic lymphoma) and marginal zone (MALT) lymphomas arising in the post-transplant setting are",
"    <strong>",
"     not",
"    </strong>",
"    considered PTLD. Despite the use of the term &ldquo;monomorphic&rdquo;, cases of monomorphic PTLD may demonstrate significant variability in tumor cell size and morphology. The degree of pleomorphism is consistent with that seen in the corresponding lymphoma subtype in the immunocompetent host.",
"   </p>",
"   <p>",
"    Monomorphic PTLD is further classified according to the subtype of lymphoma. The vast majority of these tumors are B cell lymphomas, most commonly diffuse large B cell lymphoma (DLBCL) and less commonly Burkitt lymphoma (BL) or a plasma cell neoplasm (eg, myeloma or extramedullary plasmacytoma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/100-102\">",
"     100-102",
"    </a>",
"    ]. Lymphomas of T cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/103-108\">",
"     103-108",
"    </a>",
"    ] or NK cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/105\">",
"     105",
"    </a>",
"    ] origin are uncommon, but, when seen, are usually classified as peripheral T cell lymphoma, not otherwise specified (PTCL, NOS). Very few cases of T cell PTLD had been reported in kidney transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/107\">",
"     107",
"    </a>",
"    ]. The diagnosis of each of these lymphoma subtypes is described briefly below and presented in more detail separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Diffuse large B cell lymphoma",
"      </strong>",
"      &mdash; DLBCL is a heterogeneous group of tumors consisting of large, transformed B cells with prominent nucleoli and basophilic cytoplasm, a diffuse growth pattern and a high proliferation fraction (",
"      <a class=\"graphic graphic_picture graphicRef81533 \" href=\"mobipreview.htm?2/7/2165\">",
"       picture 1",
"      </a>",
"      ). Tumor cells express pan B cell antigens. No single cytogenetic change is typical or diagnostic. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=see_link&amp;anchor=H5#H5\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Pathology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Burkitt lymphoma",
"      </strong>",
"      &mdash; BL tumor cells are monomorphic, medium-sized cells with round nuclei, multiple nucleoli, and basophilic cytoplasm, often with prominent cytoplasmic lipid vacuoles (",
"      <a class=\"graphic graphic_picture graphicRef57366 \" href=\"mobipreview.htm?38/38/39524\">",
"       picture 2",
"      </a>",
"      ). There is an extremely high rate of proliferation. BL cells express surface IgM and B cell-associated antigens, as well as CD10. They lack CD5 and BCL-2. BL is strongly (but not uniformly) associated with a translocation between the long arm of chromosome 8, the site of the c-MYC oncogene (8q24), and one of three locations on Ig genes: t(8;14), t(2;8), or t(8;22). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/56/35720?source=see_link&amp;anchor=H4#H4\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\", section on 'Pathology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Plasma cell neoplasm",
"      </strong>",
"      &mdash; The morphological features of plasma cell neoplasms can resemble mature or immature plasma cells. Mature plasma cells are oval with abundant basophilic cytoplasm, a round eccentrically located nucleus, a perinuclear hof, and a &ldquo;clock-face&rdquo; chromatin pattern without nucleoli (",
"      <a class=\"graphic graphic_picture graphicRef63684 \" href=\"mobipreview.htm?19/27/19888\">",
"       picture 3",
"      </a>",
"      ). Immature plasma cells have dispersed nuclear chromatin, prominent nucleoli and a high nuclear to cytoplasmic ratio. Plasma cell neoplasms demonstrate either kappa or lambda light chains in the cytoplasm, but not both; surface immunoglobulin is absent. The tumor cells usually express CD79a, CD138, and CD38, and may express CD56. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=see_link&amp;anchor=H19#H19\">",
"       \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Morphology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Peripheral T cell lymphoma, not otherwise specified",
"      </strong>",
"      &mdash; PTCL, NOS are usually comprised of variable mixtures of small, intermediate, and large atypical cells. The immunophenotype varies greatly from case to case, but always demonstrates expression of one or more of the pan-T antigens. Roughly half of cases demonstrate an aberrant immunophenotype, defined by the loss of a pan-T cell antigen that is expressed by most normal mature T cells (eg, CD5 or CD7). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/36/35400?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified\", section on 'Pathology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27548880\">",
"    <span class=\"h2\">",
"     Classical Hodgkin lymphoma-like PTLD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classical Hodgkin lymphoma-like PTLD is the least common form of PTLD. Biopsy of involved tissue should fulfill the criteria required for the diagnosis of classical HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/1\">",
"     1",
"    </a>",
"    ]. On light microscopy, the tumor contains a minority of neoplastic cells (Reed-Sternberg cells and their variants) in an inflammatory background. The neoplastic cells typically express CD15 and CD30, variably express CD20, and do not express CD3 or CD45 (",
"    <a class=\"graphic graphic_table graphicRef57079 \" href=\"mobipreview.htm?17/23/17788\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15578?source=see_link&amp;anchor=H23#H23\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21103713\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accurate diagnosis of PTLD requires a high index of suspicion, since the disorder may present subtly",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extranodally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/109\">",
"     109",
"    </a>",
"    ]. The diagnosis of PTLD should be suspected in a patient who has undergone allogeneic transplantation presenting with adenopathy, B symptoms (fever, weight loss, night sweats), unexplained hematologic or biochemical abnormalities,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs or symptoms attributable to the infiltration of extralymphatic tissues. PTLD may also cause symptoms similar to those seen with organ rejection or similar to side effects from immunosuppressive medications. The initial evaluation is based upon the presenting symptoms and similar to that used in the evaluation of suspected lymphoma in the non-transplant population. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Patient history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiologic evidence of a mass or the presence of elevated serum markers (such as increased LDH levels) are suggestive of PTLD, with positive positron emission tomography (PET) scanning (possibly indicating metabolically active areas) also favoring the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/110\">",
"     110",
"    </a>",
"    ]. A rising EBV viral load may also be suggestive of the diagnosis. To ensure an accurate diagnosis, a tissue biopsy is required, preferably an excisional biopsy, which will allow enough tissue to be obtained to fully characterize the lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/97\">",
"     97",
"    </a>",
"    ]. Tissue obtained by biopsy should be reviewed by an expert hematopathologist and evaluated for morphology, immunophenotype, EBER, and molecular genetic studies and antigen receptor genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21103720\">",
"    <span class=\"h2\">",
"     Central nervous system lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary central nervous system PTLD is uncommon and its diagnosis and treatment are difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/111\">",
"     111",
"    </a>",
"    ]. The diagnosis is suspected in transplant recipients with mental status changes or new neurologic findings. Diagnostic tests include gadolinium-enhanced MRI of the head, cerebral spinal fluid (CSF) analysis for EBV by PCR and cytology with cell markers by flow cytometry, and peripheral titration of circulating EBV load in plasma or white cells.",
"   </p>",
"   <p>",
"    An MR study with gadolinium enhancing lesions, a positive analysis of the spinal fluid for EBV by PCR, and an increased EBV load in the peripheral blood are highly suggestive of this diagnosis.",
"   </p>",
"   <p>",
"    However, the diagnosis should be confirmed either by the presence of malignant lymphocytes in the CSF or by direct biopsy of the lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/111\">",
"     111",
"    </a>",
"    ]. Use of glucocorticoids, which may be unavoidable in the post-transplant setting, may confound such testing, as these agents are lymphocytotoxic and are known to alter proper radiologic and histopathologic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30217?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21103727\">",
"    <span class=\"h2\">",
"     Cardiac lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirming the presence of cardiac lymphoma in heart transplant recipients is similarly difficult; the diagnosis is frequently established on postmortem examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/112\">",
"     112",
"    </a>",
"    ]. Historically, it was first made pre-mortem in endomyocardial biopsies in which the EBV genome was demonstrated in the lymphoid infiltrates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]; in the current era, the diagnostic test of choice is in situ hybridization for EBV EBER RNA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17930?source=see_link\">",
"     \"Cardiac tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27243666\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As delineated above, the different forms of PTLD are diagnosed histologically and distinguished by a number of features. These include disruption of underlying tissue architecture, clonality, immunoglobulin gene rearrangements, whether EBV can be detected within the tumor, and whether the tumor meets criteria for one of the B cell or",
"    <span class=\"nowrap\">",
"     T/NK",
"    </span>",
"    cell lymphomas recognized in immunocompetent patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27548826\">",
"     'Pathologic features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Optimally, neoplastic forms of EBV-positive PTLD should have the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Disruption of underlying tissue architecture by a lymphoid proliferation",
"     </li>",
"     <li>",
"      Presence of mono- or oligoclonal lymphoid cell populations as determined by immunoglobulin light chain expression and antigen receptor gene rearrangements",
"     </li>",
"     <li>",
"      EBV infection of many cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If any two of these three features are present in combination with a lymphoid tumor, the diagnosis of a polymorphic, monomorphic, or classical Hodgkin lymphoma PTLD is made. Subclassification is dependent upon whether the sample meets the criteria for one of the B cell or",
"    <span class=\"nowrap\">",
"     T/NK",
"    </span>",
"    cell lymphomas recognized in immunocompetent patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/63/31738/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Polymorphic PTLD does not meet the criteria for one of these B cell or",
"      <span class=\"nowrap\">",
"       T/NK",
"      </span>",
"      cell lymphomas.",
"     </li>",
"     <li>",
"      Monomorphic PTLD meets the criteria for a non Hodgkin B cell or",
"      <span class=\"nowrap\">",
"       T/NK",
"      </span>",
"      cell lymphoma.",
"     </li>",
"     <li>",
"      Classical Hodgkin lymphoma-type PTLD meets the criteria for classical Hodgkin lymphoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of importance, small B cell lymphoid neoplasms (eg, follicular lymphomas, small lymphocytic lymphoma) and marginal zone (MALT) lymphomas arising in the post-transplant setting are",
"    <strong>",
"     not",
"    </strong>",
"    considered PTLD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16931767\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of PTLD includes other disorders with a similar presentation. As described above, most patients present with unexplained fever, drenching night sweats, or weight loss (systemic B symptoms). These symptoms can also be seen in various opportunistic infections, such as disseminated mycobacterial or fungal infections. Patients with systemic symptoms should have blood cultures drawn to rule out disseminated bacterial, mycobacterial, and fungal infections; lumbar puncture as clinically indicated; and those with pulmonary symptoms should have sputum evaluated for acid fast bacilli, Pneumocystis carinii (jirovecii) pneumonia, and fungal infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among solid organ transplant recipients, PTLD involving the allograft may have pathologic features that morphologically resemble those seen with graft rejection. Since the treatment options for rejection and PTLD are markedly different, additional studies must be performed to differentiate the two possibilities. Particularly informative studies include immunophenotyping for B and T cell antigens, including kappa and lambda light chains, polymerase chain reaction studies for antigen receptor gene rearrangements, in situ hybridization for EBV EBER RNA, and serum and urine protein electrophoresis. Imaging studies should include the graft, abdomen, pelvis, and any other clinically relevant areas. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12505?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\", section on 'Histologic findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21105568\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphoproliferative disorders are serious and potentially fatal complications of chronic immunosuppression in solid organ and hematopoietic cell (HCT) transplant recipients. While the overall incidence of lymphoproliferative disease is approximately 1 percent in the transplant population, the incidence varies dramatically with type of allograft, being lowest among HCT, renal, and liver transplants, higher among heart and lung transplants, and highest among intestinal and multiorgan transplants. (See",
"      <a class=\"local\" href=\"#H16929638\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of PTLD in most patients relates to the outgrowth of EBV-positive B cell proliferations in the setting of chronic T cell immunosuppression. However, EBV-negative tumors and T cell tumors can also occur. (See",
"      <a class=\"local\" href=\"#H21103657\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principal risk factors underlying the development of a post-transplant lymphoproliferative disorder (PTLD) are the degree of overall immunosuppression and the EBV serostatus of the recipient. Additional risk factors include time post-transplant. (See",
"      <a class=\"local\" href=\"#H16930159\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of patients with PTLD is highly variable and depends at least partially upon the type of PTLD and the areas of involvement. Non-specific constitutional symptoms such as fever, weight loss, and fatigue are common. Other symptoms may be related to viral infection, lymphadenopathy, dysfunction of involved organs, or compression of surrounding structures. More than half of patients with PTLD present with extranodal masses. Involved organs include the gastrointestinal tract (stomach, intestine), lungs, skin, liver, central nervous system, and the allograft itself. (See",
"      <a class=\"local\" href=\"#H21103671\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three main types of PTLD occur in transplant recipients including polyclonal, morphologically benign lymphoproliferation (early lesions); polyclonal or monoclonal polymorphic B cell proliferations with some features of malignant lymphoma; and monoclonal proliferations, often with clonal cytogenetic abnormalities that meet criteria for B cell or T cell lymphoma seen in immunocompetent patients (both non-Hodgkin and Hodgkin type). (See",
"      <a class=\"local\" href=\"#H27548826\">",
"       'Pathologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An accurate diagnosis of PTLD requires a high index of suspicion. Radiologic evidence of a mass, or elevated serum markers (such as increased LDH levels) are suggestive of PTLD; positive positron emission tomography (PET) scanning also favors the diagnosis. A tissue biopsy, preferably an excisional biopsy, with review by an expert hematopathologist, is required to ensure an accurate diagnosis. Diagnosis of central nervous system or cardiac lymphoma is particularly difficult. (See",
"      <a class=\"local\" href=\"#H21103713\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27243666\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/2\">",
"      Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 1995; 46:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/3\">",
"      Patton DF, Wilkowski CW, Hanson CA, et al. Epstein-Barr virus--determined clonality in posttransplant lymphoproliferative disease. Transplantation 1990; 49:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/4\">",
"      Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982; 306:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/5\">",
"      Randhawa PS, Jaffe R, Demetris AJ, et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med 1992; 327:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/6\">",
"      Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005; 16:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/7\">",
"      Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/8\">",
"      Izumi KM, Kaye KM, Kieff ED. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci U S A 1997; 94:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/9\">",
"      Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998; 338:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/10\">",
"      Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001; 1:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/11\">",
"      Kaiser C, Laux G, Eick D, et al. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol 1999; 73:4481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/12\">",
"      McAulay KA, Haque T, Crawford DH. Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease. Br J Cancer 2009; 101:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/13\">",
"      Weissmann DJ, Ferry JA, Harris NL, et al. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995; 103:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/14\">",
"      Petit B, Le Meur Y, Jaccard A, et al. Influence of host-recipient origin on clinical aspects of posttransplantation lymphoproliferative disorders in kidney transplantation. Transplantation 2002; 73:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/15\">",
"      Hjelle B, Evans-Holm M, Yen TS, et al. A poorly differentiated lymphoma of donor origin in a renal allograft recipient. Transplantation 1989; 47:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/16\">",
"      Cheung AN, Chan AC, Chung LP, et al. Post-transplantation lymphoproliferative disorder of donor origin in a sex-mismatched renal allograft as proven by chromosome in situ hybridization. Mod Pathol 1998; 11:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/17\">",
"      Ballen KK, Cutler C, Yeap BY, et al. Donor-derived second hematologic malignancies after cord blood transplantation. Biol Blood Marrow Transplant 2010; 16:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/18\">",
"      O'Reilly RJ, Small TN, Papadopoulos E, et al. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997; 157:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/19\">",
"      van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT. Blood 2001; 98:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/20\">",
"      Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114:4002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/21\">",
"      Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108:2874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/22\">",
"      Lucas KG, Small TN, Heller G, et al. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996; 87:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/23\">",
"      Meij P, van Esser JW, Niesters HG, et al. Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003; 101:4290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/24\">",
"      G&ouml;rzer I, Puchhammer-St&ouml;ckl E, van Esser JW, et al. Associations among Epstein-Barr virus subtypes, human leukocyte antigen class I alleles, and the development of posttransplantation lymphoproliferative disorder in bone marrow transplant recipients. Clin Infect Dis 2007; 44:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/25\">",
"      Agbalika F, Larghero J, Esperou H, et al. Epstein-Barr virus early-antigen antibodies before allogeneic haematopoietic stem cell transplantation as a marker of risk of post-transplant lymphoproliferative disorders. Br J Haematol 2007; 136:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/26\">",
"      Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998; 16:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/27\">",
"      Craig FE, Johnson LR, Harvey SA, et al. Gene expression profiling of Epstein-Barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders. Diagn Mol Pathol 2007; 16:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/28\">",
"      Kapelushnik J, Ariad S, Benharroch D, et al. Post renal transplantation human herpesvirus 8-associated lymphoproliferative disorder and Kaposi's sarcoma. Br J Haematol 2001; 113:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/29\">",
"      Dotti G, Fiocchi R, Motta T, et al. Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. Leukemia 1999; 13:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/30\">",
"      Matsushima AY, Strauchen JA, Lee G, et al. Posttransplantation plasmacytic proliferations related to Kaposi's sarcoma-associated herpesvirus. Am J Surg Pathol 1999; 23:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/31\">",
"      Penn I. Cancers complicating organ transplantation. N Engl J Med 1990; 323:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/32\">",
"      Adami J, G&auml;bel H, Lindel&ouml;f B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/33\">",
"      Andreone P, Gramenzi A, Lorenzini S, et al. Posttransplantation lymphoproliferative disorders. Arch Intern Med 2003; 163:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/34\">",
"      Caillard S, Lelong C, Pessione F, et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant 2006; 6:2735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/35\">",
"      Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/36\">",
"      Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/37\">",
"      Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 1996; 2:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/38\">",
"      Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/39\">",
"      Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation 1993; 56:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/40\">",
"      Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation 2005; 80:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/41\">",
"      Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/42\">",
"      Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/43\">",
"      Aris RM, Maia DM, Neuringer IP, et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-na&iuml;ve lung transplant recipient. Am J Respir Crit Care Med 1996; 154:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/44\">",
"      Levine SM, Angel L, Anzueto A, et al. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients. Chest 1999; 116:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/45\">",
"      Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001; 3:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/46\">",
"      Smith JM, Rudser K, Gillen D, et al. Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System. Transplantation 2006; 81:175.",
"     </a>",
"    </li>",
"    <li>",
"     Immunosuppression and Lymphoproliferative Disorders, Penn I (Ed), PRO/COM, University of Cincinnati Medical Center, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/48\">",
"      McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008; 8:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/49\">",
"      Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/50\">",
"      Opelz G, D&ouml;hler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/51\">",
"      Opelz G, Naujokat C, Daniel V, et al. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006; 81:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/52\">",
"      Shapiro R, Scantlebury VP, Jordan ML, et al. FK506 in pediatric kidney transplantation--primary and rescue experience. Pediatr Nephrol 1995; 9 Suppl:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/53\">",
"      Dharnidharka VR, Sullivan EK, Stablein DM, et al. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 71:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/54\">",
"      Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002; 6:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/55\">",
"      Rappaport DC, Chamberlain DW, Shepherd FA, Hutcheon MA. Lymphoproliferative disorders after lung transplantation: imaging features. Radiology 1998; 206:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/56\">",
"      Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/57\">",
"      Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007; 7:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/58\">",
"      Durrbach A, Pestana JM, Pearson T, et al. A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study). Am J Transpl 2010; 10:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/59\">",
"      Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113:4992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/60\">",
"      Funch DP, Ko HH, Travasso J, et al. Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. Transplantation 2005; 80:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/61\">",
"      Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007; 7:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/62\">",
"      Savani BN, Pohlmann PR, Jagasia M, et al. Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD? Blood 2009; 113:6263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/63\">",
"      Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/64\">",
"      Shahinian VB, Muirhead N, Jevnikar AM, et al. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients. Transplantation 2003; 75:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/65\">",
"      Zangwill SD, Hsu DT, Kichuk MR, et al. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transplant 1998; 17:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/66\">",
"      Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/67\">",
"      Bakker NA, van Imhoff GW, Verschuuren EA, et al. HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. Transplantation 2005; 80:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/68\">",
"      Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/69\">",
"      Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients. Transplantation 1995; 59:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/70\">",
"      Eisen HJ, Hicks D, Kant JA, et al. Diagnosis of posttransplantation lymphoproliferative disorder by endomyocardial biopsy in a cardiac allograft recipient. J Heart Lung Transplant 1994; 13:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/71\">",
"      Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/72\">",
"      Randhawa PS, Yousem SA, Paradis IL, et al. The clinical spectrum, pathology, and clonal analysis of Epstein-Barr virus-associated lymphoproliferative disorders in heart-lung transplant recipients. Am J Clin Pathol 1989; 92:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/73\">",
"      Kew CE 2nd, Lopez-Ben R, Smith JK, et al. Postransplant lymphoproliferative disorder localized near the allograft in renal transplantation. Transplantation 2000; 69:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/74\">",
"      Dotti G, Fiocchi R, Motta T, et al. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 2000; 69:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/75\">",
"      Dotti G, Fiocchi R, Motta T, et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation 2002; 74:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/76\">",
"      Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 2001; 72:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/77\">",
"      Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/78\">",
"      Green M, Bueno J, Rowe D, et al. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 2000; 70:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/79\">",
"      Tsai DE, Douglas L, Andreadis C, et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant 2008; 8:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/80\">",
"      Baldanti F, Rognoni V, Cascina A, et al. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients. Virol J 2011; 8:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/81\">",
"      Shimizu H, Saitoh T, Koya H, et al. Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder. Int J Hematol 2011; 94:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/82\">",
"      Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/83\">",
"      EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant 2002; 17 Suppl 4:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/84\">",
"      van Esser JW, Niesters HG, Thijsen SF, et al. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol 2001; 113:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/85\">",
"      Hoshino Y, Kimura H, Tanaka N, et al. Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation. Br J Haematol 2001; 115:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/86\">",
"      Lankester AC, van Tol MJ, Vossen JM, et al. Epstein-Barr virus (EBV)-DNA quantification in pediatric allogenic stem cell recipients: prediction of EBV-associated lymphoproliferative disease. Blood 2002; 99:2630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/87\">",
"      Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103:3979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/88\">",
"      Aalto SM, Juvonen E, Tarkkanen J, et al. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis 2007; 45:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/89\">",
"      Allen U, Hebert D, Petric M, et al. Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease. Clin Infect Dis 2001; 33:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/90\">",
"      Sirvent-Von Bueltzingsloewen A, Morand P, Buisson M, et al. A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants. Bone Marrow Transplant 2002; 29:21.",
"     </a>",
"    </li>",
"    <li>",
"     Cincinnati Children's Hospital Medical Center. Evidence based clinical practice guideline for management of EBV-associated post-transplant lymphoproliferative disease (PTLD) in solid organ transplant. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2011 Jun. 18",
"    </li>",
"    <li>",
"     Hunt S (chair). The international society of heart and lung transplantation guidelines for the care of heart transplant recipients. TASK FORCE 3: Long-term Care of Heart Transplant Recipients. August 6, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/93\">",
"      Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol 2010; 149:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/94\">",
"      Badley AD, Portela DF, Patel R, et al. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transpl Surg 1996; 2:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/95\">",
"      Pageaux GP, Bonnardet A, Picot MC, et al. Prevalence of monoclonal immunoglobulins after liver transplantation: relationship with posttransplant lymphoproliferative disorders. Transplantation 1998; 65:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/96\">",
"      Lemoine A, Pham P, Azoulay D, et al. Detection of gammopathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplants. Blood 2001; 98:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/97\">",
"      Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/98\">",
"      Green M, Avery RK, Preiksaitis J. Guidelines for the prevention and management of infectious complications of solid organ transplantation. Am J Transplant 2004; 4(Suppl)10:51.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf (Accessed on May 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/100\">",
"      Caillard S, Agodoa LY, Bohen EM, Abbott KC. Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation 2006; 81:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/101\">",
"      Wang TF, Klein JL, Woodard PK, et al. Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature. J Clin Oncol 2012; 30:e278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/102\">",
"      Perry AM, Aoun P, Coulter DW, et al. Early onset, EBV(-) PTLD in pediatric liver-small bowel transplantation recipients: a spectrum of plasma cell neoplasms with favorable prognosis. Blood 2013; 121:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/103\">",
"      Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995; 13:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/104\">",
"      Hanson MN, Morrison VA, Peterson BA, et al. Posttransplant T-cell lymphoproliferative disorders--an aggressive, late complication of solid-organ transplantation. Blood 1996; 88:3626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/105\">",
"      Draoua HY, Tsao L, Mancini DM, et al. T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. Br J Haematol 2004; 127:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/106\">",
"      Ravat FE, Spittle MF, Russell-Jones R. Primary cutaneous T-cell lymphoma occurring after organ transplantation. J Am Acad Dermatol 2006; 54:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/107\">",
"      Rajakariar R, Bhattacharyya M, Norton A, et al. Post transplant T-cell lymphoma: a case series of four patients from a single unit and review of the literature. Am J Transplant 2004; 4:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/108\">",
"      Jamali FR, Otrock ZK, Soweid AM, et al. An overview of the pathogenesis and natural history of post-transplant T-cell lymphoma (corrected and republished article originally printed in Leukemia &amp; Lymphoma, June 2007; 48(6): 1237 - 1241). Leuk Lymphoma 2007; 48:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/109\">",
"      Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11 Suppl 15:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/110\">",
"      Bakker NA, Pruim J, de Graaf W, et al. PTLD visualization by FDG-PET: improved detection of extranodal localizations. Am J Transplant 2006; 6:1984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/111\">",
"      Cavaliere R, Petroni G, Lopes MB, et al. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 2010; 116:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/112\">",
"      Sibley RK, Olivari MT, Ring WS, Bolman RM. Endomyocardial biopsy in the cardiac allograft recipient. A review of 570 biopsies. Ann Surg 1986; 203:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/113\">",
"      Kowal-Vern A, Swinnen LJ, Shankey V, et al. Flow and image cytometric DNA analysis of postcardiac transplant lymphomas. Mod Pathol 1994; 7:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/63/31738/abstract/114\">",
"      Montone KT, Budgeon LR, Brigati DJ. Detection of Epstein-Barr virus genomes by in situ DNA hybridization with a terminally biotin-labeled synthetic oligonucleotide probe from the EBV Not I and Pst I tandem repeat regions. Mod Pathol 1990; 3:89.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83230 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-543E46505B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_63_31738=[""].join("\n");
var outline_f30_63_31738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21105568\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21103650\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21103657\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3062230\">",
"      EBV positive disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3062244\">",
"      - Solid organ transplant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3062252\">",
"      - Hematopoietic cell transplant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3062237\">",
"      EBV negative disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16929521\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16929638\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16930159\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16930166\">",
"      - Degree of immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16930173\">",
"      - EBV serostatus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16930180\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16931449\">",
"      - Risk factors among HCT recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21103671\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17288290\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17288449\">",
"      Measurement of Epstein-Barr viral load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17288456\">",
"      Abnormal laboratory results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27548826\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27548856\">",
"      Benign polyclonal lymphoproliferation (early lesions)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27548864\">",
"      Polymorphic PTLD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27548872\">",
"      Monomorphic PTLD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27548880\">",
"      Classical Hodgkin lymphoma-like PTLD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21103713\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21103720\">",
"      Central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21103727\">",
"      Cardiac lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27243666\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16931767\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21105568\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/83230\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/83230|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/28/18893\" title=\"figure 1\">",
"      NHL in transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/83230|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/7/2165\" title=\"picture 1\">",
"      Diffuse large B cell NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/38/39524\" title=\"picture 2\">",
"      Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/27/19888\" title=\"picture 3\">",
"      Plasma cell",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/83230|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/23/17788\" title=\"table 1\">",
"      Hodgkin immunophenotype",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30969?source=related_link\">",
"      AIDS-related lymphomas: Primary effusion lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12505?source=related_link\">",
"      Clinical manifestations and diagnosis of acute renal allograft rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/36/35400?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30217?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/56/35720?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15578?source=related_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28280?source=related_link\">",
"      Malignancy after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/2/3114?source=related_link\">",
"      Virology of Epstein-Barr virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_63_31739="Frequency biochem abnormalities";
var content_f30_63_31739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of biochemical abnormalities in the urine by gender and stone formation status",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Women",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Men",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Cases, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Controls, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Cases, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Control, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercalciuria",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperuricosuria",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperoxaluria",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypocitraturia",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Curhan, GC, Willett, WC, Speizer, FE, et al. Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 2001; 59:2290.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_63_31739=[""].join("\n");
var outline_f30_63_31739=null;
var title_f30_63_31740="Beta-lactam oral desensitization protocol";
var content_f30_63_31740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F79351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F79351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Beta-lactam oral desensitization protocol",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Beta-lactam concentration (mg/mL)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose number",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Amount given",
"        <sup>",
"         &Delta;",
"        </sup>",
"        (mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose given (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        0.5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        0.10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        0.20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        0.40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"       <td>",
"        0.80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"       <td>",
"        1.60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        3.20",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        5",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        4.8",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        50",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        400",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Upon completion of the steps above, observe patient for 30 minutes and then give full therapeutic dose by route of choice.",
"    <div class=\"footnotes\">",
"     * Dilutions prepared from antibiotic syrup, 250 mg/5 mL.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Dose approximately doubled every 15 minutes.",
"      <br>",
"       &Delta; Drug amount given in 30 mL water or flavored beverage.",
"       <br/>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Sullivan TJ. Drug allergy. In: Allergy: Principles and Practice, 4th Edition, Middleton EJ, Reed CE, Eliss EF, et al (Eds), St. Louis: Mosby, 1993. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_63_31740=[""].join("\n");
var outline_f30_63_31740=null;
var title_f30_63_31741="Abciximab and tirofiban produce similar outcomes at six months";
var content_f30_63_31741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Abciximab and tirofiban produce similar outcomes six months after PCI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 295px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the TARGET trial of 4809 patients undergoing stenting, the primary end point (composite of death, nonfatal myocardial infarction, or urgent target vessel revascularization) was significantly lower with abciximab compared to tirofiban at 30 days, but no difference was apparent at six months.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Moliterno DJ, Yakubov SJ, DiBattiste PM, et al. Lancet 2002; 360:355.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_63_31741=[""].join("\n");
var outline_f30_63_31741=null;
var title_f30_63_31742="Retransplantation survival";
var content_f30_63_31742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Survival after lung retransplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 372px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Survival estimates of initial lung transplantation, modern lung retransplantation, and historical lung retransplantation recipients after adjustment for age (55 years), sex (female), race/ethnicity (non-Hispanic white), procedure type (double), mechanical ventilation (none), and pulmonary diagnosis (chronic obstructive pulmonary disease).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kawut SM, Lederer DJ, Keshavjee S, et al. Outcomes after lung transplantation in the modern era. Am J Respir Crit Care Med 2008; 177:114. Offical Journal of the American Thoracic Society. Copyright &copy; American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_63_31742=[""].join("\n");
var outline_f30_63_31742=null;
var title_f30_63_31743="Gram stain sputum 7";
var content_f30_63_31743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain sputum 7",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAW4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDQtWt8xxblLS7inPLAYJxz2yP0rSjQ72PzbTgYyeMccf57Vl29wUABD5PbbxwcfT8/8a04nJX5k7Zr86lc+lcSxHGrHBUsOoLDFGpNbQW4kvNqwg/MzDgU+Byy5KsB2zWZ4p0+XU7RIoZ1RA2WVhncKzSTklJ2QU43mky1cXdnaWou3lXyMA5Az2/+sKvWdxFe2yyQtvjPOQcf/XrzpoZLgz2l5ObaBGAQHoceldXYXX2e1iSBlbYMHHcU6tFQSs7v9DsrYTljdG3cKMEY59+ajhJDZP0FZt5rKQwGWRgkfQknpWbceJYbYuSfMKrvAUdRURpTlsjnjh5s6d3B4U9+RjNBXPXOOvU1k6HrdrqasU4ZTggjpWvvQEsDlR3FRKLi+WSszOVNwdmRPvBkbnbgnGck8cUk0LOvB6d/b/GrLLuU4OOnT/Ck2lUPXp3pXEmVGXO1eTk/eH8PB9x+nr+NRGFdzBkx/snn86lO5XIP8XSrOFY7sqM8dM+tO5V2ipbuk0ZaFlZQduUOVDDscdCP/wBdTkAkDaMHg9+Kk8pBJvESbzj5sDPT1qOVDvBVtpx3GQeaV1cVweIMx2jJxgFvw/L8Ky721YybgSVra3qpCnr1prsCmFGT1zjpQpNFwk0YsMbKoDDJFTlW2MFAbg4H8vpU1zJGrNyAQefyqNbiPgBufandvU1d3qAChxuYZPbvj/JqGW3TGRnHsKtgK6jIHTrQVCgKMED0ovYnmsc/qsQaBlOCmew7/WrekW6w2xdcksPTNN1sfJuQdTyKNHeQxHzEKqOhrZtukdDbdI041AiGcMAc5OMdePxH9KkSIF/daahyhCgDkkD8c1KxkCnyym8jhmz+HFYHJqWIYk+8ASSB3OKlC5Ynkgeozk9yKZC244yAQM9amIIXCqHUngD9TUMhjYF3Rqxfcdo560yZG3AK3tjH+fSrG05GeOO3+etNK5Y8spGe/J7VN9QTsRW8Z2lJGbgnp15JOP1FRyRbz86Op656/wD6quKoVQoCCMfdAJ/ljtx3Of5sk/2gCO5zSuCeuhktGW2knLH1PtVaeLJUBQyHrub/AD/Or8jYkbHQ8/Sq8hJ6gitE2dEWZjxAuHIwR39frTHiQuXPRfX+ft+HqauSxLGmclQTk5NV8EkjI4/lW6lc0WpFB8gC8hc4z2A9vbj9fpU5IIxKF3dBhs+3+FRAEDt0/CozL1GT9Kpq7K5bjZ1jzg/XgVUSDeC6kFjyDngcVaAAUnOT1qPzMybVUjjrWkW1sWkQtGVQ4TO3nBPX15qtLbq0eMA9yMfritFlbb93g981E0YPXk+lXGbRSMeS3BULtRlUAAbOv+c9Ky76xt3wPLj2hum0c8YrpLiIYBwD/WqE0IPIPT1rrpVWtbjsmc4dIsim1bWPI7smcdevf1rNubKzlndTZxL5YABbC5zk9q6sRYHb8qytXiuhIGtIiwPUj6V30a8nKzf4kujC234HocG/5TjOfTp2rStmVcA9B07f15rK87ySAxIPYGrkU6uFwwI9q8GSOGUWzYDjHz8jrxVDW7kRWcphdY5tuUYruGevIyMj1HH1qzHIBEehU/zrC1qJZ7KZfOaIkZDj+Hms4JOSuFCCctTyPXL+/wBQmmcy4KMcoOK1PAutXMV6sFxKTCeBnsc07UtK+0PJcRsjmLkspHzD1rFBjt75SpIXIINfVWp1qLppf8A9f2DjNTb02PU9RSKeHyZcgPyGXvWRc7otQtnhRWVBtYN2HardtfxpbrKzBosZJPasu+1fTHLMHG8dxnmvFo05p8tm0aRpOLaZ0drcQwEtHGIwTubHetW21FXZW+8leYr4njhucKrSR4xXW6HffbIBNa8r/EAKjEYOVNc0kc9WjGV2nc7q3uQ6jBPPtS3EzfdjAZh61j2t6YQSVFOj1aKUlZCEcetedyPsefKg73SNWRicb0OO/fNQPO0B+ZcqfXnFNtps7jG2Qe9TKocN5gLZ9Tx/9altuZ2toyaJw6Eo4PTOBmnyYCgtjJ7VmraPbTNJAcKP4fWrMN0s3yvlWA6dOaXoEodYjtzsD8pzSHf5XJ78e3NLE+5dykbew71I6gLuzz796GF7aGBfGRZn4BGcCqsWTKdoxXQT2oYbhyfrVIWLhyVOc1rGatY2VTQdaSP04BHJJ4q2QMhgDz+GOBRHaBIxwcgdjjNOuJkjXaQMY4x2rOTXQyvzPQz5ovPu9jHK1bkiCHC9Dxnr+dPtIsqXYg+pqWRTtPYD061LfQqUuhBEuPmPfOeKsBc8HkZ9Kgfcg+VHcY524P8A9c1ctwCgJzhhnihmbYRRYYkc/h0qSSVo1LMM9zkcnvQN2WxjOafgScMNxHfGeKhsn1K5ucE7vToBz+FIZlzyN2ORnmh4gcj09KrNEd2ccn9PpT0LsjSQgxgevFK6gpuyDn+GoI0KAbhz65qfaB7EHJ9KhojYoyW75yOmOlQmEA5bB7YNazIoXhjg8VVZFU/LndnueKakUpMy54Ny4Kgr02n+tVZoyvGOO2K3JolfrnpziqM1puHBIP8A9atYzNYVEY8uf6k1XOMEgg81rfYkVCXZiR1yax9euIdLtBNNG+wkLkCuim+eSjHc6YNS0Qm2T+Bhg9yM4pfnXAYKW9V/T9KzH1+zjmEX7zgqAdvrXSizBAZn4xnOO2K1qKVO3OrXKn7m5URW25PT0prQuQMYwOp7VesDb3iSfZ5N4jbDcdDVw2mRjb+dYOdnZmLq2OflUY9D6YrnfEd+2nWwkEJdy20KK7e5se6KCeBk9uaozaarjD/MOvIrooVoxknJXRcaqtoc3Awe0ikkXa7KDip47VpcsTkHtitIWKqxznI9az5NPljvZJUuSI3HC+hroVVSvZ2LdRPqdaIEc/dBPoV4xzViO2ReVUY7gjp/n+tRwZDdVwoII9Mnj9KthCow3IzXCzzOZiNGEQjvXJ67FfJPH5OGtiMSLXWyAnkE9ajlhSU4fG71ohPkd9zWjU5Hc4G9so7bTrme0j+fyznr6V5ruMpZnPHpXvF3YFkeMKuxgQR6153rPgicXDPakLETkLzkV7GXY2nG6qOzZ6Ln7aKt9xy0OpSrYtbsztGTxg1VkJZGLLgj17it6PwpqBnKugCYwD6U648N6rHIm+MOmcfKOteosRQT92SL5ak42l6GFAryQk20e9umBzXovgSyuYLdmlQq0mDgCqnhDwpeRXJmuECjJwoPT616XpenG3OWwWx6dK8jM8fGSdKGpnKcaUNXrbYypLadnG5WGfQVhanF5UpJJr0N7fcpU5yfasPUtCN0CUYbq8mjWUZa7GNHEq/vGBpmoMi7SxwD07V1Fhdx3ESB2xXNT6ZNawOrxB1cZV1/nTLGWWAAFsYGPatKkI1FzRNqlOFRXidoqEggHAqrc246N8vPyuOop+nXqSgQsQH7Zq3InmEdCork1T1PPd4PUowusKKkjDJ/I+9WYiGGOpqHULCK6hAJwR0NZSXc1lKUul3IBjeB1qlHm23LUFNabnRxpuHU98f5/CleHAOOSvYVl2+qKx4bKngcVdW6kuDiGMgnvUOLRk4SW46eRYYs55x0NczqOl3V/fW1ylzJAkZ+aNejV0wswBulILerdKyL97+PUrZLWNDEWzIxHQdq0pNp3i9TWk0tEalsoChSOCMcGnSISpAyPX1zUkGEQNjr7UpIOef0rIyb1KcSsi5JLcnJNWLc5QADac+vf/OahPQ8cjmoISxkwc5NO1x2uaq7WAYj5h6VGwweefc96sxAeWpYdutVLoFmwD74qCFuRpcHgAAnParER3AbuCOmazYd6O29TycA+n0q8vAGDkmm0VJFoBMEHk/UnvmkkGOVAPTqcVCGZegNSE5Ocnj14qCLCbyEIIznpVKRmWXg8ccCrwyCOhGKrTkLu2gEjp2poqLGNIzHnOCOSKlTgfNzVUsST06VLEc8envVWG0OkVdoPX6CqOq2EWoWUlvMPkcYzgcVo5AUbulMZldSVI2jjr3pptO6HGTi7o5+y0S1t7SOAxpL5ZyHdQTntWgUIBHGOnI6ijUJ4rSIzysFjA5NYV34lgKhbaCSZ2G4YXqK3jGrWd1qbqM6upt2lvBbKy20ax7zlivc1eTI42n1qjYkvEkpQqHAbae2RV1Cdo7qehFZO99TCatoNmBZcEdT3qnKmCQq8nvVuQnb0Uj3NV2IJbtk5PNUhIzJVC4YnLY61Qvot+AJjA4/iXBJHpyD7Vo3TAMxJXZjjjHPfn8qx7ibE2cHp6/59K6aV27o3jFtHQ24PmFMLjOMkn37dv8A61aIyODwO1UYSIjiXn09QPSr8RD4KkGspM5miO+V1VTFgkjvRjeuXGCBzzVoEnA4/GkkRmYc/KOvHBqBJlbd8/t2PWopN5OAuVHcirrxKMevbtVaeKQqMkjHtRZMpSsRhgTghQD2qaOGKRwNg9jiswhxLgsQc9MVqWUmRhv1FEoJalOpJbMuRRBeFGB1qaEcAyYBycDOcimQyqzkLIjMvUd6kUNvJPPoeOaiyOebk9ycAk5GCMdhTJF6cnP1pVYqcDrxmpEHBJGT60WIu0QPGJF2v16VRn0i3njAdNrdcg9K1Nu0cn8xQu0nJxj6UlpsaRqSWxzc+nyWshYIWQD7+enpTI9SeAEMPkPBJro70KkRA9OmM1yN+FRnZFye69jWkPf3OmFXnVpF9b9HT5WyT74p9xbpcW7I2SxHFYVoiTOXiJSQdUPUVuWSMSBOCp6dOtOceXYbXK7oyoIzY/Kygtu7jrXTafMksWeMDg9sVW1Cx8yMnGSOlY1tcTWNyVbeUPqal/vNepo17aPmdbKoMbAnKn07GoWVSVOOR0qva3C3IVlcEdxVsDOQTkjqaz9TlcXEiByuMAqO/ekKjccgYPqetK6hMZYUBcksMYFAFeNZ2umLBfIz8uBU8aqXJQg08Arlh260mcZcfKD+AoeoN3J1jwwHXJ71HdJtBIxnqSafCSsgJ9ap6mTlmQk0luJLUiYksegqaMbV3YGBWPHK+TljnJ/GtOBjtUNzVOLRo0XIAGQc/Keae0I7kYpsRAAwCB6HtSmT5SOduPzrPUhkL7QRsPI61VklwpLcCpnOcqBmqshbeCBmrSGiVEHVu/FMMMyah58Vx+4MZSSDy/4uxz60kZA7kGklcumAxBz1pjSZKxzwCMHoOtOVP3ePTnGMVymnR6mmuXM9w7rbZwke7II9a6Pziy47Vc4cjte5pOHLsxlzbw3ERjmUMjdQaZb2lrbwgQoq7R8vHanOcdTk9hRg8HJ296m7ta5SbStcGkA5AGc1Ir/Jk8H2NKqIF68+9RSuqZyRge/ekTa42WRBhCwDt0GMZAH/AOqqkkqRMy55NV7/AFKOFCXkUDHrXIXGvJNclUYjGQpJ6110cNOrqlodVHCylqdDqd/FEuWcBfeududRiaT5RuFULmVpsrK7Mc9xwKs2On+aWyQRjqK9GnQhSjeR3KhGnHU9FNzF5aoeQewqEySqyvCDtzyuOKsRAOQAvB6ZGOK0EXCgYHt2rynZHhqaiQ287SbCEIz/AA4xj/OKu5eVThQMdz/MVEUVzy2D2oDPC43AGP8AUVFuxm3fYd5IUbmO49RTZzujKqcEd/WpUdZFJGDxn6UOitxuOeD9RSJv3Md4mDDIP1q/bw5ALg5IqxJGpGQOcdD6U6NQp+XPPrTchuVzmofD19ZeJBd2V2BZy5aVGbJ+grsI/ugP97FIFJOcZJpUUhueh9+KJzlOzl0FOq57kjYA3YGDTiUVeQcdaYd5/MdqjlmCE+3Oc1CM0rkudwOcH1FACgkjrVATkSZyFU/rT/MAX5T8x96dh2Fv8PGT7da5qSJjMc8kn8q6dl8xBnkCq4tVDHp704y5TSErGJHoxZxKh2N1zXQQxpHEvmKGZasQJsHOMdcUTruO5ePYVMpOW5bqOWjIJGO0lRmMfw+lZN/bw3qHnDDgnPOa2I0wx5JBNZ+oW7LL5sQOT1ANTHR6GlOVmcsGm0/+NsA8Ecc1u6XriSoY5yFbs3r7VTu4/tIdm+VsYwRxWIIZI5CpTvkc4rq5Y1V7256ChGqve3Otv7uJIQ8rfu+uR0q5aTpJCDGQY2Ga4+K4mRfLkGYzwc8jFallq0SgREbMDGccVlKk0tNTGph7LQ6F9wDNkLt+Y+47j8qmkwuMAt/DgVm2l08m8u8bKT8oUYwPer1srbdoOUHRTyR9D6VizilFxepLnbzj2ps0AkXnv0xzU8YGDvbJyegxgZOBj6Y/+tQpBYDgZxnBpE3MifS0midZQSj/ACnDEEg+45H1qW1t1t0WMtI4X+KRtzH6mtO6OI8qATWBc3DeYcnaBVJtqxUbyNAv1x9OKj3nHX261nLcAnH3gvQ0rz5B5+lPlHystl9voMimqQW9cj0qsHwC3H40ocb946nrTsPlJSVVskDkVA8gySP8aZPJkAcYHfOMVVmYg5zxTSKUbkquS2B0q0Tn6/Wsh51jIJcD60yTWIol5kzx2rT2cpfCjaNGUnoa+PnD859aZM+CCWAA9TXLXXiOTIEKKFJxuJrJvtUnlb5ZCRnFbwwVST10OyGCk9ztby/EUZbIGOnNYF/r7BGEPyjrntWMNThkiZLkuHVflOT1rFln3g7iSPWuyhgUn7yOulhIx+IfqGoTXRcSOTxxUVlbNLMjSLgLz/8ArpsxDH5RtPvWjpsDS/PK4XjAAPLV6UmqcNNDolFIVVVpyqEsMd/XvW7aIsKdevUEZqrZ2KwsZC+SR09BUsX2k3MwaNfLH3CO4rhqyU9EzkrST0O8QnzEOMKMjr3/AM+lWoecsGJB/KqsBDRjurE8irSkYyMbRXktHzrJshR75qGSfDgE5H1pZFyFI4/WqUuVzjk9O1CRKVy1G4BbBwPSrSEY3FsdwKyCXIwucEHkHpVy3dmCrk4AyOaTQ3EuNJj3A9qDICVyO+emenQ1A+Rnv7io45lDHHXH51LQlE0jOMhlPTjg0LdBQF4yfeqiknOAOeCPWnBCfvEZPTtSsTZdS9KwI3Kfw61SKnIYtuXHNSxr8pJP17c05cAEEAjmi1gTsULoqAenr1qOGYkgAZI7Ut6uNxJP4VVhLYXaOnvVpaGq1RtRS5UZ4qQ5cgAcD1qlbsSccg+tWA5Jxjj+YqGiLE/mYY5/KkJLoy889SOtRI+cDk9cChAXQ54Q9qloaLEW1FIIJ461DLHj5sEj0qXZtB6gmkI6DP4mpsClrcozWqyjcoAI9B2rOvbTzF4TBUdcVsyJIJkCOBEBkjvmmyxGRCM8gdc1V7anRTquJyjwttKvn64FUZ4tql4yd38q6CZPKYmc4AH3gKy1aG9idoBkAkZ6VvCb36HoQqX1M6w1CS2lHmAsO4z06Y/z7V1ltfmUJLEzEZwV9c1xlwhDHuT+lW9J1B0uIoXCFQ2QCMkHBGR+Z/Ota1JTXNEqrRU1dHoEU6H72enrT4poGcsjDPQ461jW+ox+ZsLkEno3U/56VekWOZRgqG74rgcbbnmyp23L07hlBz1681iXaKwPck4pJJJ4N/mNvjz0Haqf2yN8YyTnGMd6qMWKMGtUQrEYnJDYHpQXAY5HA75qSRsjIP41XkPIya133NU7j2mOOCeOeab9q2557Z9KglO0cnp71n3E/PJGPatI0+Y1jC5fub5EjO5gM+pxWRcaxFHkFycdhVDV50EDFyd2OK5g3kgidFwNx6+1ehh8GpK53UaEbXZr3usmXcf4DwBmsv7exbOTs9AaocnqcqKdMVWPKLgnpivUhQhDRI7I2S0NOOR5lbgbR0706JjbsS6GTI7npUGnh1K7cDd1Zj/KpL9hFOGOBCeAPU1DXvcpumrXK8scrgv5bDByT7UzzN3ynBXselacEjspZ1XkHA6ZqqbQLtdxlf7hGaamtmF2QbAVbkM2cBa67SrSL7JCwVWbbycdDWNYWRnkDiLOehNdlbwrFCiEKQBzjjFcOMrWSijlxNWysil5IJz94emOM0kkgjAHQ+i8mrF24GAgBYnA9qYrRwsMruZlySRz/n/CuNNtXOGUrK7Oktd6EYiCxkZLZA5z6frVtSeDxzVCFtp6jHqTVlHB78jnNc7PHaLTtkYYg5OKYysUJVRkjjJ70hkHOeB0p24E49fWkRYQxL1PGe1SImBwBTSyhenFPMhACkZwKkNRec/MOD61Xa3WR23gg57HpxTmlO/BI6dTTxyvqScZpbFK6HRRNHwGJHqx6U4Fieeg9+lSr90AEYFIvyn+E4pEXuS5XYB1A5p2doOACKj34/h5HenLMh44z6CnYhlC8beDkcjtUUA+VSR7AVamAIOFz9KZFtUdOv1q+honoShwOF69iKVJSxxjnPSnLGC/BAApvHIA5JqNAJMttIVuQOM84/DNLEzk/N0PA96ZHjAz19KmcfKNoxnj/wCvUsZKpG0b85Jx1pjkgDntgkUjI/YjH6iobiRkZgVI4xx9agqMbslQKs+5mbJHZv8AIp+9fm6g4rjbfxSg1G4iuiI4UbCtg8mt038e0NuAXHBOK0nTlD4kbzw047ly4hSdSGAIrIvLGSEh4cGMc4HUVftb6N2UBwSB2/nV9lBAIxj+dQm4sSlKnucfcIrPu8sP6isK6EEFyJ1yYwc8NjBrttStI5WxGSk55BIxu68D34rk9V064gk3SodnUkDiuvDzV7Nno4erGWhopHHeWStAWjyQQzckeoq1ak28ZAfLYzz6/WsbT9USBfJlTag9K1DIJBmI7gecipnGUXZ7E1INb7E39pFxtZSpxnBqKZFlwwPzeorL1W4MFnLMiGVk52L1qXS7hngjcqQHUHDdRR7O0edEOnZXRM88qLhkOB3FVJ78IoIBzWq3zDJPWuZ8SXzWHlFYFeNz8znotaUIqpLlS1CmlJ7Cy6r82G5A9O1ZV1fwrMHkkOBztqG6vWlGIcAHuB1rOQpu/fD8SK9Slh4rVo7o0kh+oXou5Ac4XoBVZHiG4S7iQOAPWkumQsREAE9RTI1JUjcceg712xilGyOiKHI0Yjyxyeu30prFEKPCF2n74br+FLIksaKyqGz6DmoZS6x+ZsKkc5I61SVyrl1J4ZZPNMYIjG3hsVBhEcCSYNFuJ9cGobWb92PKTDk5YY/WrsWnxyRneCd56ehqXaG5SfMro0bRQ2GwWjAH5VNFE0t2wL/u/wC6egpLex2W6IzMAOwNNgyuoPbBZAAu7f8AwmuNtO9mKc0bsbxw87hn0p51BQu0OB61ntCHjYMSG9aLayYoNx3bjjpzXI4Q3kzmko7sqalqc7X8MVs0bAnPPeumZQFUSEKcdT3qrDo1t5kcpRTInKselaM4KgBNn/AgTWVWpCXLGC2OSvNPSJftpNzbSc9+mMDsKm3MMsTkVWhcfj0IP8v1qdQrH7oyDkGsbHlEkcpwrEnkDGeKsK+0jnrnpVdRlQXB6jvin/Lyc+2M1LRLJ9wznBwe9P3rjkfgarBuMY79c0NwNoJPrU2Cw4kFhzz35/lU8RZRjGKp5O7IJJqzEQScn05pNDlsWYi2758gD0p7E46Y7DtTI8Yx1GcZqYkYGceo96Rk3qQOSdpyAO+eeeKSR2PORg96cw67gNpHpVZkUNgkjPvTVhpEiyE9TyScVNGVJ5J45PtVLzlyBkKAOfapwyZyHyuOmabQNWLUZyCoJyTwcUh/2Tz3zzTIyODu/SiT5uTgZ6VFg6iCVwDlR14wO1TW9wWzvDA/SqizRq2wuMjpmrScEDk56ZNKSLLkUoCfMSfpxTTslyu4bSMH6VEX2L+PNPXYwVl78nFZ2FtqcjJ4VSG4eQv5toyh0jfIKn1NMOQgV8ZXjiuwKiT7xwCOKy9R0nfIpt5ACW5B7jvW6quT99nbDEuWkjn45Psz+cuQc4yK6i0uWmhVwAeOaof2OwIEmDk9BWtbwrGm1etRUlGWqFWnGSGbBLIjyKrFCWQsMlSRjI9DgkfialurdGhwQGyMjuKstEi24lDfgaoC8jLBWbj0PWs9Wcyb3Rk6jottN8ypscflXN3MN7psn7oboyeB2rtZp0dhn8Kz7hRK+wr271vTqSjo9UdlLESWktjjdS1ES2s0fNvcOOHA6UthqMcNvDHM7SyAYZiK2rzQoXkDBu3esa606a2DeWgdDXbCdKceVHfGdOasiwdUb+HYR0rN1FkvoWguipjJ+7VDUrpbBAuCWJGFPWpLedZLcSXgO/ttHH/666I0eRKcTRUorYJLJUiTZgIg7HpVJLcXTMUVmX+92q+5Uxbo43bJ9apJJPbJJHDwpGVBPc1vBytvqapDv7MwCo796r2VsftK+SwmiyQ5HY+lMljn+zQCaaVHHU9R1qY30MMf7lgjd+OprT37WTuaRTGa1cGziDRj5s4AxXPz38jBTMScnp6VLrskt0Y25b1IrHMkzHYUJz0Jruw9BKCb3OHF4qVKbgr2NOwvEj1EKxOCcYxXVNdRQwGYjKr1xXG2FqQ/nTHDdhWzYyyQx7Ww2T0rPE04yd0dGDlUlTftFvqjo7e5S4gSWPJU9ARg1HZ3VzNLL58PlID8pPU1HEzEqFAVByRiltLr7RcSxRqSqj5ZOxrz3Gydl/wDSasaG4FlCmtG3gbKkNx6CqlpCWTcqke561s2ylY1LdT69q4qs7aI46srEib1Tsc9wOtRSSEsQBgjrmpt25cknJ7Cqks5T+Ede1c0VdnEX4GBUDPTB/yKtoSe+KoRH5sY4qQ3CIQGYqSMANxVM5eW+xpIRtPOBQVK4YE+wqujh48MBVgEYGB9etSZ2sMLHIOfwp5cNtB6nsOxqtcqeMHgdqkU74lcZUgYPaky7dSQ8HIHNWISAAGOTx+FUYjvAJ6Z44xU5dUUHjOPTrSYpLoXFcrGcketQi8TzFVmUZ6c9KybvVFjYgnB71yN94haDVxEY2KtyHxwK0p4edXSKNKdJS3O18SXt7BbxtpirNIzgMPQVU0vULy9hlF7biFw21ec5FYEerK5G584rX0K/Se6EbYJPqKqVJwhZx+Z0OiowOitrYRoCSN2KnBGMYGe1Zthr1lfy3CQs5MDBWLDGf8AOKsu/mAsmc1i007SOFxb1ZMrMO2RnmpNysPm/wD1VnNcyIB5i8EY3CnrP5sYCkZAx0pWHyMmleIHbjcc9cdaWOdwQo5PrVWOEr8+CAantoyHzxz04oaRpZJF1JeWODntVpHBRSBx7UyCMDBJyOtWpQFGVHPtWTMZNCBFYDBxT1XPJ6rVVpgrsDx6D1qubwhyCT34IosJRbNh7fKq25Tu7+tRahE1ljdtIPtXO6t4j/s+80+z8qSV7rJQoB8oHUmrV3qcl0Nsj7lXoSKTg0k2tGaRpybG3dw8pwjFcEZBqs8QcFu4HrVe51CFABJIqk9OaWGQygMduMYB9RVJaHR7OUVdksaNgkuB7nmnyIVXhuSfSiMgjjtUczkDKn8D2pmbu2VNSeSK2kaBTJKBlUz96sXT/tiFp7olTIP9Sf4a05rkQjLt361gatrAiYqpBbtx0+tdNGEpe7FbnZQhJqxk6zZLNdtPOWByOBUbK8Vu0uGlVBkIO9Uru7muMl+/OSKaLyQWvlhvxAr2I058qTPVgrIv2t1KLd5LpCu/hFHHHP8An8KrvMXcW+w+XIv+sU5xVZruWRUjkw0ajoetU5pXL4gkWMA9+4q40dWyuXlVy5I10IXhT5WiPy7jkuKzRK0wHnw7GHB4xVh5fMMU85xMnGAetZ+o3ZkHmZKqD0rppQd7WJqTVOPM38v62ILyUmcxoxVV9KrM7xzKd4aoZ5GNyzIMxuOGoby44j5jZPqK7owskeDVxDnKTvszQe6hhA8xwCe2atWKNeHhjsJ4wa51YY2Ys4LH610/hKJvPbglDyM9qxrxVODktzqwWKqYiqozXu+X6mxZSumyKRSkeSC0hwa17S1jTiJFCtz8vQ+9R3FlDdhBcoTsztxxWjYQJBEioMKoxzXh1aqautz0asi9ZptVWIIHpVokKe471XEoSPjnHtQJdy88fWvPabdzgndvUsBwBhR0GMDpiomClvmwD9BUTSndx0qR2XYC2MdMmi1jBqwz+0Yxqq2GyfzvL8wv5fyAduelM1fR01FYnEjx3EQ+Qg8Z96uibcMEHj17VKnHvj9avmcWpR0ZzxbiLpsMkFskcsm91ABarjFiQD064qKNgTjGPak3lsgDBHes3rqS7ydywGLKVz2quY2C7WchRzj1pv2hI8hnAx71Xe+iIw77hU2fQuMJF5XTbgk7ex9qrXd3GVOJAR6elZ0lyEARCpX1zzVG72hcowwferjSu9TohQvuZ2rXUbMzEknpxXNzzzSS8KcDpn0reNqssoVjhSeaeNPV2JiVQM9T6V6tKpCkrG/1fsYNrKwYZGAetdDpUohnR0JJFH9mp8q7Rnu1KlgUbKsScdKVWrCorD9k0rHSwwW5iJgVY/MbcwToT71rW8apCo3EA+prk7a4uY5gFH7nbnOec1uWupZUb48HHPevMqQkvM5p0pJaG0tuTFyfao4oNr5X8cUW93HINw4+p61J9qUABtu081hqcrUloSztIsWY0BGc1SF8gkCyZXsaln1CNY8RgMe2DVGC1NwTLPzzjFJW6mkael5GrBqMQU/vAAB+FOGo5H7oBlPcis6W1iVflUH6VVurtLTarkjJ4oUFJ6DjTi9jSlvWz85A+lUproE5JrG1/wC0vaItmWDlwTtOCBVL+0LaffCs482Lhxmt4UOZcyN4Ukbp1EqQSAQOhx0rA8TazJbWZaNsMxwKLuSfyoTbFSmfnz1xXK67qAnleIgMo7ehrrwuFUpp2O6lRSTkU31Oe5Ia5kJx0r0Hw3dt/Z0YdvMHY+1eY4RioKlQPQ123huWNbNEjYsAcc9q7cfSi6asiuVzi09TsRebMe9LLOFTBYe1V/KSWJckY69aDEi/M3IUcZ7V4VkcDgrmJqBuJXyFOPUDpzWO8Cidhc70HZsdTXX6ZeW9/vNtIH2NtbjpVqa0ilAWRFYDsRXVHEOk+Vqxqq/J7tjgNVjjihjS3kLsx6egrKEcguAHK+WeuDXcanocEmGhARs84HWufvbC4tnIZCVfjeF6V6GHxEZRsnqdlOrGfUyVt52ZhKMIT8pHeqs9jI8jYB2Dmr1yj28uxHLA9KdFb3IGSHIPUda61Ua1ubuMZK0jFYEBwobA7VGlm0ykv39a6SPS2eYMRtHpVqHRzuJY4HYYpvFxjszN0ITfv7HMw2whjChdy+lQ3djDMu0LtNdXdaYoDAOqfWqo0qLILStIcdhxRHFL4rlToU5Q9nZNGDpWjiV1LMxIP6V2VlZpbRAJgY702xsVgAaLJ+varyRSyNgKQM5ziuTE4l1XvoKlCnh4csFYfbqvu3rVK/1gR3Agt1DyKcSKcjA9aknkMSSMMHyxyMj8qx1kS5kme62xiVeFIwy4rGlTUnzS1QuW5vafqC3rTIilSjdT3pdVN21oRp5Bl9+1YsUEjIl5pkjuVAQIf1q3a6fdLch3uXUuwcr/ADolThGXMnt0ZjOMUa9ss7WsYlIM+0b8VMgJXAZlI/ugE/qDTPO8uTHbHOalV42GVIweRzwfxrkk3vY45oeJosZLAjqCKfHcqTtQsTXMm4kgmBkXHrkVsR3UYhDGRQT0xVzpOJDo2Whqs+1GkdtoUZOe1VbPUYr5HW2uIpcddrDioIZzOHjkBKsMHPFVoLKz06Z3gL75MZLuWJ/OoUFZp79DPkkpIsSxy4chVLn1NVRdLCxWWIbx6VY+1J9oZN6l8Z25qOdYbwtHwrIM7gOauPaS0OqGm5m3F0zzmReFx0WnRy/aWCKm0+p7VXuYngZluAQP4GXv9ajtIT5m5DtPrmuvljy3R2JRtoTXBeJx53zt61JDPuAEZG/IwKSaJjgklgKdY2omlC7WGfSpbjy3Y+ZJalpWccSMF59O9TphyRjaWHWtO00ZLdldm3r6HnFbP2aB02lAPwrinWV/dOKpiYrY5tLWcYMalsjt3q/Z2bBcy4BPatu3VFBVMYAxSuivkydfbvWTqNnJLEN6EH2ZFg2sefUDtVHU1iht3kLYVASST0rRIBQ4OAKyrxCzNHIMowwQaUdyabu7s40alPKuJbpEjaTCmIdPY1sWWpT2umXTJKyXLP8AKs54/DNaNtZ20IKi3jKlt2CvetuS3s5UUXUMbAcLuGeSegroq1oPRR0OudeKVmivpjzT6bBLOys7LklemaSaISN84VsHIyKutFCsAiiG1MbQB/DxWVpummwjkQyyTMxLZauVWd3sc6kndjL5W2kjkgVx9hJCZ7yea0Nu275mYfert5kY8AHB9qyLy1Eu6OVcq3XiuqjUUU0+ptTlYwNX1FoLVjAfkYfKRXEzSMxWQck9a7nxDZJBaRAJhBxx2rjbmzaFiwB2E8V7OBcOW6OqqpSgnHYgWTsW5rc0idoJIwjHaeaxxFt2mROvf1rpNKg8yA+VGqYxh36H2rbEyio6mmGTV+Y6/S7zzkOTyOKi1sCaW2tzeGCVzwCPvUulQvHGBLsB6/L3/wA8Vpy28dxLC0kSs6cgkZ2187KUYVLownJRndFi1gttLtTtRELcsVHU+tZOra8lknmMj7WO0YHJpLLTb5NQma7ufNgY5RQK0ZoEJUPGCoORkZrNKEZ3k+Yx91O71INNnF3ZpKARkZww5qZtrJh1BHoadvjRRudUVuAen5VLJGjRsHQFGBBUjIIqG1e5LdndGBe6OZLtfKRFhcYfj5h9DRFo5s7SRbVt8vXa561uMAANowB04qrcTJDlnOM9BWyr1GlE6I1Zy0M2c+W6IIDvZf1oayvZVz5ohHsMmpi0l4ykIBg5ye9aSuSny4GOCaqVRxtbc0lUcTGg0xyw+1FWJ6sO9XUtYYiAoGO9XUGIz8zN6+1ROgJ3HvxWbqyk9WR7RsZDbRbifLAGOtSMoJC4GPakLbR7Uxpdv3cYPrU6sm7bMx9BtWmuGbeBK4b73Q1PNplnM6M0AZ412hj6VcEgIGTz9aeCpGcZ/pWjq1OrG5yRzXk6nGWjs4IooRJ8uB2rfjiwAXAL8Z+tTgncO30oxk5PHoPWnOq59DOdRyM+6gydwHNZzSPDJtWMEnLEKM4+tbcpU5C7S+fuk81WljUjIABJ6nvVwnbcjn0sc7cTySk8DBqvFnAQg7icfSrAiLM2z5Tnp6UmXSZRIhwvI7V6CaSsjoUtNDYtVSJVX5gemDUs9mshLyMSR0H9aqQagAw82Mk+oq4bqSSRSAFX1PJrjkpp3MWpXuV0jtxdFjGvmAfePXFW7eeAofJgJPfjGalSxMhD8Hd3NaFrbLCMKgGe9ZTmmRKrFIyn0+W7cEkBcdD0q7b6SkcZyVBP91a0VXHH5ipAuMAd6ydST0MpYiWyM5LCEsFVcgfrVyGyijYMiBT7DrVmIKhyF6dxUwYEZPH1qW2zKVaTG7QQOQKYYt3c8+nUU/ACfITx3p0YZc469fSkZ8w+GE56k05owMg5pVfoGyMd6kB3R5x+HpRchtmdLkvwx+lRyqWHAz7VPMvBwQT3pqlTwoHPemaKViosXIIxj2q3C7BP3g78ZHSmztsO3nPtTAxRgcDpjGaT1NG+ZF5ACnFNBTcVJJOKapDITG3/ANaq7ko25lyPapsStSSWMYIXpVOWJSW7/WpRI3IJJ75NNBz6VWppFtGXfwxyWzRzoSh6j0965FPD85u2BObctkZ7ivQXto3BZhk9MVELYNIAyAhT8uRnFb0cTKkmonTTxHKrHL3Ph6OXy2IACDBAWlh0hfsD2jSPjduyODXW/Y4j8pjQ+2OBThaxgcYHPGKPrc7WuU8W2Ztlb7IwiggLhQT9Kv28ZDgt6VMEwDwOKV+MlRlgOAD1Nc8pNs55VOYQjLcGo1IYEn6c0PIc/Xj2qNZNqDd3/SosCRBf2MF3JC04bMZ3KAeDUjSncM4wO1RT3UZDKc59qrSs842rhFPUnrWii2knsaxi3uOvL3a4EfzE+lVYojNIWnJ+h7UuyONhtBLetS2zZiJY5BPetUlFe6br3VoTLH5Y2jkVMuBkD8qh3YXO7B6ZpEc5x261m02ZttlkhQepzUErgHHapNwJHcYqB/mc59OtKKBEckoQ49T3pm4E8frSSKm/kE49aYvXv1/OtkkaCkkY5/KrAdQo5/CqkpJPykAisn7TcC5kjkLBVOQe1aRpc41HmOnDJknP0pkkyjGO4rHS92Y3dCMk1Os6S4IORUexa3MZQaLMjjBKng/pVd3Yc5yffp+n0604nPA4PeqtwHZlwV2c53DPPGOc/X86uEUYt2GXkW2XehAzyRXOa5f3Ml0LS2BWY42nGAfauvdUuJQMnp61FFYBpsOBkd8ZropVY03eSvYcJ2ja9jPsI3MCLOR5oHOOla0Nq7BQQQp/CrMFosbhsA+1X0dVxxyD+Vc9Sq5PQU699h1tCsKAAn3ye9WVcYHY1GTlcKePX1qSM4XkE/hXO/M5m76ilTnPFSqpLc9qhMvzcA57Cnq+RnJH1NIh3Jt3AHQUuARkgVDC7PGrspUsASp6rkZ596kJ7DHNKwrD0XBI49OvNOAPXIx+tRBsd+alPOAp69qBC7iOT696RpAqc4+bgDNLjjrx0pjouQVxkcjigERkHO4gcUpjGM8ZpxJUANz+HWmuzYbaAADgc0yiIYLlAyFgM4yM49am2Jt5XJ6gZ61z9vcas2sNFdWS/ZMnbL3HpXQqx9PpROLjuaTVhyxqEwowD19zTXK5yQPXFKzEH1HTikZN5wQRgdaghEUqrIAccH0pvkqMY4FT7TsCggDrSBQDyeKZSZXMLK25HYj0PSmF2RhnkDrV0KrL3BqvNwPu7qEO4LKrKpGTxnilY57Yx0GOKhEYyGRsf7PanPKyg7o2IHpzRbsNLsJ5p24xnHv0qNpMHk5JprzIoJDA/wAzVGWeVmYLA+3HDZoUWzWMSzJJgZJOAaqXLM5DbSAD3p8e99oZCOckE8065z3Bx6VaVmarRlISDPQAH0FSK5OCB71XcHd9aVW5xnmtXE2RIxII7H1qVH2gLwf8ars29kXPTk1OzDA2ik0NjzgrzSKQGC7vzoHNQPE5mUgnaPepSQkicsA3ykfWl3gjGKhMUu/OQEH51E74XarYNNRuSyUjLMx5xVN5DuI7fSrIcFdpP/16YACQMVcdNy4shdiqbicDrVApJOqtLGVHBxnp7VsMAoOc881CfK67lBx3rSE7dBqRg3cFxbL8p8yE/mtWLaUKi847VNqdwghKggs3TFZ8IUNlmyD1A9a6o3nH3jVptGwsx25zz7VXuJU3Al1TOcYbGfWq63KiNs8Y75qm1wyr+9yVbkNn/JpQpanHUh2OrgVScqCpNWFIVznGTVS2JSIKDk1M2euOlcrRxFzII59aSLBQKG4HBx61XVhjAY5PPFTblLDPXoTmosJosxdCR0zjmpw+5fkbnj6VXRgFAyAMcU5CFPHUVm0BMxyc9D09afGp3VX8zLerVMrkADPbGaTQmSEkEdvc05COAKhZuwYYoDelFhExU9jinMW6KVDY+XPT2qv5zbjn6U5W3D5yOxxn05osOzJ4mk3HzMDHbPNPLYwB1x0qvnC4TG0dOcU4OO2CffvSaFYk3sRycg80gPXBJzUW3fk5IOOgNIPlb/HtRZDsSeZhQCR9KQEjcA3UkjPaoy+5hjBByc85qZCoHTr6Clawx43BwFYkdG3HoP5n8T3qUZLHpnpVYnGRj8aajnGTnmlYXKWh0yB+XFNbpgA/WkWQHOOD0pjhsHjj60WCw6OQjdjgVTun28hs+1SlztAI+tRzqMD+lCLSGQygABupqyjKeM5HeqKJhyec9OasHjJzxQ0OwlxbxyMTtH9aqKvlDaCSOuTVrd3qrdKpUhhxn1oXY0i3sG4A59O9RSy56UyQq0eM+3WoHbPBOQKtRNYojlKhcnBqLzVAJzjFNnm4AOMAVRhlaecADESnJ966Ywurs6Yx0NeBSRubALdBUwGVPcAZx61DGcgdMCnoxCkgjPUViyWypou+ZZnZ5SC+Ar8YrZCL37GmRMFAzn1pJHB6cA+9ROXPK5lKTbHzlVjJzjvxWFcyZJCA+ua0pJN3yLzxWbPG5fcpwK1oq24ohBnAz1qR5QjLyB3pigRAYPzHoKglRgQZGLNkk+wrWybOiGu5ZuGlmULDgL0JqBdNG0mVm/OtSFUEKs3XGc02N0kkJc8elQqjWkSXN9DnLjS5JGJhk4Xj5qV7Tyows2c+q1tsP3hCEbetNYIQS3BJyfet1Xl1Hzs5i4fyUfJAXPAxjFYU2pLIdrMwUHgqSM1c8T3DSXDxZxGDxjrXLT9QCAffNezhaKlHmkc2LreyVkj2OFtigdSe+c81ajOcc/nWZHJhTkc+vvU6yN0zhcY/n/8AWrw3E5bF9GHXjjjp/n1pQ4zk85qp5gyd35+9IJG3e3oO9RYfKy/G+TgtwPWnqxIyKpK3I5A+ven+YF9SBzjNQ0HKWUclgRhs+lTxSBwCvKnkH1qgrhmBJOM/XP41YWTA+X1ycnFJoTRcMmVOOPY0zd1A4/GqoZRgDIHWkaYDO1hkEKT7/wCSKOUSQjTuJPUegqeKYkA9M0wPuXBxz3I71GjIrHJ2tRa5e5dEoyASM9s9acGwc7u3TFVlIGSM+mf6CnK4QEZ5x6ZqbCsWo5AF3HgdTmnqQ6tht3vmqivvHIGP9oZ5+lSCbAb0HPAz2zQ0KxKhAPfPT60/ICdye1V2Ylsj8eMf578U0EO2P4jx9KmwWLauV5ZuD+NLvCg9N2egqqJs8fNxx06U4jA3g5bp71Nh2LKsCwJGD6U+fBj4PvVRJAWOCcZ+mf8AOKkdgVJGMjnmnYGiN5juwOaUHv6VWnJ6odpx/EOlMRyDwTnHbkCixVi0zbl4yKjkYkDFRGRiCvVu/vUby4BHHTkYo5SkidjkDnpVWckMQuMelPlcBc9T7VRkcIu1RgDoAOlVGNy4oZLKckZ/Wqc11gcGoriVt/t1qhNJtQs3AIziuynSudcIk13dlYSF+arGmDbbAtjcTnFc1FNLczui52E8n0roYW8uMFmOAPoMCuirS5I8pq3daGgJlQc8duKmjkVmBzkdcCsfzwXwzcHge1TLKiAYOBXNKkQ4G0kgJ5NLKcgEk/TNZq3UZGA3WpDMOepNYum0zJwLCAEk7hioLifap2AZHemQmV8nAC+3Gat29nvOZvu+9Oyi9SbqLuytplq9w/nvkr0GOK0LiBeh4I6VciAiARMDbjgdqSWJnyTj6VnKblK5i6zcjO24Tk8DsKgCqXbsCaNV862tZpII90noB1rPZbuazieNhFKQCykdK1hC6vc2i7rcuMUgRmduPc1iz61bmbYCPrVzUFkksZkHLbe3rXmzTH7S6NkMODXoYPCxrJtvYqVWFFJy6nQa+GuED2wVj3Irl7lXwCS0ZP1qU31xbvtB3Dt6VfilgueSiqepxxn/ADmvXpxlRjbdHHVnTxbai7Psz//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_63_31743=[""].join("\n");
var outline_f30_63_31743=null;
